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Summary 
The human papillomavirus (HPV) belongs to the family of Papillomaviridae with more than 200 
members, including HPVs but also papillomaviruses (PV) infecting for example cattle or rodents. Due 
to the causative association of HPV infection with the development of cervical cancer intensive 
investigation on HPV has been conducted over the last decades. Therefore, many aspects on the viral 
structure, infection as well as the transforming properties especially of the high risk HPV types have 
already been deciphered. In the course of these investigations, the HPV minor capsid protein L2 has 
been identified as an important player in the establishment of viral infection. Even though, the 
protein is dispensable for capsid formation, it has been demonstrated to have several functions 
crucial for e.g. DNA encapsidation, viral entry and the delivery of the viral genome to the host cell 
nucleus. However, the exact function of L2 during some of these processes is still unknown and 
under continuous investigation. In this context, many functional domains of the L2 protein have been 
identified especially in the highly conserved N-terminus of the protein however the function of the 
remaining parts is still unrevealed. Regarding the importance of the L2 protein for viral infection 
further investigation on potential functions still represents a promising field of research. 
The objective of this thesis was the identification of novel cellular interaction partners of L2. To this 
end, three independent experimental approaches were established, allowing the co-purification of 
interacting proteins. A) Tandem affinity purification (TAP) a two-step purification method based on 
the overexpression of HPV16 L2 as fusion protein with the TAP tag. B) Immunoprecipitation (IP) of 
HPV16 L2 from pseudovirus (PsV) infected cells, mimicking the natural infection pathway of HPV16. 
C) Peptide pull down of cellular proteins using immobilized HPV16 L2 epitopes which are targets for 
neutralizing antibodies. For identification of the co-purified interaction candidates the samples 
derived from the different experimental approaches were analyzed by mass spectrometry (MS). 
Based on the results, the insulin receptor substrate 4 (IRS4), the 14-3-3 zeta/delta (YWHAZ), the 
exportin-2 (CSE1L) as well as the calpain 2 (CAPN2) and the cullin-associated and neddylation-
dissociated 1 (CAND1) proteins were selected as most promising candidates for functional studies. 
These five proteins were validated as L2 binding partners by Co-IP and immunofluorescence (IF) after 
overexpression. An inhibitory effect on HPV16 L2 PsV transduction of the downregulation of protein 
expression was demonstrated for IRS4, YWHAZ and CSE1L. In contrast, knockdown of CAPN2 and 
CAND1 had neither inhibitory nor enhancing influence on PsV transduction. While the obtained data 
suggests a role of IRS4, YWHAZ and CSE1L during the infection process of HPV16, interaction with 
CAPN2 and CAND1, respectively is supposed to be important in a different step of the viral life cycle. 
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Zusammenfassung 
Der Humane Papillomvirus (HPV) gehört zur Familie der Papillomaviridae, die mehr als 200 
verschiedene Typen umfasst. Darunter befinden sich neben den HPV unter anderem auch 
Papillomviren (PV), die Rinder oder Nagetiere infizieren. Auf Grund der Assoziation zwischen HPV 
Infektion und der Entstehung von Zervixkarzinomen fand in den letzten Jahrzehnten eine intensive 
HPV Forschung statt. Viele Aspekte, wie die Struktur, der Infektionsvorgang und der Mechanismus 
der Zelltransformation durch HPV wurden dadurch aufgedeckt. In diesem Zusammenhang wurde 
auch gezeigt, dass das L2 Strukturprotein wichtige Funktionen bei verschiedenen Schritten des 
viralen Lebenszyklus erfüllt. Obwohl das L2 Protein für den Aufbau des Kapsids nicht essentiell ist, 
wurde eine wichtige Funktion bei der Verpackung des viralen Genoms, dem Eintritt in die Zelle, sowie 
dem Transport durch die Zelle nachgewiesen. Die Mechansimen wurden jedoch noch nicht im Detail 
erforscht. Es konnten aber schon diverse funktionelle Domänen des L2 Proteins identifiziert werden, 
speziell solche, die sich im konservierten Amino-Terminus befinden. 
Das Ziel der vorliegenden Arbeit war es daher neue, zelluläre Interaktionspartner von L2 zu 
identifizieren, um dadurch weiteren Einblick in die Funktionen des Proteins zu gewinnen. Um dieses 
Ziel zu erreichen, wurden drei unabhängige Methoden etabliert. A) Die Tandem Affinitäts Reinigung 
(TAP), welche auf der Expression des HPV16 L2 als Fusionsprotein mit dem TAP-Tag basiert. B) Co-
Immunopräzipitation von L2 aus Pseudovirus-infizierten Zellen, welche den natürlichen 
Infektionsverlauf von HPV nachahmt. C) Peptid-Pull-Down, bei dem HPV16 L2 Epitope immobilisiert 
wurden um interagierende, zelluläre Protein zu isolieren. Um die gereinigten Proteine zu 
identifizieren wurden die verschiedenen Proben im Massenspektrometer (MS) analysiert. Als 
vielversprechende Kandidaten wurden Insulin Rezeptor Substrat 4 (IRS4), 14-3-3 zeta/delta, Exportin-
2 (CSE1L), sowie Calpain 2 (CAPN2) und Cullin-assoziierte und Neddylations-dissoziierte 1 (CAND1) 
ausgewählt. Eine Interaktion dieser fünf Proteine mit L2 konnte durch Co-IP und Immunfluoreszenz 
Analysen validiert werden. Des Weiteren konnte ein inhibierender Einfluss auf die Transduktion 
durch PsV nach Herunterregulierung der Proteinexpression für die Interaktionspartner IRS4, YWHAZ 
und CSE1L festgestellt werden. Für CAPN2, sowie CAND1 konnte weder eine Inhibierung noch eine 
Verstärkung der Transduktionseffizienz von PsV beobachtet werden. Auf Grund der vorliegenden 
Daten wird daher vermutet, das IRS4, YWHAZ und CSE1L womöglich eine Rolle während des 
Infektionsprozesses spielen, während CAPN2, sowie CAND1 möglicherweise eine andere, noch 
unbekannte Funktion im HPV Lebenszyklus spielen.     
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1. Introduction 
1.1. Human Papillomavirus (HPV) 
The human papillomavirus (HPV) belong to the taxonomic family of Papillomaviridae and represents 
a group of non-enveloped dsDNA viruses with a genome size of ~8kb. The Papillomaviridae are highly 
diverse, occurring in most mammals and birds. Among the family of Papillomaviridae, more than 200 
human PV (HPV) types have been isolated and characterized so far and been divided in different 
genera.  
 
Figure 1Phylogenetic tree of 200 PV types. Classification of 200 papillomaviruses based on the homology of the L1 protein. 
The species of Betapapillomaviruses are indicated by the outer semi circles. Human papillomaviruses (HPV), alpha, beta, 
gamma, mu and nu are highlighted with red boxes. The remaining genera (pi, omicron, xi, lambda, kappa, lota, theta, eta, 
zeta, epsilon and delta) comprise the animal PVs are not specifically indicated. PVs are defined with the corresponding 
number at the associated branches [1]. 
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HPVs of the alpha genus are known to infect mucosal but also cutaneous epithelial cells of the genital 
and upper respiratory tract as well as the skin. Within the alpha genus, low risk types, e.g. HPV6 and 
HPV11, can cause benign genital warts, whereas the high risk types (e.g. HPV16 and HPV18) are 
causatively associated to cervical cancer [2-4]. HPVs of the β-genus are exclusively infecting the 
cutaneous epithelial and are suggested to play a role in the formation of Non-Melanoma Skin Cancer 
(NMSC). The remaining genera (gamma, mu and nu) have been associated to the development of 
cutaneous papillomas and warts [5]. Until now, 17 different high risk types have been described in 
the alpha genus of HPV, namely HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 59, 66, 68, 73 and 
82. Within these high risk HPVs, HPV16 and HPV18 have the highest, transformation potential 
causing 50% and 20% of cervical cancer cases, respectively [6, 7]. Cervical cancer is a major burden 
worldwide and represents the fourth most frequent cancer in women 
(http://globocan.iarc.fr/old/FactSheets/ cancers/cervix-new.asp). During their life time most sexually 
active women get infected with mucosal HPV types, though most of the infections stay asymptomatic 
and can be cleared by the immune system. Only in a minority of infected women, the infection will 
progress to low and/or high grade cervical interepithelial neoplasia (CIN). However, even high grade 
CIN lesion can still regress and infection can be cleared whereas only a few will further progress to 
cervical carcinoma [8].  
The HPV genome contains 8 open reading frames (ORFs), encoding for three regulatory proteins (E1, 
E2 and E4), two structural proteins (L1 and L2) and three oncoproteins (E5, E6 and E7), which are 
regulated by the long control region (LCR), located between the ORFs L1 and E6 [9].  
 
Figure 2 Organization of the HPV16 genome. HPV16 has a genome size of about 8kb and contains 8 open reading frames 
(ORF). It encodes for three regulatory proteins, E1 and E2 controlling for example transcription of viral genes and genome 
amplification and three structural proteins L1, L2 and E4. L1 and L2 are essential for capsid assembly and encapsidation of 
the viral genome. Moreover, the genome contains three oncoproteins, E5, E6 and E7 which play a major role during viral 
infection and cancer progression of the infected cells. Figure adopted from [10].  
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HPV-driven cervical cancer is characterized by a high expression level of the oncoproteins E6 and E7 
as well as integration of the episomal HPV genome into the host genome [11]. It has been 
demonstrated that E6 and E7 play a major role in the development of HPV associated cancer, since 
they are directly involved in the transformation process. The E6 protein targets p53, a transcription 
factor regulating cell cycle arrest and apoptosis, for proteasomal degradation [12, 13]. And E7 
regulates cell cycle division by binding to hypo-phosphorylated pRB [14, 15]. Binding of E7 with pRB 
disrupts pRB-E2F interaction, leading the infected cells to progression into S-phase[16] . Therefore, 
high expression levels of E6 and E7 increase the chance for infected cells to progress to CIN and 
cervical cancer [17, 18].   
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1.2. The HPV Capsid 
The viral DNA is encased by a non-enveloped icosahedral capsid of about 50-60nm, composed of 72 
capsomers of five L1 molecules each. In general, the capsid is formed by the major capsid protein L1 
while the minor capsid protein L2 is finally incorporated into the L1 capsid structure. It has been 
demonstrated that L1, in absence of L2, is able to spontaneously self-assemble and form virus-like 
particles (VLPs) with similar morphology to native virions [4, 19]. The virus-like particles are produced 
either by expressing L1 alone or together with L2. In both systems the capsids possess the correct 
size (~55nm) and density in the gradient, comparable to native virions [19].  
HPV capsid structure and localization of the L2 molecules 
Stabilization of the viral capsid is achieved by maturation of the previously immature and still flexible 
virion. In the mature capsid state, the L1 molecules are cross-linked by disulfide bonds between 
neighboring L1 molecules [20]. The bonds have been demonstrated to be essential for the 
stabilization of the viral capsid [21]. The L1 pentamers form a knobby exterior surface and the N- and 
C-termini of L1 form the floor between the knobs. Furthermore it has been demonstrated that 
flexible C-terminal arms play a major role in the formation of the disulfide bonds between 
neighboring pentamers. In the mature capsid, each L1 molecule participates either in disulfide-linked 
dimers or ring-shaped trimers [22, 23]. For capsid assembly of L1/L2 capsids, L2 translocates into the 
nucleus, mainly into the PML bodies, before L1 pentamers are recruited, initiating the assembly of 
the viral capsid [24]. It was postulated that co-expression of L1 and L2 leads to 10-100fold higher 
capsid yields compared to L1 only expression, leading to the suggestion that L2 might also be 
involved in capsid stabilization [19]. Further analysis of L2 within the viral capsid revealed a diversity 
of different PsV preparations to have more than the previously suggested 12 L2 molecules [25, 26]. 
Buck et al. (2008) could show an average of 36 L2 molecules incorporated into PsV capsids and 
revealed up to 72 L2 binding sites within the L1 pentameric capsid structure. Furthermore Cryo-EM 
analyses (Figure 3) could demonstrate that L2 is mainly located around the base of the capsomer 
lumen in close apposition of neighboring L2 molecules. The predicted contact between neighboring 
L2 molecules was further shown to be specific in the assembled capsids [27].  The interaction of the 
L2 protein with the L1 capsomers is suggested to be found in the central cavity of the L1 pentamers 
and non-covalent [28]. The analysis of potential interaction domains of HPV11 L2 revealed a single 
domain within amino acid 396 and 439 to participate in L1 interaction. In the corresponding domain, 
conserved proline residues have been identified which were found to be conserved in a variety of 
HPV types. This hydrophobic stretch seems to play a major role in anchoring the L2 protein in the 
capsid [24].  
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Figure 3 Computerized reconstruction of a HPV16 L1+L2 capsid. Reconstruction of the capsids was generated based on 
results from the Cryo-EM analysis after capsid preparation in 293TT cells and maturation overnight. A Exterior surface of 
the L1+L2 capsid with the knobby structure formed by the L1 pentamers. B View of the interior capsid. C Interior view of the 
capsid, showing the L2 densities in red detected in the Cryo-EM. Figure adopted from [27]. 
The L2 protein is known to be mainly hidden within the viral capsid although the precise localization 
within the capsid is still unknown. However, several groups could identify different regions to be 
accessible when L2 is incorporated into the L1 capsid. For example, the region between amino acid 1-
120 of HPV16 seems to be available for binding [29-31]. A recently proposed model of PV infection 
suggests several conformational changes within the viral capsid during the entry process. Some L2 
regions might get accessible upon a distinct conformational change, which alters the availability of L2 
on the surface of the capsid. Gambhira et al. described an epitope at amino acid 17-36 which has 
been demonstrated to get available for antibody binding after binding to the ECM, followed by furin 
cleavage of the very N-terminal part of L2 [26, 32, 33]. Whereas, Richards et al. as well as Yang et al. 
described two epitopes (aa 100-120 and aa 13-31) to be constitutively exposed on the surface of PV 
capsids [31, 34]. 
Prophylactic HPV vaccines based on the structural proteins L1 and L2 
To date, there are two HPV vaccines available on the market and both are L1 VLP-based vaccines to 
prevent HPV infection with the most prominent high risk types, HPV16 and HPV18. While 
Cervarix®(GlaxoSmithKline) is a bivalent vaccine, composed of HPV16 L1 and HPV18 L1 VLPs, 
Gardasil® (Merck) is a quadrivalent vaccine and covers protection against two additional HPV types 
(HPV6 and HPV11). Though L1-based vaccines induce high titers of neutralizing antibodies, the 
protection is limited strictly to the distinct types included in the formulation of the vaccine [35]. In 
order to generate a second generation vaccine, several HPV L2 peptides have been demonstrated to 
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induce cross-protection against a high number of HPV types [30, 36-39]. Especially highly conserved 
N-terminal L2 epitopes represent the targets for neutralizing and cross-neutralizing antibodies [30]. 
However, the mechanism of neutralization and the function of these epitopes for viral infection have 
not been revealed so far. Their ability to elicit (cross-) neutralizing antibody responses might be an 
evidence for an essential role in during the infection process. Binding of neutralizing antibodies to 
these epitopes is suggested to inhibit a crucial function which might be crucial e.g. for the interaction 
with a specific cellular interaction partner. 
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1.3. Minor Capsid Protein L2 
L2 has been described to have important functions in several processes of DNA encapsidation and 
viral infection. The L2 protein is highly conserved between different papillomavirus types and is 
known to fulfill comparable functions in the PVs. Even though the protein is under 500 amino acids 
and therefore should have a molecular size of around 55 kDa in SDS-PAGE, it has been observed that 
the protein runs at a molecular weight of 64-78 kDa. This phenomenon could not be explained until 
now, since the only post-translational modification known is the SUMOylation at lysine 35 [40-42]. 
Little is known about the higher order structure of papillomavirus L2 proteins. The highly conserved 
N-terminal part of L2 was shown to contain two cysteine residues (C22 and C28) that are 100% 
conserved across the Papillomaviridae. These cysteines are able to generate intra-molecular disulfide 
hairpin loops that seem crucial for PV infectivity. Experiments targeting C22 and C28 demonstrated 
that exchanging either one lead to a loss of infectivity of the corresponding PV [43, 44].  
1.3.1. The role of L2 in capsid assembly and genome encapsidation 
Assembly of the viral capsid 
Within the nucleus L2 is recruited to the PML bodies, facilitated by a specific region at amino acid 
390-420 [45, 46]. Furthermore it has been shown that PML localization of L2 leads to an 
accumulation of L1 and DAXX in the PML bodies. This process might play a role in the assembly of 
viral capsids [47, 48]. Also other viral proteins were detected to accumulate in the PML bodies, for 
example the viral E2 protein. Since E2 has not been identified to be important for viral assembly but 
rather for transcription and replication, recruitment of E2 is supposed to induce replication of the 
viral genome [25, 49]. Beside viral proteins, several cellular proteins have been demonstrated to co-
localize and interact with L2 in the PML bodies. Among other proteins, transcriptional regulators, like 
PATZ and TBX2 and 3 have been identified. Especially PATZ was previously suggested to be an 
important protein, regulating gene transcription and cell differentiation during formation of 
papillomas [50, 51].     
Encapsidation of the viral genome 
The minor capsid protein L2 is also known to play an important role in the encapsidation of the viral 
genome. L2 has been shown to recruit other viral proteins to the ND-10 of the host nucleus. In the 
ND-10, or PML bodies, L2 co-localizes with L1, the viral DNA and E2 and is supposed to organize the 
encapsidation of DNA and the assembly of the L1/L2 viral capsid [45, 52]. Conserved regions at the N- 
and C-terminus of the L2 protein have been described to have DNA binding activity, consisting of 
positively charged basic amino acids [53, 54]. L2 is crucial for encapsidation of the viral genome of 
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different PV types [53, 55-57]. Deleting one of the two regions of L2 did not lead to inhibition of DNA 
encapsidation but rendered the particles non-infectious. Since the regions, described to have DNA 
binding activity, overlap with the nuclear localization signals (NLS) at the N- and C-terminus of L2, 
results gained from the deletion of both regions remain controversial [58-61]. The DNA binding 
activity of L2 is not sequence specific but rather depends on ionic interaction due to the affinity of 
negatively charged DNA and the positively charged amino acid regions of L2 [61].  
1.3.2. HPV entry – from the cell surface to the nucleus   
Binding to heparan sulfate proteoglycans (HSPG) 
The published data about the viral cell binding and entry process are still debated and based on the 
use of L1 and L1/L2 VLPs or PsV. To date, binding and cell entry of PV have not been completely 
revealed, however there are models of the entry process under discussion [33, 62]. The general 
opinion about the binding of HPV to the surface coincides about the initial binding to heparan sulfate 
proteoglycans (HSPGs) either on the cell surface or at the extracellular matrix [33, 63, 64]. HSPGs are 
reported to have different activities in a variety of biological process amongst others these proteins 
serve as attachment receptors for viral and bacterial pathogens [65, 66]. In keratinocytes, the target 
cells of PVs, the most prominent HSPG is known to be syndecan-1. This protein consists of a core 
transmembrane domain (TM) as well as an ectodomain containing between 3 and 5 HS chains. 
Syndecan-1 was described to be highly expressed during wound healing, correlating with the 
necessity of epithelial micro lesions for efficient, natural PV infection [67]. In addition to syndecan-1, 
several HSPGs have also been described as potential binding receptors of different PVs [68, 69]. The 
binding to HSPGs is based on two specific lysine residues in the L1 protein which are located at 
position 278 and 361 of the HPV16 L1 protein [70, 71]. Additionally, modifications, for example 
sulfation of the HSPG receptor seem to have a crucial effect on HPV (especially HPV16 and HPV33) 
binding [72]. The binding of L1 to the corresponding HSPGs leads to a conformational change in the 
L1 protein. This event is supposed to play a role in the transfer of virions to a potential secondary 
receptor facilitating viral entry [73].  
Exposure of the HPV L2 N-terminus and furin cleavage   
In the common binding models, the viral L2 protein, mainly hidden within the capsid, is suggested to 
expose the N-terminal part following the conformational changes in the L1 protein and the 
interaction of L2 with cyclophillin B (CyPB) [34, 74, 75]. CyPB is a peptidyl-prolyl cis-/trans-isomerase, 
known to associate with syndecan-1 after secretion to the extracellular space [76, 77]. After 
exposure of the L2 N-terminus the protein is cleaved at amino acid 12 by a furin protein convertase, 
removing the N-terminal located NLS [33, 34, 63, 73]. In addition, furin cleavage seems to be crucial 
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for infectivity of different PV types. The furin cleavage motif is highly conserved and several PV types 
show decreased infection potential after exposure to furin inhibitors [34]. Moreover, distinct point 
mutations of the furin cleavage site led to the production of infection deficient particles. Further 
analysis of these non-infectious particles showed proper incorporation of L2 and viral DNA during the 
capsid assembly. Whereas the following steps, like cell surface binding as well as uncoating of the 
viral DNA, have been demonstrated to be not affected by these mutations. However, Richards et al. 
could show an accumulation of the L2/viral genome complex in the endosomal compartment. The 
same results could be observed using furin inhibitors. Cleavage by furin protein convertase therefore 
seems to be crucial to facilitate the endosomal escape of the L2/viral genome complex and further 
transport to the nucleus [34].  
 
Figure 4 HPV surface interaction, conformational changes and binding to the target cell. A HPVs are transferred to the 
basement membrane through micro-lesions and bind to the HSPGs. B This binding induces a conformational change in the 
viral L1 capsid protein which leads to the exposure of the L2 N-terminus. The furin cleavage site then gets susceptible for 
the protein convertase which releases aa 1-12. C After a second conformational change in the capsid, the virion is 
transferred to the target cell and binds to a still unknown secondary receptor from where the particle is internalized. Figure 
adopted from [78].   
Furthermore, CyPB is suggested to have additional functions after virus internalization, specifically 
during dissociation of L1 and the L2/viral genome complex [79]. Since furin cleavage also induces a 
second conformational change of the capsid and exposes additional epitopes of L2, another 
hypothesis suggests L2 to bind to the still unknown secondary receptor at the surface of the target 
cell. This suggestion is supported by the identification of two independent L2 epitopes (aa 13-31 and 
aa 108-120) targeted by neutralizing antibodies. The epitope aa 13-31 has been shown to bind the 
cell surface and further contains the highly conserved cysteines (C22 and C28) which are both 
essential for viral infection [31, 37, 43]. In addition, the L2 epitope aa 108-120 has also been reported 
to bind epithelial cells and show high conservation between different types [37]. The involvement of 
a secondary receptor for viral entry is further based on the observation that HSPGs and CyPB do not 
induce endocytosis. These findings strongly support the existence of a secondary receptor or a co-
receptor initiating the internalization of the viral capsids into the host cell [74, 80].  
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Cellular factors involved in the uptake of HPV 
Several publications describe α6-integrin as a promising secondary receptor candidate because of the 
known interactions between integrins, tetraspanins, HSPGs, CyPB and intracellular signaling 
pathways [64, 69, 81]. Additionally, HPV16 PsV have been shown to interact with a HSPG/growth 
factor (GF) complex inducing signaling cascades through the corresponding growth factor receptors 
(GFR). In this context, the PsV are suggested to be covered by HSPG/GF complexes allowing the 
binding to the GFR. One example is the induction of the PI3K/Akt/mTOR signaling pathway by 
activation of the EGFR after binding of HPV16 PsV [62, 82]. The function of L2 during the binding and 
internalization of the virus is still under discussion. While some data clearly show a better infectivity 
of PsV with a high average of L2 incorporation, binding of HPV33 VLPs on HeLa cells have been 
described to be comparable for L1 and L1/L2 VLPs [27, 83, 84]. In 2012, Woodham and colleagues 
identified annexin A2 as an interaction partner of the L2 surface binding epitope 108-126, therefore 
revealing an additional candidate for receptor binding of L2 [85]. The Ca2+- and phospholipid binding 
protein annexin A2 consists of two A2 monomers together with a S100A10 dimer in a 
heterotetrameric complex [86]. The complex is known to be involved in several processes like endo- 
and exocytosis, cell adhesion, membrane fusion as well as binding, uptake and trafficking of a variety 
of viruses [87, 88]. For example, annexin A2 is a receptor for cytomegalovirus (CMV), facilitating CMV 
infection together with a variety of additional molecules, including HSPGs, integrins and EGFR [89, 
90]. The use of a complex set of molecules for viral entry would correlate with the slow and 
asynchronous uptake of HPV because of many rate limiting steps as conformational changes, furin 
cleavage and recruitment of a multitude of surface molecules [80, 91, 92]. Though the process of PV 
internalization could not be completely revealed to date, some of the common pathways have 
already been excluded. The endocytosis of HPV16 could be demonstrated to be clathrin-, caveolae-, 
lipid raft-, flotillin-, cholesterol- and dynamin- independent. However, actin polymerization seems to 
be crucial for HPV16 infection in contrast to Rho-like GTPase activity. The ligand-induced uptake of 
HPV16 might be a new pathway which is closely related to micropinocytosis, depending on multiple 
factors like EGFR, PKC, PI3K and maybe other tyrosine and/or serine/threonine kinases [92, 93].     
Internalization and trafficking of the Viral Particles 
Different PV types have been reported to use variable cellular pathways during the internalization 
process [93-95]. Beside the different PV types, another variable factor for the selection of the 
internalization pathway might be the cell type or the PV genome used in the distinct experiment. 
Whereas L1 only VLPs were shown to enter immune cells via a clathrin-mediated or caveolae-
dependent pathway, L1/L2 VLPs are internalized by clathrin- and caveolae-independent mechanisms 
[96, 97]. This observation leads to the suggestion that L2 might affect directly the selected 
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internalization pathway of the corresponding PV. Studies using Langerhans cells demonstrated 
maturation of L1 VLP-infected cells while L1/L2 VLP treated cells did not enter the maturation 
process [98]. Consistent to these findings, L2 might have another crucial function in escaping the 
immune system which might be due to the selection of an alternative uptake pathway [98]. Infection 
of epithelial cells, the natural target of PVs, led to uptake of the virions and transfer to early 
endosomes followed by transition to late endosomes, an acidification-dependent process [93].  
 
Figure 5 Intracellular trafficking of HPV16. After binding of the virus to the cell surface and the corresponding 
conformational changes in the capsid, the virus is internalized probably by a micropinocytosis related process. During 
internalization the virion is suggested to interaction with different factors, like integrin α6, tetraspanin, GFR and an 
unknown uptake receptor. Actin polymerization leads to the release of the HPV16 containing endocytic vesicle into the 
cytoplasm of the target cell. Acidification of the endosome and interaction with CyPB further lead to the disassembly of L1 
from the L2/viral DNA complex. Several cellular factors, e.g. Rab 7b and Rab 9a, are suggested to play a role in the transition 
of the L2/viral DNA complex to the trans Golgi network (TGN) from where the complex is further transported to the 
nucleus. However, the process of TGN to nucleus trafficking is still unrevealed. Figure adopted from [99].   
Several host cell proteins have been identified, permitting entry and transport of the virions. In PV 
infection CyPB might fulfill two distinct functions during the internalization of the virions. First of all, 
it is supposed to induce the previously described conformational change in the PV capsid, allowing 
furin cleavage [75]. Secondly, CyPB might facilitate the uncoating of the viral DNA in the late 
endosomes, leading to the dissociation of L1 and L2/viral genome complex [79]. While the L2/viral 
genome complex has been reported to escape the late endosome and travel through the trans Golgi 
network (TGN) after dissociation from L1, L1 remains in the late endosomes [100, 101]. In context of 
the described pathway, Day and colleagues described the furin cleavage to be crucial for the PV for 
entry to the TGN and further passage of the L2/viral genome complex. The TGN has been reported to 
be an essential subcellular compartment for transfer of the L2/viral genome complex to the nucleus 
Introduction 
 
14 
 
[102].This data was demonstrated by the dependence of HPV16 infection on Rab7b and Rab9a 
GTPases, which are known to be necessary for the transport of cargos between different cellular 
compartments. Rab7b and Rab9a have been published to be directly involved in transition of cargo 
proteins from the late endosome to the TGN [103]. Other compartments, like the caveosomes and 
the endoplasmatic reticulum (ER) have also been described to be important for intracellular 
trafficking of different PV (BPV1, HPV31 and HPV16) [104-106]. 
Endosomal escape of the L2/viral genome complex 
After encapsidation of the viral DNA, the L2/viral genome complex needs to escape the endosomal 
compartment and further travel to the host cell nucleus. Especially the mechanism leading to the 
endosomal escape is under continuous investigation and not completely understood to date. Kamper 
at al., identified a hydrophobic and basic cluster at the C-terminus of HPV33 L2 which is supposed to 
be able to invade cellular membranes and potentially destabilize the endosomal membrane. Further 
investigations on this L2 region by mutation experiments showed an impaired infectivity of the 
corresponding virus. In this context, the L2/DNA complex was observed to be retained in the late 
endosomes instead of being transported to the nucleus [107]. Another region of L2 which might be 
involved in the endosomal escape of the L2/DNA complex has been described to be a 
transmembrane-like domain at aa 45-67 including several GxxxG motifs [108]. The corresponding 
GxxxG motifs are highly conserved between different PV types which might point to an important 
function of the specific domain. Furthermore, the authors found the structure of this area to be 
alpha-helical with the GxxxG motifs on opposite faces of the helix. This localization allows the self-
association of motifs either homo- or heterotypically. This process might form higher order 
structures, therefore allowing the penetration of the endosomal membrane. This suggestion is 
strongly supported by experiments using altered GxxxG motifs, leading impaired endosomal escape 
of the L2/DNA complex [108].  
A cellular protein, identified to play a role in the endosomal compartment, is sorting nexin 17 
(SNX17), a cytosolic adapter protein involved in endosomal recycling. L2 sequences of several types 
show a conserved SNX17 binding site at around amino acid 245-257. Publications from 2012 and 
2013 demonstrated that knockdown of SNX17 or mutation of the potential SNX17 binding site in L2, 
induced retention of L2 in the late endosome followed by lysosomal degradation [109, 110]. SNX17 is 
strongly connected to the sorting process of cargo proteins within the endosomal network. SNX17 
protects integrins from lysosomal degradation by targeting the intergrins towards a recycling 
pathway [111, 112]. Recently, L2 has been reported to interact with SNX27, which belongs to the 
same protein family as SNX17 [113]. SNX27 is known to at least indirectly interact with the retromer 
complex [114]. SNX27 might be involved in the association of L2 with the retromer complex which 
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has previously been reported by Popa et al. [115]. Association of L2 with the retromer complex was 
described to mediate the endosomal escape and transport of the L2/viral genome complex to the 
TGN [115]. 
 In addition, the dependence of the L2/viral DNA transport on the Rab GTPases might also point to 
the trafficking of L2/viral DNA through the TGN to nucleus. Along this line an interaction of L2 with 
the dynein light chain Tctex1, described to be localized in the Golgi and the interphase nuclei was 
reported [116-118]. Though the final steps of L2/viral genome transport to the nucleus have not 
been revealed, the findings might confirm the hypothesis of L2/viral DNA nuclear entry during 
mitosis and nuclear envelope breakdown. In this context, the Tctex1 might be involved in the 
transition of the L2/viral DNA complex from the Golgi to the kinetochores of mitotic cells [117, 118]. 
However, the details of TGN to nucleus transition of the L2/viral genome complex are still under 
constant research and need to be further elucidated.   
Nuclear Entry of the L2/viral genome complex 
The L2 protein sequence is known to contain two NLS however the mechanism of nuclear entry is not 
completely understood by now.  Pyeon et al. claim that entry of the host cell into mitosis and the 
nuclear breakdown are crucial events for L2 nuclear entry. According to the publication from 2009, 
L2 does not enter the host cell nucleus through the nuclear pores mediated by the NLS sequence of 
L2 [119]. Besides, a nuclear retention signal at amino acid 296-316 has been described, which seems 
to be important for viral infection. In context of a nuclear entry during nuclear breakdown, these 
regions are suggested to facilitate association of L2/viral genome with the nuclear matrix during 
metaphase [120].  
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1.4. Objective 
The HPV minor capsid protein L2 has been reported to be crucial for infectious viral entry and a 
variety of processes during the viral life cycle of several HPVs. Even though some functional domains, 
especially in the highly conserved N-terminus of L2, have already been described (Figure 6), there are 
still many regions in the protein sequence that might play a role in the infection process or during 
formation of new virions after infection.  
 
Figure 6 Summary of described L2 functional domains and epitopes for binding of neutralizing antibodies. Functional 
domains of the PV L2 protein are highlighted with the colored bars, like described in the caption. The furin cleavage site is 
marked by a black arrow, whereas the epitopes for neutralizing antibodies are indicated by the red antibody symbol. Figure 
adopted from [121].  
The objective of the PhD project is the analysis of unrevealed HPV L2 domains to get further insight 
into the functional role of L2. Therefore, the aim of my thesis is the identification and validation of 
cellular proteins interacting with the HPV16 minor capsid protein L2. The first approach (Figure 7, A 
Tandem Affinity Purification (TAP)) focused on the identification of specific interaction candidates 
after overexpression of a tagged HPV16 L2 protein. The tandem-affinity purification (TAP) was used 
to co-purify interacting cellular proteins together with a TAP-tag containing HPV16 L2 fusion protein, 
followed by mass spectrometry (MS) analysis to identify co-purified proteins. In a second approach 
(Figure 7, B Co-Immunoprecipitation (Co-IP)), HPV16 L2 and its potential interaction partners were 
(co-)purified by immunoprecipitation (IP), from cells previously infected with HPV16 PsV. L2-specific 
and L1-specific antibodies were used for precipitation and the co-purified set of proteins was further 
analyzed by MS. Based on the identification of (cross-) neutralizing epitopes (aa 20-38, aa 28-42 and 
aa 64-81) at the N-terminal part of HPV16 L2 [30], the third approach (Figure 7, C Peptide Pull Down 
(PPD)) of the thesis relied on the immobilization of the corresponding epitopes and the identification 
of potential interaction partners by pull-down from cellular extracts. This approach should provide 
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further insight into the function of the specific epitopes within the L2 protein and their role during 
viral infection.  
 
Figure 7 Overview of the PhD thesis workflow. Potential interaction candidates of HPV16 L2 were identified, using three 
independent approaches. A Tandem Affinity Purification, based on the overexpression of a TAP-tagged HPV16 L2 protein 
and the co-puification of interacting proteins. B Co-immunoprecipitation (IP) of HPV16 capsids from cells infected with 
HPV16 PsV and co-purification of potential binding partners. C Peptide Pull Down (PPD), focusing on three biotinylated 
HPV16 L2 epitopes, immobilized on avidin beads and further used for pull-down of interacting proteins from cell extracts. 
To validate potential candidates, the candidates were overexpressed and analyzed in either an alternative precipitation 
method for binding to L2 or immunofluorescence (IF) for co-localization with L2. Additionally, the candidates were down 
regulated by siRNA or shRNA and transduction efficiency of HPV16 PsV was analyzed. Potential binding sites were identified 
by in silico analysis using the eukaryotic linear motif (ELM) online tool. Further investigations on the mechanism have not 
been executed during the experimental phase of the PhD thesis.    
Identified interaction candidates were further validated for their ability to physically bind HPV16 L2 
by alternative precipitation methods and co-localization by immunofluorescence. In addition, HPV16 
PsV transduction was analyzed after downregulation of the expression levels of distinct candidates 
by siRNA and shRNA, respectively. In order to identify potential interaction sites of the validated 
candidates, L2 protein sequences of different low and high risk HPV types were analyzed using the 
eukaryotic linear motif (ELM) online tool for in silico analysis.  Further investigations on the 
mechanism of the corresponding interactions, like the mutation of identified binding sites and the 
analysis of specific steps of the viral life cycle, have not been executed during the thesis. 
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2. Material 
2.1. Biological Material 
2.1.1. Prokaryotic Cells 
Strain Genotyp Company 
E.coli MegaX 
DH10αTM T1R 
F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara leu)7697 
galU galK λ– rpsL nupG tonA 
Invitrogen 
E.coli Solo Pack Gold 
Competent Cells 
Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
Hte [FÅL proAB lacIqZΔM15 Tn10 (TetR)Amy 
CamR] 
Stratagene, Agilent 
Technologies 
E.coli RosettaTM  
F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 
(CamR) 
Merck4Biosciences 
E.coli SURE (Stop 
Unwanted 
Rearrangement 
Events) Competent 
Bacteria 
e14-(McrA-) Δ(mcrCB-hsdSMR-mrr)171 endA1 
gyrA96 thi-1 supE44 relA1 lac recB recJ sbcC 
umuC::Tn5 (KanR) uvrC 
[F´ proAB lacIqZΔM15 Tn10 (Tetr)] 
Stratagene, Agilent 
Technologies 
2.1.2. Eukaryotic Cells 
Cell Line Description 
HaCaT 
Keratinocyte cell line derived from adult human skin. Spontaneously transformed 
and immortal cell line. Described as aneuploid. Culture medium: supplemented 
DMEM  
HEK 293 
Human embryonic kidney cells derived from a healthy aborted human embryo and 
transformed with E1A/B of Adenovirus 5. Described as hypotriploid. Culture 
medium: supplemented DMEM  
HEK 293TT 
HEK 293 cells stably expressing two copies of the Simian virus (SV) 40 large T-
antigen. Cultured under selective conditions using 62,5µM Hygromycin B. Culture 
medium: supplemented DMEM  
HeLa 
Immortal cell line derived from HPV18 positive human cervical carcinoma of 
Henrietta Lacks. The cells are hypertriploid (3n+). Culture medium: supplemented 
DMEM 
HeLa T 
HeLa cells stably expressing one copy of the Simian virus (SV) 40 large T-antigen. 
Cultured under selective conditions using 125µM Hygromycin B. Culture medium: 
supplemented DMEM 
Phoenix 
Phoenix cells are derived from HEK 293T cells. Constructs capable of producing gag-
pol as well as envelope proteins were introduced into the 293T cells. Therefore the 
cells stably express lentiviral packaging proteins and can be used for Lentivirus 
production. Culture medium: high glucose DMEM, supplemented with 10% FCS, 1% 
P/S, 1% glutamine and 10µg/ml ciprofloxacin 
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2.1.3. Pseudoviruses (PSV) 
HPV type Reporter Plasmid Source 
HPV16 Gaussia Luciferase, GFP #988 #1998 N. Thönes/M. Müller 
HPV18 Gaussia Luciferase, GFP #1165 #1166 #1998 J. Schiller/M. Müller 
HPV31 Gaussia Luciferase, GFP #1698 #1998 J. Schiller/C. Buck/M. Müller 
HPV45 Gaussia Luciferase, GFP #2271 #2273 #1998 I. Rubio/M. Müller 
2.1.4. Adeno-associated Viruses (AAV) 
AAV type Reporter Plasmid Source 
AAV2 Gaussia Luciferase, ssDNA #2772 #1814 #3193 A. Sacher/M. Müller 
AAV2 Gaussia Luciferase, scDNA #2772 #1814 #2485 A. Sacher/M. Müller 
2.1.5. Lentiviruses 
shRNA Packaging Plasmids Source 
#3311 pLKO.1 SHC002 shRNA ctrl. #3294 #3295 #3296 This thesis 
#3312 pLKO.1 SHC003 GFP turbo #3294 #3295 #3296 This thesis 
#3344 IRS4_2 shRNA #3294 #3295 #3296 This thesis 
#3345 YWHAZ_1 shRNA #3294 #3295 #3296 This thesis 
#3347 CSE1L_1 shRNA #3294 #3295 #3296 This thesis 
#3348 SPOP_1 shRNA #3294 #3295 #3296 This thesis 
2.2. Media and Supplements 
2.2.1. Procaryotic Cells 
Designation Composition 
Agar Plates 
98,5% LB medium (v/v) 
1.5% bacto-agar (w/v) 
autoclaved 
antibiotics added when < 40⁰C 
Luria Broth (LB) medium 
1% Trypton (w/v) 
0.5% Yeast Extract (w/v) 
0.5% NaCl (w/v) 
in H2O, pH 7.5 
autoclaved 
Antibiotics 
Ampicilin (Amp): 100mg/ml 
Kanamycin (Kan): 25mg/ml 
Zeocin (Zeo): 100mg/ml 
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2.2.2. Eukaryotic Cells 
Media Company 
Dulbecco´s Modified Eagle Medium (DMEM) 
Sigma-Aldrich, Deisenhofen, 
Germany 
 
Supplements Concentration Company 
FCS  PAN Biotec, Aidenbach, Germany 
L-glutamin (200mM) 200mM Genaxxon, Ulm, Germany 
Penicillin/Streptomycin  
(10.000 units/ml Pen and 
10.000µg/ml Strep) 
10.000U/ml Gibco Life Technologies, Paisley, UK 
2.3. Molecular Cloning 
2.3.1. Oligonucleotides for Cloning of HPV16L2 Fragments for TAP 
As template DNA for the PCR of the following HPV16L2 fragments, #893 pUF3 containing the 
humanized HPV16L2 full-length sequence were used.  
BamHI restriction sites were added to the primer sequences, to allow cloning of the amplified DNA 
sequences into the destination vector #2175 pZOME1_C. To improve translation of the HPV16L2 
fragments, the Kozak sequences was included into the forward primer sequences of HPV16L2_Fr2  
(aa 129-334) and HPV16L2_Fr3 (aa 262-473). 
Designation Sequence 5´-3´ 
HPV16L2_Fr1 (aa 1-193)F CTTTGGATCCGCCACCATGAGGCACAAG     
HPV16L2_Fr1 (aa 1-193)R CTTTGGATCCGTAGTTGTGGGTGCTGATGG      
HPV16L2_Fr2 (aa 129-334)F ATTTGGATCCGCCACCATGGACGTGAGCGGCTTCAGCATCACC    
HPV16L2_Fr2 (aa 129-334)R CTTTGGATCCGGTGCTCAGGTCGTAGTAGTAGTG 
HPV16L2_Fr3 (aa 262-473)F CTTTGGATCCGCCACCATGGACGTGGACAACACCCTGTACTTC 
HPV16L2_Fr3 (aa 262-473)R ATTTGGATCCCGCGGCCAGGCTCACG 
highlighted in blue, BamHI restriction site 
highlighted in green, Kozak sequence 
2.3.2. Oligonucleotides for siRNA knockdown 
Designation Taget Sequence Order # (Qiagen, Hilden, Germany) 
Hs-SNX17_1 Flexi tube siRNA CTGGCCCTCGATGCCAAAT SI00107877 
Hs-SNX17_2 Flexi tube siRNA CAGCGAGACTTTCAACAGT SI00107884 
Hs-SNX17_3 Flexi tube siRNA CTCCGCCTACGTGGCCTAT SI00107891 
Hs-SNX17_5 Flexi tube siRNA TACATGCAAGCTGTTCGGC SI03108378 
Hs-IRS4_3 Flexi tube siRNA GAGGGTGACTACATTGAAG SI00053494 
Hs-IRS4_5 Flexi tube siRNA GCGGCGCGTGATCACCCTA SI02631398 
Hs-IRS4_6 Flexi tube siRNA CAGCTCTAGTGACTACGTC SI03068226 
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Hs-IRS4_7 Flexi tube siRNA CAGGCGCTACTTCGTGCTC SI03070620 
Hs-YWHAZ_3 Flexi tube siRNA CAGGTTTATGTTACTTCTA SI00764813 
Hs-YWHAZ_6 Flexi tube siRNA Sequence not provided SI04135663 
Hs-YWHAZ_7 Flexi tube siRNA Sequence not provided SI04295375 
Hs-YWHAZ_8 Flexi tube siRNA Sequence not provided SI04330900 
Hs-CSE1L_2 Flexi tube siRNA CTGACGGTATCAAATATAT SI00025298 
Hs-CSE1L_3 Flexi tube siRNA Sequence not provided SI00025305 
Hs-CSE1L_4 Flexi tube siRNA CAAATGAACTTGTAAACCT SI00025312 
Hs-CSE1L_7 Flexi tube siRNA CAGGATAATGTTATCAAAG SI02654015 
Hs-CAPN2_4 Flexi tube siRNA CTGGAACACTATAGACCCA SI00338114 
Hs-CAPN2_5 Flexi tube siRNA CACCAGCGATACCTACAAG SI03057306 
Hs-CAPN2_6 Flexi tube siRNA CTCGGAGGCCATCACGTTT SI03091648 
Hs-CAPN2_8 Flexi tube siRNA Sequence not provided SI05168996 
Hs-SPOP_2 Flexi tube siRNA CAGGCTCACAAGGCTATCT SI00732214 
Hs-SPOP_6 Flexi tube siRNA Sequence not provided SI04137630 
Hs-SPOP_8 Flexi tube siRNA Sequence not provided SI04327155 
AllStars negative control siRNA Sequence not provided SI03650318 
2.3.3. Oligonucleotides for shRNA knockdown 
All oligonucleotides listed, were ordered and produced at MWG Eurofins in Ebersberg, Germany. 
Designation Sequence 5´-3´ 
IRS4_1 fwd CCGGGCGGAGCCACCCTTCTATAAACTGCAGTTTATAGAAGGGTGGCTCCGCTTTTTG 
IRS4_1 rev AATTCAAAAAGCGGAGCCACCCTTCTATAAACTGCAGTTTATAGAAGGGTGGCTCCGC 
IRS4_2 fwd CCGGCTGAGTGCTGTATGGATATTTCTGCAGAAATATCCATACAGCACTCAGTTTTTG 
IRS4_2 rev AATTCAAAAACTGAGTGCTGTATGGATATTTCTGCAGAAATATCCATACAGCACTCAG 
YWHAZ_1 fwd CCGGGCAGAGAGCAAAGTCTTCTATCTGCAGATAGAAGACTTTGCTCTCTGC-TTTTTG 
YWHAZ_1 rev AATTCAAAAAGCAGAGAGCAAAGTCTTCTATCTGCAGATAGAAGACTTTGCTCTCTGC 
YWHAZ_2 fwd CCGGGCTCGAGAATACAGAGAGAAACTGCAGTTTCTCTCTGTATTCTCGAGCTTTTTG 
YWHAZ_2 rev AATTCAAAAAGCTCGAGAATACAGAGAGAAACTGCAGTTTCTCTCTGTATTCTCGAGC 
CSE1L_1 fwd CCGGCGCTGACAAGTATCTGTGAAACTGCAGTTTCACAGATACTTGTCAGCGTTTTTG 
CSE1L_1 rev AATTCAAAAACGCTGACAAGTATCTGTGAAACTGCAGTTTCACAGATACTTGTCAGCG 
CSE1L_2 fwd CCGGGCATGGAATTACACAAGCAAACTGCAGTTTGCTTGTGTAATTCCATGCTTTTTG 
CSE1L_2 rev AATTCAAAAAGCATGGAATTACACAAGCAAACTGCAGTTTGCTTGTGTAATTCCATGC 
SPOP_1 fwd CCGGCACAAGGCTATCTTAGCAGCTCTGCAGAGCTGCTAAGATAGCCTTGTGTTTTTG 
SPOP_1 rev AATTCAAAAACACAAGGCTATCTTAGCAGCTCTGCAGAGCTGCTAAGATAGCCTTGTG 
SPOP_2 fwd CCGGCTCCTACATGTGGACCATCAACTGCAGTTGATGGTCCACATGTAGGAGTTTTTG 
SPOP_2 rev AATTCAAAAACTCCTACATGTGGACCATCAACTGCAGTTGATGGTCCACATGTAGGAG 
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2.3.4. Plasmids 
Designation Description Reference 
#3 Bluescript KS empty M. Müller 
#893 pUF3 with HPV16L2 M. Müller 
#988 pCDNA 4.0 TO with HPV16 L1 and L2 (IRES)  M. Müller 
#1998 pGF with Gaussia luciferase and GFP C. Buck 
#2175 pZOME1-C eukaryotic vector for TAP M. Müller 
#2459 pZOME1-C with HPV16L2 TAP-tag H. Seitz 
#2800 pZOME1-C with HPV16L2_Fr1 (aa 1-193)  This thesis 
#2801 pZOME1-C with HPV16L2_Fr3 (aa 262-473) This thesis 
#2873 pZOME1-C with HPV16L2_Fr2 (aa 130-334)  This thesis 
#2957 
pDEST15 E.coli expression vector (GST-Tag) Gateway 
compatible 
GPCF, DKFZ 
#2958 
pDEST Mammalian expression vector (N-terminal 
Myc), Gateway compatible 
GPCF, DKFZ 
 
#2959 
pDEST Mammalian expression vector (N-terminal 
Flag), Gateway compatible  
 
GPCF, DKFZ 
#2960 
pDEST Mammalian expression vector (w/o tag), 
Gateway compatible 
GPCF, DKFZ 
#3136 
CSE1L cDNA (closed) in pENTR221, Gateway 
compatible 
GPCF, DKFZ 
#3137 Skp1 cDNA (closed) in pENTR221, Gateway compatible GPCF, DKFZ 
#3138 
YWHAZ cDNA (closed) in pENTR221, Gateway 
compatible 
GPCF, DKFZ 
#3139 
HNRNPK cDNA (closed) in pENTR221, Gateway 
compatible 
GPCF, DKFZ 
#3140 
PSMD12 cDNA (closed) in pENTR221, Gateway 
compatible 
GPCF, DKFZ 
#3142 PSMD12 in pDEST w/o tag (#3140 in 2960)  This thesis 
#3143 Skp1 in pDEST w/o tag (#3137 in 2960)  This thesis 
#3144 CSE1L in pDEST w/o tag (#3136 in 2960) This thesis 
#3145 YWHAZ in pDEST w/o tag (#3138 in 2960)  This thesis 
#3146 HNRNPK in pDEST w/o tag (#3139 in 2960) This thesis 
#3147 N-GST-PSMD12 in pDEST (#3140 in 2957) This thesis 
#3148 N-GST-CSE1L in pDEST (#3136 in 2957)  This thesis 
#3149 N-GST-HNRNPK in pDEST (#3139 in 2957)  This thesis 
#3150 N-Flag-PSMD12 in pDEST (#3140 in 2959)  This thesis 
#3151 N-Flag-Skp1 in pDEST (#3137 in 2959) This thesis 
#3152 N-Flag-CSE1L in pDEST (#3136 in 2959)  This thesis 
#3153 N-Flag-YWHAZ in pDEST (#3138 in 2959)  This thesis 
#3154 N-Flag-HNRNPK in pDEST (#3139 in 2959)  This thesis 
#3155 N-Myc-PSMD12 in pDEST (#3140 in 2958)  This thesis 
#3156 N-Myc-CSE1L in pDEST (#3136 in 2958)  This thesis 
#3157 N-Myc-YWHAZ in pDEST (#3138 in 2958)  This thesis 
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#3158 N-Myc-HNRNPK in pDEST (#3139 in 2958)  This thesis 
#3159 N-Myc-Skp1 in pDEST (#3137 in 2958)  This thesis 
#3185 
eEF1A1 cDNA (closed) in pENTR221, Gateway 
compatible 
GPCF, DKFZ 
#3186 IRS4 cDNA (closed) in pENTR223, Gateway compatible GPCF, DKFZ 
#3188 N-Myc-IRS4 in pDEST (#3186 in #2958) This thesis 
#3189 N-Myc-eEF1A1 in pDEST (#3185 in #2958) This thesis 
#3190 N-Flag-eEF1A1 in pDEST (#3185 in #2959) This thesis 
#3191 N-Flag-IRS4 in pDEST (#3186 in #2959) This thesis 
#3199 N-GST-HNRNPK in pDEST (#3139 in #2957)  This thesis 
#3200 N-GST-CSE1L in pDEST (#3139 in #2957)  This thesis 
#3265 SNX17-GFP Dr. Lawrence Banks 
#3266 SNX-Flag Dr. Lawrence Banks 
#3294 pMDLg/pRRE (Gag/Pol) Addgene, Plasmid #12251 
#3295 pRSV-Rev (Rev) Addgene, Plasmid #12253 
#3296 pMD2.G (VSV G) Addgene, Plasmid #12259 
#3311 
pLKo.1 SHC002 shRNA ctrl. (non-mammalian shRNA 
control) 
Sigma-Aldrich, 
Deisenhofen, 
Germany 
#3312 pLKO.1 SHC003 GFP turbo (positive control) 
Sigma-Aldrich, 
Deisenhofen, Germany 
#3310 pLKO.1 TRC control Addgene, Plasmid #10879 
#3343 IRS4_1 shRNA in pLKO.1 TRC control This thesis 
#3344 IRS4_2 shRNA in pLKO.1 TRC control This thesis 
#3345 YWHAZ_1 shRNA pLKO.1 TRC control This thesis 
#3347 CSE1L_1 shRNA pLKO.1 TRC control This thesis 
#3348 SPOP_1 shRNA pLKO.1 TRC control This thesis 
2.3.5. Enzymes 
Designation Company 
Calf intestine alkaline phosphatase (CIP) New England Biolabs, Frankfurt, Germany 
KOD HiFi Polymerase Novagen/Merck, Darmstadt, Germany 
Quick Ligase New England Biolabs, Frankfurt, Germany 
Restriction enzymes New England Biolabs, Frankfurt, Germany 
RNAse Roche, Mannheim, Germany 
T4 DNA Ligase  New England Biolabs, Frankfurt, Germany 
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2.3.6. Buffers and Solutions for DNA Purification and Analysis 
2.3.6.1. Purification of plasmid DNA  
Designation Composition 
Alkali lysis buffer 
200mM NaOH 
1% SDS (w/v) 
in H2O 
Chloroform-isoamyl alcohol mix (CIA) Chloroform-isoamyl alcohol mix 24:1 
Glucose buffer 
50mM glucose 
10mM EDTA 
25mM Tris HCl 
in H2O, pH 8.0 
Phenol mix 
Phenol-CIA mix 1:1 
100µg hydroxyquinoline per 100ml 
Sodium acetate 
3M sodium acetate 
in H2O, pH 5.2 
1x TE buffer 
10mM Tris 
1mM EDTA 
in H2O, pH 8.0 
2.3.6.2. Agarose Gel Electrophoresis 
Designation Composition/Company 
1% agarose gel 
1% agarose (w/v) 
1x TAE buffer 
0.006% ethidium bromid (v/v)  
Ethidium bromide Roth, Karlsruhe, Germany 
Lambda/HindII marker New England Biolabs, Frankfurt, Germany 
6x loading buffer New England Biolabs, Frankfurt, Germany 
1x TAE buffer 
40mM Tris 
5.71% acetic acid (v/v) 
10% 500mM EDTA, pH 8.0 (v/v) 
in H2O 
Quick-LoadTM 100bp DNA ladder New England Biolabs, Frankfurt, Germany 
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2.4. Buffers and Solutions for Protein Analysis 
2.4.1. SDS-polyacrylamid gels 
Designation Composition 
12.5% separation gel for 5 mini gels 
18.75ml 30% acrylamide solution 
16.88ml 1M Tris/HCl buffer, pH 8.8 
8.48ml H2O 
450µl 10% SDS 
450µl 10% APS 
22.5µl TEMED 
3% stacking gel for 5 mini gels 
1.5ml 30% acrylamide solution 
1.95ml 1M Tris/HCl buffer, pH 6.8 
11.25ml H2O 
150µl 10% SDS 
150µl 10% APS 
22.5µl TEMED 
2.4.2. Electrophoresis 
Designation Composition 
3x protein loading buffer 
30% glycerol 
6% SDS 
15% β-mercaptoethanol 
0.003% bromphenol blue 
187.5mM Tris 
in H2O, pH 6.8 
1x TGS buffer (running buffer) 
2.5mM Tris 
1.45% glycine 
0.1% SDS 
in H2O, pH 8.3 
Tris buffer pH 6.8 
1M Tris/HCl 
0.03% bromphenol blue 
in H2O, pH 6.8 
Tris buffer pH 8.8 
1M Tris/HCl 
in H2O, pH 8.8 
2.4.3. Western Blot Analysis 
Designation Composition 
Blocking buffer 
5% skim milk 
in PBS-T 
1x EMBL buffer 
48mM Tris 
39mM glycine 
1.3mM SDS 
20% methanol 
in H2O, pH 8.2 
1x PBS-T 
0.3% Tween 20 (v/v) 
in 1x PBS 
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2.5. Immunological Methods 
2.5.1. Antibodies 
Designation Description Reference 
14-3-3 ζ (C-
16): sc-1019 
Polyclonal rabbit antibody detecting human YWHAZ. 
Reactive in ELISA, WB, IF, IP and IHC(P). 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
Actin (C4) 
Mouse monoclonal antibody detecting human actin. 
The detected epitope lies between amino acid 18-40. 
Reactive in WB, IF and IHC. 
MP Biomedicals, Solon, 
USA 
AlexaFlour488 
(anti-mouse) 
Goat-anti-mouse coupled with AlexaFlour 488 
Life Technologies, 
Darmstadt, Germany 
AlexaFlour488 
(anti-rabbit) 
Goat-anti-rabbit coupled with AlexaFlour 488 
Life Technologies, 
Darmstadt, Germany 
AlexaFlour594 
(anti-mouse) 
Goat-anti-mouse coupled with AlexaFlour 594 
Life Technologies, 
Darmstadt, Germany 
AlexaFlour 
594 
(anti-rabbit) 
Goat-anti-rabbit coupled with AlexaFlour 594 
Life Technologies, 
Darmstadt, Germany 
Calpain 2 
(CAPN2) 
Mouse monoclonal, used as hybridoma supernatant. 
Reactive in ELISA, WB and IF. 
This thesis 
CAS (H-2):  
sc-271537 
Mouse monoclonal antibody detecting human CSE1L. 
Raised against amino acid 672-971. Reactive in ELISA, 
WB, IF and IP. 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
DAGPO Donkey-anti-goat coupled with HRP 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
GAMPO Goat-anti-mouse coupled with HRP 
Dianova, Hamburg, 
Germany 
GARPO Goat-anti-rabbit coupled with HRP 
Dianova, Hamburg, 
Germany 
Anti-IRS4  
06-771 
Polyclonal rabbit antibody detecting human IRS4. 
Raised against amino acid 1240-1257. Reactive in WB 
and IP. 
Merck Millipore, 
Darmstadt, Germany 
K1L2 
Mouse monoclonal antibody detecting amino acid 74-
77 of HPV16 L2. Reactive in ELISA, WB, and IF. 
I. Rubio/M.Müller 
K4L2 
Mouse monoclonal antibody, detecting amino acid 21-
31 of HPV16 L2. Reactive in ELISA, WB, and IF. 
I. Rubio/M.Müller 
K8L2 
Mouse monoclonal antibody, detecting amino acid 32-
38 of HPV16 L2. Reactive in ELISA, WB, and IF. 
I. Rubio/M.Müller 
K18L2 
Mouse monoclonal antibody, detecting amino acid 22-
30 of HPV16 L2. Reactive in ELISA, WB, and IF. 
I. Rubio/M.Müller 
MD2H11 
Mouse monoclonal antibody, recognizing HPV16 L1 in 
WB, ELISA and IF 
M. Durchdewald/ 
M.Müller 
Myc 
hybridoma 
9E10 mouse monoclonal antibody, raised against myc. 
Used as hybridoma snt. Reactive in WB and IF. 
 
Myc (9E10) 
Mouse monoclonal antibody detecting the epitope 
EQKLISEEDL of human c-myc. 
New England Biolabs, 
Frankfurt, Germany 
Myc (71D10) 
Rabbit monoclonal antibody detecting the epitope 
EQKLISEEDL of human c-myc. 
Cell Signaling Technology, 
Leiden, Netherlands 
Serum #7 
Polyclonal serum derived from a rabbit immunized 
with HPV16 L2-GST. 
M. Müller 
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SNX17 (H-10): 
sc-166957 
Mouse monoclonal antibody detecting SNX17, amino 
acid 270-470. Reactive in ELISA, WB, IF and IP. 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
SPOP (B-8):  
sc-377206 
Mouse monoclonal antibody detecting human SPOP. 
Raised against amino acid 351-374. Reactive in ELISA, 
WB, IF and IP. 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
SPOP (C-14):  
sc-66649 
Goat polyclonal antibody detecting an epitope at the 
C-terminus of human SPOP. Reactive in ELISA, WB, IF 
and IP. 
Santa Cruz Biotechnology, 
Heidelberg, Germany 
2.5.2. Immunoprecipitation (IP) from PSV Infected Cells 
2.5.2.1. Buffers and Solutions 
Designation Composition 
Acetate buffer 
100mM NaAc 
500mM NaCl 
In H2O, pH 4.0 
Blocking buffer 
100mM Tris/HCl 
in H2O, pH 8.0 
Coupling buffer 
100mM NaHCO3 
500mM NaCl 
in H2O, pH 8.3 
EBC lysis buffer 
50mM Tris/HCl pH 8.0 
120mM NaCl 
0.5% NP-40 
1x protease inhibitor tablet (Roche) per 7ml 
in H2O 
3x Loading buffer w/o β-mercapthoethanol  
30% glycerol 
6% SDS 
0.003% bromphenol blue 
187.5mM Tris 
in H2O, pH 6.8 
NET-N buffer 
20mM Tris/HCl, pH 8.0 
100mM NaCl 
1mM EDTA 
1% NP-40 
2.5.2.2. Beads 
Designation Company 
CNBr Activated Sepharose® 4 Fast Flow GE Healthcare, Buckinghamshire, UK 
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2.5.3. Immunoprecipitation (IP) of Overexpressed Proteins 
2.5.3.1. Buffers and Solutions 
Designation Composition 
Non-denaturing lysis buffer (NDLB) 
20mM Tris-HCl, pH 8.0 
137mM NaCl 
10% glycerol 
1% NP-40 
2mM EDTA 
1x protease inhibitor tablet (Roche) per 7ml 
in H2O 
NET-N buffer 
20mM Tris-HCl, pH 8.0 
100mM NaCl 
1mM EDTA 
1% NP-40 
2.5.3.2. Beads 
Designation Company 
GammaBindTM Plus SepharoseTM GE Healthcare, Buckinghamshire, UK 
2.5.4. Immunofluorescence (IF) 
Designation Composition/Company 
Blocking Solution 
1% BSA (w/v) 
in 1x PBS 
DAPI 
100mg/ml 
in 1x PBS 
Fixation Solution 
2% PFA (w/v) 
in 1x PBS 
Mounting medium 
Dianova, Hamburg, 
Germany 
Permeabilization Solution 
0.2% TritonX-100 (v/v) 
in 1x PBS 
Quenching Solution 
50mM Ammoniumchloride 
in 1x PBS 
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2.5.5. Enzyme-linked Immunosorbant Assay (ELISA) 
2.5.5.1. Buffers and Solutions 
Designation Composition 
ABTS 
10mg/ml 2,2´-azino-bis 
(3-ethyl-benzothiazoline-6-sulfonate) 
in H2O 
Blocking buffer 
2% Casein (w/v) 
in 1xPBS 
Coating buffer 
2,5µg/ml Streptavidin 
in H2O 
ELISA substrate buffer 
100mM NaOAc 
50mM NaH2PO4 
 in H2O, pH 4.2 
Streptavidin (1mg/ml) 
250µg/ml streptavidin 
in H2O 
Substrate solution (volume per plate) 
9,5ml ELISA substrate buffer 
0.5ml ABTS 
 4µ H2O2 
2.5.5.2. Peptides 
Designation Sequence Company 
HPV16L2 aa20-38 Biotin-KTCKQAGTCPPDIIPKVEG PSL GmbH, Heidelberg, Germany 
HPV16L2 aa28-42 Biotin-CPPDIIPKVEGKTIA PSL GmbH, Heidelberg, Germany 
HPV16L2 64-82 Biotin-SGTGGRTGYIPLGTRPPT PSL GmbH, Heidelberg, Germany 
2.6. Tandem-Affinity Purification (TAP) 
2.6.1. Buffers and Solutions 
Designation Composition 
Calmodulin binding buffer 
10mM Tris-HCl, pH 8.0 
150mM NaCl 
1mM MgOAc 
1mM Imidazole 
0.1% NP-40 
2mM CaCl2 
10mM β-mercaptoethanol (to be added freshly) 
in H2O 
Calmodulin elution buffer 
50mM NH4HCO3, pH 8.0 
25mM EGTA 
in H2O 
Calmodulin wash buffer 
50mM NH4HCO3, pH 8.0 
75mM NaCl 
1mM MgOAc 
1mM Imidazole 
2mM CaCl2 
in H2O  
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Lysis Buffer 
10% glycerol 
50mM Tris-HCl, pH 8.0 
100mM KCl 
0.1% NP-40 
2mM DTT (to be added freshly) 
1x protease inhibitor tablet (Roche) per reaction 
in H2O 
TEV-buffer 
10mM Tris-HCl, pH 8.0 
150mM NaCl 
0.1% NP-40 
0.5mM EDTA 
1mM DTT (to be added freshly) 
in H2O 
2.6.2. Beads 
Designation Company 
Calmodulin Seoharose 4B GE Healthcare, Buckinghamshire, UK 
IgG SepharoseTM 6 Fast Flow GE Healthcare, Buckinghamshire, UK 
2.7. Peptide Pull Down (PPD) 
2.7.1. Buffers and Solutions 
Designation Composition 
EBC lysis buffer 
50mM Tris/HCl pH 8.0 
120mM NaCl 
0.5% NP-40 
1x protease inhibitor tablet (Roche) per 7ml 
in H2O 
Glycine 
100mM glycine pH 2.8 
in H2O 
PBS 
137mM NaCl 
2,7mM KCl 
4,3mM Na2HPO4 
1,47mM KH2Po4 pH 7.4 
in H2O 
Sodium azide 
10% sodium azide (w/v) 
 in H2O 
TritonX-100 
20% TritonX-100 (v/v) 
 in H2O 
2.7.2. Beads 
Designation Company 
PierceTM Avidin Agarose Thermo Scientific, Schwerte, Germany 
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2.7.3. Peptides 
Designation Sequence Company 
HPV16L2 aa20-38 Biotin-KTCKQAGTCPPDIIPKVEG PSL GmbH, Heidelberg, Germany 
HPV16L2 aa28-42 Biotin-CPPDIIPKVEGKTIA PSL GmbH, Heidelberg, Germany 
HPV16L2 64-82 Biotin-SGTGGRTGYIPLGTRPPT PSL GmbH, Heidelberg, Germany 
2.8. Pseudovirus Production 
2.8.1. Material 
Designation Company 
Benzonase (100.000 U/ml) Merck, Darmstadt, Germany 
Brij58 Sigma-Aldrich, Taufkirchen, Germany 
1x DPBS Gibco Life Technologies, Paisley, UK 
OptiPrepTM (60% w/v) Sigma-Aldrich, Taufkirchen, Germany 
RNase A/T1 mix Fermentas Thermo Scientific, St.Leon-Rot, Germany 
TurbofectTM transfection reagent Fermentas Thermo Scienific, St.Leon-Rot, Germany 
2.8.2. Buffers and Solutions 
Designation Composition/Company 
Brij58 
10% Brij58 (w/v) 
in H2O 
Lysis buffer 
140µl DPBS 
9µl 10% Brij58 
1µl RNase A/T1 mix 
NaCl 
5M NaCl 
in H2O 
2.9. Lentivirus Production 
2.9.1. Buffers and Solutions 
Designation Composition/Company 
Polyethylenimine (PEI) transfection reagent 
1mg/ml PEI 
in H2O, pH 7.0-7.4 
 
Polyscience Inc., Eppelheim, Germany 
1x Phosphate buffered saline (PBS) 
137mM NaCl 
27mM KCl 
10mM Na2HPO4 
1.8mM KH2PO4 
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2.10. Chemicals 
All chemicals were of analytical grade or better and purchased from one of the following companies. 
Company Location 
Applichem Darmstadt, Germany 
Fulka Neu-Ulm, Germany 
Gibco BRL Eggenstein, Germany 
Life Technologies Karlsruhe, Germany 
Fisher-Scientific Schwerte, Germany 
Merck Darmstadt, Germany 
Roche Diagnostics Mannheim, Germany 
Roth Karlsruhe, Germany 
Serva Heidelberg, Germany 
Sigma-Aldrich Munich, Germany 
2.11. Kits 
Designation Company 
Chemiluniscence Kit PicoDetect Applichem, Darmstadt, Germany 
Gaussia Glow-juice BIG Kit PJK, Kleinbittersdorf, Germany 
Qiagen MaxiPrep Kit  Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
StrataClone Blunt PCR Cloning Kit 
Stratagene Agilent Technologies, La Jolla, 
USA 
2.12. Laboratory Equipment 
2.12.1. Electrical Equipment 
Designation Company 
1420 Multilabel Counter Viktor Perkin Elmar, Norwalk, USA 
800 W microwave Bosch, Gerlingen-Schillerhohe, Germany 
Bacterial culture shaker Informs AG, Bottmingen, Switzerland 
Beckmann XL70 Ultracentrifuge Beckmann Coulter, Krefeld, Germany 
Bio GARD cell culture hood The Baker Company, Sanford, USA 
C1000™ Touch Thermal Cycler BioRad, Munich, Germany 
Combimag Red/RET magnetic stirrer IKA, Staufen, Germany 
Developing Machine AgfaCurix60   Agfa, Munich, Germany 
Duomax 1030 shaker Heidolph, Kelheim, Germany 
EconoPump BioRad, Munich, Germany 
Material 
 
33 
 
Electrophoresis chamber Carl Roth GmbH, Karlsruhe, Germany 
Electrophoresis gel slides Carl Roth GmbH, Karlsruhe, Germany 
Electrophoresis power supply ST 606 T Gibco BRL, Eggenstein,  Germany 
Electrophoresis power supply ST PS 305 Gibco BRL, Eggenstein, Germany 
F12-6x500 Rotor Thermo Scientific, Waltham, USA 
Function Line incubator Heraeus, Hanau, Germany 
Gel Doc EZ Imager BioRad, Munich, Germany 
GFC water bath Grant Instruments, Cambridge, UK 
Horizontal Gel Electrophoresis Horizon 11.14 Gibco BRL, Eggenstein, Germany 
Ice maker Hoshizaki, Willich-Munchheide, Germany 
Impulse Sealer RNS Corp, Taipei, Taiwan 
Incubator Innova 4230 New Brunswick Scientific, Edison, USA 
Integra pipetboy Integra Bioscience GmbH, Fernwald, Germany 
Labotect CO2 incubator  Labotect, Göttingen, Germany 
Leica DMIL microscope Leica Microsystems, Wetzlar, Germany 
Liebherr Comfort Liebherr, Biberach, Germany 
Liebherr MedLine Liebherr, Biberach, Germany 
Liebherr Premium Liebherr, Biberach, Germany 
Liebherr ProfiLine Liebherr, Biberach, Germany 
Megafuge 1.0 Heraeus, Hanau, Germany 
Megafuge 1 S-R Heraeus, Hanau, Germany 
MicroPulser™ Electroporator BioRad, Munich, Germany 
Microscope for cell culture Diavert Leitz, Wetzlar, Germany 
Microscope for cell culture Wilorat S Helmut Hund, Wetzlar, Germany 
MilliQ ultra-pure water unit Millipore Merck, Darmstadt, Germany 
MR 2000/2002 magnetic stirrer Heidolph, Kelheim, Germany 
Multifuge 1 S-R Heraeus, Hanau, Germany 
Multiskan GO (ELISA reader) Thermo Scientific, Waltham, USA 
Nanodrop spectrophotometer PegLab, Erlangen, Germany 
Neubauer Counting Chamber Neolab Migge, Heidelberg, Germany 
Nitrogen tank Chrono Messer, Krefeld, Germany 
pH meter Sartorius, Göttingen, Germany 
Polyacrylamid Gel Electrophoresis Chamber Hoefer, San Francisco, USA 
PreCision 50-1200µl (multichannel) Biozym, Hessisch-Oldendorf, Germany 
Refrigerated Sorvall RC6+ centrifuge Thermo Scientific, Waltham, USA 
Refrigerated tabletop centrifuge 5417R Eppendorf, Hamburg, Germany 
Refrigerators and freezers Liebherr, Ochsenhausen, Germany 
Research Pro 1200 (multichannel) Eppendorf, Hamburg, Germany 
Research Pro 300 (multichannel) Eppendorf, Hamburg, Germany 
Sanyo CO2 icubator Sanyo/Panasonic Healthcare 
Sartorius Scale Sartorius, Göttingen, Germany 
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Sterile GARDR III Advance cell culture hood The Baker Company, Sanford, USA 
SW32-Ti Beckman Coulter, Krefeld, Germany 
SW41-Ti Beckman Coulter, Krefeld, Germany 
Tabletop centrifuge 5415 C Eppendorf, Hamburg, Germany 
Test-tube rotator Snijders Scientific, Tilburg, Netherlands 
TH-604 Thermo Scientific, Waltham, USA 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Transblot SD chamber BioRad, Munich, Germany 
UC water bath Julabo, Seelbach, Germany 
Ultracentrifuge SorvallR Discovery 90 SE Sorvall Hitachi, Newton, USA 
Ultra-low freezer Eppendorf Inc., Ensfield, USA 
Varifuge RF Heraeus, Hanau, Germany 
Vibramax-VXR IKA, Staufen, Germany 
Vortex Genie 2™ Bender and Hobein, Ismaning, Germany 
Western Blot Transfer Chamber BioRad, Munich, Germany 
Western Blot Exposition Cassette Kodak, Stuttgart, Germany 
Zeiss Cell Observer Zeiss, Jena, Germany 
2.12.2. Common use Equipment 
Designation Company 
1,5 ml and 2 ml reaction tubes  Eppendorf, Hamburg, Germany 
15 ml reaction tubes  TPP Trasadingen, Switzerland 
50 ml reaction tubes  Greiner, Frickenhausen, Germany 
25cm2, 75cm2 and 150cm2 tissue culture flasks TPP Trasadingen, Switzerland 
6, 10 and 15 cm cell culture plates Greiner, Frickenhausen, Germany 
6-, 12-, 24-, 48 and 96-well tissue culture plates  TPP Trasadingen, Switzerland 
96-well LIA plate Greiner, Frickenhausen, Germany 
96-well plates polysorb  Nunc, Roskilde, Denmark 
Amersham HyperfilmTM ECL  GE Healthcare, Buckinghamshire, UK 
Bottle top filter  Costar, Coning, USA 
Cell scraper  Sarstedt, Nümbrecht, Germany 
Coverglasses 15mm  Carl Roth GmbH, Karlsruhe, Germany 
Cryotubes, 2 ml  Carl Roth GmbH, Karlsruhe, Germany 
Electroporation cuvettes (25 x 2 mm)  Peqlab, Erlangen, Germany 
Examination gloves Blossom  Mexpo International Inc., USA 
Examination gloves XCEEDTM Nitril Starlab, Ahrensburg, Germany 
Nitrocellulose membrane GE Healthcare, Buckinghamshire, UK 
Objekt slide  
One-time use filter, 0.2/0.4µm Renner, Dannstadt, Germany 
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Parafilm “M”  American National Can, Chicago, USA 
Petri dishes  Greiner, Frickenhausen, Germany 
Pipettes (1000, 200, 20, 10 and 2μl)  Gilson Middleton, USA 
Pipette Tipps (200μl, 10µl) NerbePlus, Winsen/Luhe, Germany 
Pipette Tipps (1000μl, 200μl)  Greiner, Frickenhausen, Germany 
Pipette Tips (10μl)  SorensonTM Bioscience, Salt Lake City, USA 
Syringes and needles  BD Franklin Lakes, USA 
Ultracentrifuge tubes Herolab 13.2ml PA  Beranek, Weinheim, Germany 
Ultra-Centrifuge Tubes SW32  Beranek Laborgeräte, Weinheim, Germany 
Whatman filter paper 3MM Schleicher & Schuell, Dassel, Germany 
2.13. Software 
Designation Company 
Adobe CS4/CS6 Adobe, San Jose, USA 
Clone Manager 9.0  Scientific Educational Software, Cary, USA 
Eucaryotic Linear Motif Resource for functional Sites in 
Proteins (ELM) 
www.elm.eu.org/ 
Endnote X5 Thomson Reuter, New York, USA 
Fiji win64  
Graphpad Prism 5.0 GraphPad Software, La Jolla, USA 
Microsoft Office 2003, 2010 Microsoft, Redmont, USA 
Microsoft Windows XP/8 Microsoft, Redmont, USA 
String 9.0 database www.string-db.org 
Wallac 1420 Workstation Perkin Elmer, Norwalk, USA 
ZEN Black Zeiss, Jena, Germany 
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3. Methods 
3.1. Cultivation and Manipulation of Prokaryotic Cells 
3.1.1. Cultivation and Storage of Bacteria 
The cultivation of bacteria was performed either in liquid LB medium or on agar plates, containing 
selective antibiotics. After transformation (4.1.3) of the bacteria, 20-150μl bacterial culture were 
plated on Agar plates containing the corresponding antibiotics and incubated at 37⁰C o/n. Each 
colony formed, originated from a single transformed bacterial cell. Therefore, one colony represents 
a single bacterial clone and each cell within this colony contains identical plasmid DNA. For the 
cultivation of bacteria in liquid LB medium, a single colony was transferred to a proper volume of 
liquid LB medium supplemented with the corresponding antibiotics and incubated at 37⁰C o/n on a 
shaker at 200rpm. Two ml liquid culture were used for purification of plasmid DNA by MiniPrep 
(4.3.1.2), whereas larger cultures of 250ml were used for Maxi Preparation (4.3.1.3). For long-term 
storage of verified (sequenced) bacterial clones, 1ml of a liquid culture was transferred to a 2ml 
cryotube and 300µl glycerol were added. The glycerol stocks were stored at -80⁰C.  
3.1.2. Preparation of Electrocompetent Bacteria  
The electrocompetent bacteria used for transformation (4.1.3) derived from the bacterial strain 
MegaX DH10. Before preparing the starting culture, MegaX DH10 were plated from a glycerol stock 
on a LB agar plate without antibiotics and incubated at 37⁰C o/n. A single colony was transferred to 
25ml LB medium and inoculated at 37⁰C o/n on a shaker with 200rpm. After overnight incubation, 
5ml of the bacterial culture were transferred to 400ml of fresh LB medium and inoculated at 37⁰C 
and 200rpm until the culture reached an optical density (OD600) of 0.5-0.6. The bacterial culture was 
then chilled on ice for 30min and harvested by centrifugation at 6.000rpm for 10min at 4⁰C. The 
pellet was resuspended in 30ml ice-cold H2O and transferred to a dialysis tube and dialysed against 
H2O o/n at 4⁰C. The bacterial cells were then harvested by centrifugation at 4000rpm for 10min at 
4⁰C and resuspended in 600µl ice-cold 10% glycerol solution. Ten µl of the bacterial suspension were 
diluted 1:100 in 990µl 10% glycerol and the OD600 was measured. The obtained OD600 was multiplied 
with the volume of the stock suspension (600µl) and the calculated value in µl of glycerol was added 
to the bacterial solution. Aliquots of 40, 80 and 120µl were prepared and snap-frozen in liquid 
nitrogen and stored at -80⁰C.  
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3.1.3. Transformation of Bacteria by Electroporation  
For transformation, electroporation cuvettes were pre-cooled and an aliquot of electrocompetent 
bacteria (4.1.2) was thawed on ice. After the cell were thawed, 1μl of the corresponding ligation mix 
(4.3.2.4) or purified plasmid DNA was transferred to a 1,5ml reaction tube and mixed by pipetting 
with 40µl electrocompetent cells. The mix was transferred to a pre-cooled electroporation cuvette 
and exposed to an electric pulse of 2.5kV and 200Ω for approximately 5ms. This electric pulse led to 
the formation of pores in the cell wall and the following uptake of DNA by the electrocompetent 
bacteria. Subsequently after electroporation, 300μl pre-warmed (37⁰C) LB medium without 
antibiotics were added to the cells which were then incubated at 37⁰C for at least 1h. After 
incubation between 20-150μl of the bacterial suspension were plated on a selective agar plate and 
further incubated overnight at 37⁰C to allow the generation of single clone colonies. 
3.2. Cultivation and Manipulation of Eukaryotic Cell 
3.2.1. Cultivation of Mammalian Cells 
All cell lines were cultivated in an incubator at 37⁰C, 5% CO2 and 90% humidity. Passaging of the cells 
was performed when cells reached around 80% confluency. For this, the medium was aspirated and 
the attached cells were washed once with 1x PBS. To detach the cells from the cell culture flask, 
0.05% trypsin EDTA or 0.25% trypsin EDTA was added to the cells, respectively, depending on the cell 
line used. The cells were incubated for 2-3 minutes and detached by gentle tapping the flask. The 
trypsin was then neutralized by addition of supplemented medium and after proper resuspension, 
the cells were transferred to a 15ml Falcon tube for centrifugation (1900rpm/5min). The cell pellet 
was resuspended in an adequate volume of fresh, supplemented medium, counted in a 
haemocytometer and seeded for experiments and maintenance of the stem culture.   
3.2.2. Cryopreservation and Thawing of Mammalian Cells 
For cryopreservation, the cells were cultivated in 150cm2 culture flask until they reached a 
confluency of about 80%. The cells were then harvested by trypsinization and centrifugation, as 
described in 4.2.1. After centrifugation, the cell pellet was resuspended in 2ml cryomedium and 
aliqouted into 2 cryotube. Freezing of the cells was performed in a slow freeze chamber with 
isopropanol at -80⁰C for at least 24h before the cells were transferred to liquid nitrogen. To thaw 
cryopreserved cells, the vial was incubated in the water bath at 37⁰C until the suspension was 
thawed completely. The cells were immediately transferred to a 15ml Falcon tube containing 10ml 
supplemented medium and centrifuged at 1900rpm for 5min. This step was repeated once before 
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the cells were resuspended in a proper volume of supplemented medium and transferred to a new 
cell culture flask for cultivation.   
3.2.3. Transfection of Mammalian Cells with Turbofect 
For transfection of a 10cm cell culture dish, around 3-4x106 cells were seeded in 10ml supplemented 
medium and incubated at 37⁰C, 5% CO2 (see 4.2.1) for 24h. The transfection was performed by 
preparing the transfection mix, containing 10-15µg plasmid DNA in 1ml medium without 
supplements and 2µl Turbofect per µg DNA (20-30µl). To allow the formation of the transfection 
complex, the mix was incubated at RT for 15-20min. After incubation the transfection mix was added 
drop-wise to the cells. For proper protein expression the cells were incubated with the transfection 
mix for 48-72h at 37⁰C. The amount of DNA and Turbofect was adjusted corresponding to 
manufacturer´s instructions for different cell culture plates (table 1). 
Table 1: Overview of the transfection procedure in different formats 
Cell Culture Plate No. of adherent cells Amount of DNA (µg) Volume of Turbofect (µl) 
96-well plate 0,5-1,2x104 0.2µg 0.4µl 
48-well plate 1,0-3,0x104 0.5µg 1µl 
24-well plate 2,0-6,0x104 1µg 2µl 
12-well plate 0,4-1,2x105 2µg 4µl 
6-well plate 0,8-2,4x105 4µg 6µl 
15cm dish 6-8x106 20µg 40µl 
3.2.4. Transfection of Mammalian Cells with Polyethylenimine (PEI) 
For transfection of a 10cm cell culture dish, around 3-4x106 cells were seeded in 10ml supplemented 
medium and incubated at 37⁰C, 5% CO2 (see 4.2.1) for 24h. To prepare the transfection mix, 62µl H2O 
were transferred into a 15ml Falcon tube as well as 10µg DNA, 1.5ml medium without supplements 
and 31µl PEI transfection reagent. The mix was then vortexed for 10sec and incubated at RT for 
10min to allow the formation of the transfection complex. After incubation, 8.5ml supplemented 
medium were added to the transfection mix and vortexed again. To apply the transfection mix to the 
cells, the medium was aspirated, the transfection mix was added and incubated at 37⁰C, 5% CO2. The 
transfection mix was removed from the cells, 4-14h after transfection and fresh supplemented 
medium was added. For proper protein expression the cells were incubated for another 48h at 37⁰C, 
5% CO2. 
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3.2.5. siRNA Knockdown 
All siRNAs used for the knockdown experiments were obtained from Qiagen in Hilden, Germany. The 
knockdown was performed in 2.4x104 HeLa cells, seeded in 500µl supplemented medium in a 24-well 
plate and incubated for 30-120min at 37⁰C, 5% CO2. Meanwhile, the transfection mix was prepared 
by dilution of 75ng siRNA in 100µl medium without supplements. To complete the transfection mix, 
4.5µl HiPerFect transfection reagent were added to the diluted siRNA and incubated at RT for 5-
10min. The transfection mix was then added drop-wise to the cells and the plate was swirled gently 
to distribute the mix. To allow proper knockdown, the cells were incubated under normal growth 
conditions for 48h at 37⁰C.  
3.3. Molecular Biological Methods 
3.3.1. Purification of plasmid DNA 
3.3.1.1. QIAprep Spin MiniPrep Kit 
Isolation of plasmid DNA with the QIAprep Spin Mini Prep Kit was performed from a single bacterial 
colony previously cultured in 2ml liquid LB medium containing the corresponding antibiotics. The 
preparation of plasmid DNA was performed according to manufacturer´s instructions.  
3.3.1.2. MiniPrep by Birnboim-Doly Method 
Isolation of plasmid DNA according to the Birnboim-Doly method was performed from a single 
bacterial colony previously cultured in 2ml liquid LB medium containing the corresponding 
antibiotics. The cells were harvested from 1.5ml bacterial culture by centrifugation at 13.000rpm for 
2min. The cell pellet was resuspended in 100μl glucose mix and incubated on a shaker for 5-10min at 
RT. To lyse the bacterial cells for the extraction of the plasmid DNA, 200μl lysis buffer were added 
and the mixture was incubated for 5-10min on ice. By addition of 150µl 3M NaAc and incubation on 
ice for 5-10min the lysis reaction was stopped. Afterwards, 450μl phenol were added to the lysed 
cells and the sample was incubated for another 5-10min on a shaker at RT followed by centrifugation 
at 13,000rpm for 5min. The sample was removed from the centrifuge and 380μl of the supernatant 
were transferred to a fresh tube containing 450µl Isopropanol. For precipitation of the plasmid DNA, 
the sample was then incubated at -70⁰C for 10min. The precipitated DNA was collected by 
centrifugation at 13.000rpm for 20-30min at 0⁰C and washed once with 500μl 70% EtOH (13,000rpm/ 
5min/0⁰C). The washing step was repeated once using 500μl EtOH abs. instead of 70% EtOH. After 
the pellet was dried under the cell culture hood, it was resuspended in 60μl H2O. The isolated 
plasmid DNA was stored at 4⁰C. 
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3.3.1.3. Qiagen MaxiPrep Kit 
Isolation of plasmid DNA with the Qiagen MaxiPrep Kit was performed using 250ml LB medium with 
corresponding antibiotics which were inoculated with either a few µl from a liquid bacterial culture 
or from a bacterial glycerol stock. The preparation of the plasmid DNA was performed according to 
manufacturer´s instructions.  
3.3.1.4. QIAquick Gel Extraction Kit 
For purification of specific DNA fragments from an analytical agarose gel, the QIAquick Gel Extraction 
Kit from Qiagen was used. The DNA fragments were either produced by PCR or enzymatic restriction 
to cut a specific region of the plasmid DNA. After the DNA fragments were separated by agarose gel 
electrophoresis (4.3.3.1), DNA was visualized with the help of a 254nm UV-light to excise the 
corresponding part of the gel for purification. The following purification procedure was carried out 
according to the manufacturer´s instructions. After purification of the DNA, 5μl of the sample were 
analyzed on a mini agarose gel. 
3.3.2. Manipulation of DNA 
3.3.2.1. Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) was performed to amplify the DNA sequences of interest for 
cloning into selected destination vectors. The DNA sequences were amplified using corresponding 
template DNAs encoding for the sequence of interest. Primers needed for the amplification process 
were generated with the help of Clone Manager CMSuite9 (3.9) and ordered as well as produced at 
MWG Eurofins, Ebersberg, Germany. Each Primer was generated for a specific cloning process, 
containing different restriction sites and potentially necessary additional sequences (e.g. Kozak 
sequence). The sites to be included into the primer sequence were selected depending on the 
specific destination vector used for later cloning steps. All PCRs were performed using the KOD HiFi 
DNA Polymerase Kit from Novagen/Merck, according to the manufacturer´s instructions (table 2 and 
table 3). The annealing temperature, as well as the number of amplification cycles, strongly depends 
on the primers used for the PCR reaction and were determined by testing different conditions. 
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Table 2: Constituents of PCR reaction mix and volumes  
Component Volume per reaction (50µl) 
10-50ng template DNA xµl 
10x KOD Buffer #2 5µl 
dNTPs (2.5mM each) 2µl 
MgCl2 (25mM) 2µl 
Fwd Primer (100µM) 1µl 
Rev Primer (100µM) 1µl 
KOD Polymerase 1µl 
H2O Add up to 50µl 
Table 3: Standard PCR program for KOD HiFi Polymerase Kit 
Temperature Time  
98⁰C 3min  
98⁰C 20sec 
32 cycles 60⁰C 10sec 
72⁰C 25sec 
72⁰C 5min  
4⁰C ∞  
3.3.2.2. StrataClone Blunt PCR Cloning Kit (TOPO cloning) 
The cloning of blunt end PCR products into the TOPO vector was carried out using the StrataClone 
Blunt PCR Cloning Kit from Stratagene. The cloning procedure was performed according to 
manufacturer´s instructions using the Quick-Reference Protocol, provided with the kit.  
3.3.2.3. Enzymatic restriction 
To test isolated plasmid DNA for the absence or presence of a specific insert, 5μl of the DNA sample 
were transferred to a new Eppendorf tube. For enzymatic restriction a master mix was prepared 
containing the 2μl of the 10x buffer, 0.5μl RNAse, as well as 11μl H2O and 0.5μl of the specific 
enzyme/s per reaction. The 10x buffer used for the master mix is selected according to the 
recommendation of the manufacturer. Afterwards 45μl of the master mix were added to the DNA. 
The reaction was incubated at 37⁰C for at least 2h. To analyze the restricted plasmid DNA, 5μl 
reaction were mixed with 1μl 6x loading dye and a horizontal agarose gelelectrophoresis (4.3.3.1) 
was performed. For a preparative digest of DNA, which was used for ligation, the reaction was scaled 
up to a final volume of 200µl. The digest was performed overnight at 37⁰C. After incubation the 
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reaction was mixed with 6x loading dye and loaded on an analytical Agarose gel (4.3.3.1) and further 
extracted by gel purification (4.3.1.4). 
3.3.2.4. Annealing of shRNA Oligonucleotides for Cloning 
The forward and reverse oligonucleotides for the production of the lentivirus shRNA vectors were 
ordered and produced at MWG Eurofins in Ebersberg, Germany. The sequences were selected, using 
The RNAi Consortium (TRC) portal (http://www.broadinstitute.org/rnai/public/) either by a high 
score and non-overlapping target sequences or by comparison with previously verified target 
sequences used by Sigma-Aldrich for shRNA knockdown. The oligonucleotides were designed to 
create a double-stranded DNA fragment containing restriction enzyme-like cleavage ends (5´-AgeI, 
3´-EcoRI) after annealing. Therefore, a digestion for cloning was not necessary. Furthermore, the 
oligonucleotides were ordered as phosphorylated version to increase the cloning efficiency in the 
later cloning steps. To generate the shRNA encoding DNA fragments for cloning, the corresponding 
forward and reverse oligonucleotides had to be annealed. Therefore, 2.5µl of the forward oligo (top-
strand 100pmol/µl) and 2.5µl of the reverse oligo (bottom-strand 100pmol/µl) were diluted in 40µl 
H2O and 5µl 10x annealing buffer. The reaction was heated up to 95⁰C for 5min in the water bath. 
After 5min the water bath was turned off and the oligonucleotides were annealed by cooling down 
to room temperature o/n. The annealed oligonucleotides were stored at 4⁰C until direct ligation into 
the dephosphorylated destination vector. 
3.3.2.5. Dephosphorylation of DNA ends 
Dephosphorylation was performed to prevent vector self-ligation while cloning. Therefore the 5´-
phosphate groups of the cleaved vector were removed by addition of 2 units calf-intestinal alkaline 
phosphatase (CIP) after enzymatic restriction of the vector. The reaction was incubated at 37⁰C for 
15min, followed by a second incubation at 58⁰C for 15min. To remove the phosphatases after 
dephosphorylation, the vector was gel extracted as described in 4.3.1.4. 
3.3.2.6. Ligation of DNA fragments 
The ligation mix was prepared on ice, according to manufacturer´s instruction from NEB (table 4). 
Vector DNA and insert were used in a molar ratio of 1:3. The ligation mix was either incubated at RT 
for 20min or at 16⁰C o/n.  
 
 
Methods 
 
43 
 
Table 4: Ligation mix 
Component Volume per reaction (20µl) 
10x T4 DNA Ligase Buffer 2µl 
Vector DNA 0.020pmol 
Insert DNA 0.060pmol 
T4 DNA Ligase 1µl 
H2O Add up to 20µl 
3.3.3. Analysis of DNA 
3.3.3.1. Agarose Gel Electrophoresis 
The horizontal agarose gel electrophoresis was performed to analyze DNA fragments after analytical 
enzyme restriction. Therefore, 1% agarose gels were prepared in 1x TAE buffer (3.3.6.2) and 0.006% 
ethidium bromide was added (final concentration 0.72μg/ml). For standard analyses, three mini gels 
were prepared from 100ml agarose solution, whereas for analytical agarose gels, used for gel 
extraction of DNA fragments, 120ml of a 1% agarose solution was used for a single gel. Before 
application of the DNA samples to the gel, the samples were mixed with 6x DNA loading dye in a ratio 
1:6. To determine the size of the corresponding DNA fragments, λ/HindIII-marker as well as 100bp-
marker (3.3.6.2) was loaded on the gel. The electrophoresis was performed at 95V and the DNA 
fragments were visualized by 366nm UV-light. In case of an analytical gel, the voltage was increased 
to 120V for electrophoresis and further preparations were executed using a 254nm UV-light to 
prevent UV dependent mutations. 
3.3.4. Protein Analysis 
3.3.4.1. SDS-polyacrylamid Gel Electrophoresis (SDS-PAGE) 
SDS-polyacrylamide gels were prepared by combining two kinds of gels with different pore size and 
pH, the stacking gel (3% polyacrylamide, pH 6.8) and the separation gel (12.5% polyacrylamide, pH 
8.8). The protein samples were prepared by adding 3x loading buffer (containing SDS and β-
mercaptoethanol) and a denaturation step of the sample at 95⁰C for 10min. After the polymerized 
SDS polyacrylamide gel was placed into the destined running system, 1x TGS running buffer was 
added and the protein samples to be analyzed as well as 3µl protein marker were applied to the 
pockets of the gel. Until the proteins reached the interface of stacking gel to separation gel the 
power was set to 80V and increased afterwards to 120V for separation of the proteins according to 
their molecular weight.  
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3.3.4.2. Coomassie-blue Staining of Protein Gels 
After the protein samples had been separated according to their size by SDS-polyacrylamide gel 
electrophoresis (4.3.4.1), the protein bands were visualized by staining the gel with Gel Code® Blue 
Stain Reagent according to manufacturer´s instructions. 
3.3.4.3. Western Blot Analysis 
For western blot analysis, the proteins had to be transferred from the SDS-polyacrylamide gel to the 
nitrocellulose membrane, where the proteins could be analyzed by specific antibody detection. 
According to the transfer direction determined by the western blot transfer chamber, the 
polyacrylamide gel, soaked in 1x EMBL was placed on top of the nitrocellulose membrane which was 
previously placed on top of three 1xEMBL (3.4.3) saturated Whatman papers. The stack was covered 
with another three Whatman papers that had also been immersed in 1xEMBL. The transfer was then 
performed at 150mA/per gel for 75min to ensure an adequate transfer of all proteins to the 
nitrocellulose membrane. To block remaining protein binding sites on the nitrocellulose membrane, 
the membrane was incubated in 5% skim milk dissolved in 1xPBS-T at RT for 1h. Meanwhile, the 
primary antibody, directed against the protein of interest, was diluted in 5% skim milk PBS-T, 
according to manufacturer´s instructions. The antibody solution was then applied to the membrane 
and incubated either at RT for 1h or at 4⁰C o/n. After incubation with the primary antibody, excess 
antibody was removed by washing the membrane three times with 1xPBS-T for 10min. The 
corresponding secondary antibody conjugated with horse reddish peroxidase (HRP) was diluted 
1:10.000 in 5% skim milk PBS-T and added to the membrane (RT for 1h). The previously described 
washing steps were repeated after incubation of the secondary antibody to remove unbound 
antibody from the membrane. For detection of the proteins solution A, containing luminol plus 
enhancer and solution B, a peroxide solution of the chemiluniscence kit (3.9) were mixed in a 1:1 
ratio and the membrane was incubated in the substrate solution for 1min. The position of the bound 
secondary antibody and therefore indirectly the protein of interest were visualized using light 
sensitive ECL films exposed to the emitted light of the luminescence reaction.  
3.3.4.4. Determination of Protein Concentration by Bradford Assay 
To determine the concentration of protein of a specific sample, a BSA calibration curve was 
generated by titration in a 96-well plate. Therefore a 10µg/µl BSA stock solution was diluted in H2O 
to get a final concentration of 2µg/µl BSA. From this BSA starting dilution a 1:2 dilution series was 
prepared, starting at 2µg/µl up to 0.016µg/µl. H2O alone was used as blank within the Bradford 
assay. The protein samples to be tested were used in 3 different dilutions (in H2O), ranging from a 1:1 
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dilution to a 1:4 dilution. All the samples, as well as the calibration curve and the blank were tested in 
duplicates and the final volume of each sample to be measured was 5µl per well. According to 
manufacturer´s instructions the Bradford reagent was diluted 1:5 in H2O and 200µl were added to 
each well. The absorbance at 595nm was measured after incubation of the Bradford reagent at RT 
for 5min and the protein concentration of the test samples were calculated based on the BSA 
calibration curve. 
3.3.5. Mass Spectrometric Analysis 
To identify potential interaction candidates, co-purified by TAP (4.4.1) or IP (4.4.2), the samples were 
handed over to the Genomics and Proteomics Core Facility (GPCF) at DKFZ for MS analysis. The 
samples were trypsinized, excised from a SDS gel and the peptides were analyzed by MS.    
3.4. Immunological Methods   
3.4.1. Immunoprecipitation (IP) from PsV Infected Cells 
To prepare CNBr beads for IP, 0.57g CNBr sepharose powder (3.5.3.2) was gently resuspended in 
10ml 1M HCl and incubated at RT for 20min while shaking. The beads were then transferred to a 
PolyPrep Chromatography column and washed four times to dryness with 15ml 1M HCl, followed by 
two washing steps using 15ml coupling buffer (3.5.3.1). One bead volume coupling buffer was then 
used to transfer the beads to a new 15ml Falcon tube and the 50% slurry was split in 5x 1ml fractions, 
transferred to a 1.5ml tube and the supernatant was discarded after centrifugation at 1,200rpm for 
2min at 4⁰C. For antibody coupling 1µg antibody per 1µl beads was diluted in coupling buffer to a 
final volume of 750µl. The antibody suspension was added to the CNBr beads and incubated at 4⁰C 
o/n with end over end rotation. 
After the coupling process, the supernatant was removed (1,200rpm/2min/4⁰C) and the beads were 
washed 4-5 times with 1ml coupling buffer. To block remaining binding sites on the CNBr beads, 1ml 
blocking buffer (3.4.3.1) was added and incubated at RT for 2h. The beads were then washed with 
five cycles of 1ml coupling buffer, followed by 1ml acetate buffer. The washing was finished by a final 
wash with 750µl coupling buffer followed by a single wash with 20% ethanol. The beads were 
resuspended 1:1 in 20% ethanol and stored at 4⁰C until further use. 
For IP from PsV infected cells, 1,9x106 HeLa or HEK 293TT cells were seeded in 6cm dishes and 
incubated at 37⁰C, 5% CO2 o/n. The cells were then synchronized at 4⁰C for 30min and incubated for 
another 30min at 4⁰C after addition of PsV diluted 1:200 to allow binding of the viral particles to the 
cell surface. Different PsV were used for infection of the cells, containing HPV16 L1/L2 PsV, HPV16 L1 
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only PsV as well as AAV2 luciferase vectors as control. The cells were transferred to 37⁰C and 
incubated for 8h (PsV infection) and 6h (AAV2 infection), respectively. Afterwards, the cells were 
trypsinized for 30min at 4⁰C, harvested and washed with ice-cold 1xPBS. Centrifugation was 
performed at 1,900rpm for 5min. For lysate preparation, the pellet was resuspended in 500µl ice-
cold EBC lysis buffer (3.5.3.1) and centrifuged at 13,000rpm for 10min at 4⁰C. Meanwhile, 40µl of the 
antibody coupled CNBr slurry was transferred to a new 1.5ml tube and washed three times with NET-
N buffer (3.5.2.2). The cell extract was then added to the beads and incubated at 4⁰C o/n with end 
over end rotation. 
The supernatant and therefore the non-bound protein was removed from the beads by 
centrifugation at 1,200rpm for 2min at 4⁰C and the beads were washed five times with 1ml NET-N 
buffer. After the excess buffer was removed completely, the beads were resuspended in 20µl 1x 
loading buffer without β-mercaptoethanol (3.5.3.1) and boiled at 95⁰C for 10min. The supernatant 
was collected in a new 1.5ml reaction tube and 10µl 3x loading buffer (+β-mercaptoethanol) was 
added. After denaturation of the sample at 95⁰C for 10min, it was stored at -20⁰C for further analysis 
by western blot and MS.  
3.4.2. Immunoprecipitation (IP) of Overexpressed Proteins   
IP was performed from HEK 293TT cell extracts previously transfected (4.2.3) with the Myc-tagged 
potential interaction candidate together with either HPV16L2 or an empty vector. The cell extracts 
were prepared by resuspending the cell pellet, previously washed with ice-cold 1xPBS, in 500µl NDLB 
lysis buffer (3.5.4.1) and incubated on ice for 30min. The lysate was cleared by centrifugation at 
13,000rpm for 10min at 4⁰C.    
For IP, 40µl Protein G sepharose slurry were transferred into a 1.5ml tube and washed twice with 
500µl ice-cold NET-N buffer (3.5.4.1). All the centrifugation steps were performed at 1,200rpm for 
1min at 4°C. The corresponding antibodies, used for IP were coupled to the beads by the addition of 
200µl NET-N buffer containing 1µg antibody and incubation at 4⁰C o/n on a rotating wheel. 
The cleared lysate was added to the antibody-coupled beads and incubated at 4⁰C o/n with constant 
rotation. To remove unspecifically bound contaminants, the beads were washed five times with NET-
N buffer. After the last washing step, excess liquid was removed from the beads and 40µl 1x loading 
buffer were added. The sample was then denatured at 95⁰C for 10min and a small proportion (5µl) 
was used for western blot analysis whereas the remaining sample analyzed by MS. 
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3.4.3. Immunofluorescence (IF) 
For the analysis of proteins by IF, 2x104 HeLa cells were seeded on a cover glass, placed in a 24-well 
plate. The cells were transfected with the corresponding DNA constructs encoding for the proteins of 
interest (4.2.3).  
At the beginning of the staining procedure, the cells were washed once with 1xPBS and fixed on the 
cover glass with 2% PFA at RT for 15min. To reduce autofluorescence based on the aldehyde fixation, 
50mM ammoniumchlorid were added twice to the cells and incubated at RT for 5min. 
Permeabilization of the cells was performed using 0.2% TritonX-100 in PBS at RT for 10min followed 
by three washing steps with 1xPBS. Potential unspecific binding sites were blocked with 1% BSA in 
PBS at RT for 20-30min before application of the primary antibody diluted in 1% BSA at 37°C for 1h. 
Excess antibody was removed by washing the sample 4-5 times with 1xPBS to reduce unspecific 
staining and background fluorescence. The secondary antibody was also diluted in blocking solution 
(1:800) and a dilution of 1:100 DAPI (final concentration 1µg/ml) was added. The solution was 
applied to the cells and incubated at 37°C for 1h. Afterwards the cells were washed 4-5 times with 
1xPBS and the cover glass was removed from the 24-well plate. One drop of mounting medium was 
applied to the cell covered side of the cover glass which was mounted onto a slide. To avoid drying-
out of the sample, the margin of the cover glass was sealed with transparent nail polish. The sample 
was stored at 4°C under dark conditions to avoid bleaching of the fluorophores, coupled to the 
secondary antibody.    
3.4.4. Enzyme-linked Immunosorbant Assay (ELISA) 
To start the ELISA, a microtiter plate was coated with the corresponding coating buffer (3.5.7.2). In 
case of the biotinylated peptide ELISA, 50µl of a coating buffer containing 2.5µg/ml streptavidin was 
added to each well of the microtiter plate. The plate was then incubated at 37°C o/n without a lid, to 
allow the evaporation of the liquid and the coupling of the streptavidin to the surface of the plate. 
After coating, the remaining binding sites on the surface of the plate were blocked with 2% casein in 
PBS (blocking buffer) at RT for 1h. The peptides to be coupled to the plate were diluted in the 
blocking buffer to a final dilution of 0.25µg/µl. Fifty µl of the peptide solution were then added per 
well and incubated for another hour at RT. Unbound peptide was removed from the plate by three 
washing steps with 1xPBS-T before the primary antibody (1:200 in blocking buffers) was applied to 
the wells. The antibody was incubated at RT for 1h and the plate was washed three times to 
eliminate excess primary antibody. The corresponding secondary antibody with conjugated 
horseradish peroxidase was diluted 1:5,000 in 1xPBS-T and 50µl per well were added to the plate. 
After 1h at RT, the plate was washed three times with 1xPBS-T and 100µl substrate solution (3.5.7.2) 
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were added to each well. The reaction was carried out for 10-20min and the absorbance was 
measured at 450nm  
3.5. Tandem Affinity Purification (TAP) 
For TAP, 10x15cm dishes of HEK 293TT cells were transfected (4.2.3) with the corresponding DNA 
constructs. After 72h the cells were harvested by centrifugation at 1,900rpm for 5min and the cell 
pellet was washed twice with 1-5ml ice-cold 1xPBS. The cells were lysed for protein extraction by 
resuspending the pellet in 5ml lysis buffer (3.5.2.1) and incubating on ice for 30min. To remove cell 
debris from the protein extract, the reaction was centrifuged at 13,000rpm for 10min at 4⁰C and the 
supernatant was collected for purification. The first purification step was performed by binding of the 
protein A part of the TAP-tag to IgG sepharose beads. Therefore 75µl IgG sepharose beads were 
transferred to a 1.5ml tube and washed 5 times with 1ml lysis buffer. After centrifugation at 
1,200rpm for 2min at 4⁰C, the IgG sepharose beads were added to the protein extract and incubated 
on a rotating wheel at 4⁰C o/n. 
To harvest the bound protein after incubation, the sample was centrifuged at 1,200rpm for 2min at 
4⁰C, transferred to a 1,5ml tube and the beads were washed three times with 1ml lysis buffer to 
remove unspecifically bound proteins and contaminants. Another three washing steps were 
performed using 1ml of TEV buffer (3.5.2.1). To elute the protein from the IgG beads, the beads were 
resuspended in 225µl TEV buffer and 75µl TEV protease (0.7mg/ml) were added to the sample. The 
cleavage reaction was performed at 4⁰C o/n. 
The eluted protein was collected by centrifugation at 1,200rpm for 2min at 4⁰C and the supernatant 
was transferred to a 2ml tube. To avoid a loss of eluted protein with the IgG beads, the beads were 
resuspended twice in 300µl TEV buffer and centrifuged at 1,200rpm for 2min at 4⁰C and the 
supernatant was harvested in the 2ml tube together with the supernatant from the initial 
centrifugation step. The TEV protease in the 900µl collected supernatant was inhibited by the 
addition of 5µl 1M iodoacetamid (5mM) and 7µl 1M CaCl2. Meanwhile, the calmodulin beads were 
prepared for the second purification step by washing 75µl calmodulin beads 5 times with calmodulin 
binding buffer (3.5.2.1). The beads were then transferred to the collected TEV cleaved supernatant 
and incubated on a rotating wheel at 4⁰C o/n. 
The reaction was centrifuged at 1,200rpm for 2min at 4⁰C and the beads were washed twice with 
1ml calmodulin binding buffer and twice with 1ml calmodulin wash buffer (3.5.2.1). The bound 
protein was finally eluted by denaturation of the sample in 1x loading buffer (SDS and β-
mercaptoethanol) at 95⁰C for 10min. 
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Samples for analysis of the purification procedure were collected at each step of the purification 
process and denatured in 3x loading buffer for analysis by western blot.        
3.6. Peptide Pull Down (PPD) 
The PPD was performed with cell extract from HEK 293TT and HaCaT cells which had either been 
non-transfected or transfected with DNA encoding for a Myc-tagged version of the potential 
interaction candidate.  
Biotinylated HPV16L2 peptides, aa 20-38, aa 28-42 and aa 64-81 were immobilized on avidin beads. 
Therefore, 100µg lyophilized peptide were resuspended in 400µl 1xPBS to get a final peptide 
concentration of 0.25µg/µl. Avidin beads were washed 3-4 times with 400µl 1xPBS/0.1% TritonX-100. 
After the last washing step, excess buffer was removed completely and the beads were resuspended 
1:1 with the previously prepared peptide suspension. Thus, the final concentration of peptide to 
beads was 0.25µg peptide to 1µl avidin beads. To allow proper coupling of the peptides to the beads, 
the peptide-beads mix was incubated at RT for 3h on a rotating wheel. Remaining unbound peptide 
was removed afterwards by washing the beads 3 times with 1xPBS/0.1% TritonX-100. To generate a 
50% bead slurry, the bead-bound peptides were diluted 1:1 in 1xPBS containing 0.1% sodium azide. 
The bead slurry was stored up to one month at 4°C. 
The cells used for PPD were resuspended in a proper volume of EBC lysis buffer (3.5.4.1), incubated 
on ice for 30min and centrifuged at 13,000rpm for 10min at 4°C. The supernatant containing the 
protein extract was analyzed by Bradford assay and the total protein concentration was determined. 
2mg total protein was pre-cleared using 80µl of the immobilized avidin bead slurry without peptide, 
which had previously been washed twice with EBC lysis buffer. The protein extract avidin mixture 
was incubated at 4°C for 1h with rotation and the supernatant was collected afterwards by 
centrifugation. To prepare the peptide-bound beads for PPD, 40µl of the corresponding slurry was 
washed once with EBC lysis buffer and excess buffer was removed carefully. The pre-cleared protein 
extract was then added to the peptide-bound beads and incubated at 4°C o/n on a rotating wheel.  
The supernatant was removed from the beads and unspecifically bound contaminants were removed 
by washing the beads 5 times with 400µl EBC lysis buffer. Peptide-bound proteins were either eluted 
with two rounds of incubation in 2 bed volumes of 100mM glycin pH 2.8 with following pH 
neutralization using 1M Tris pH 8.0 or prepared for western blot analysis by denaturation of the 
proteins in 1x loading buffer at 95⁰C for 10min.      
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3.7. Pseudovirions (PsV) 
3.7.1. Production 
For each pseudovirus (PsV) production, 10x10cm tissue culture dishes with 3-4x106 HEK 293TT cells in 
10ml supplemented medium were prepared and incubated at 37°C, 5% CO2 for around 24h to allow 
attachment of the cells to the dish. The transfection using the corresponding plasmid DNAs, encoding 
the HPV late proteins and the Gaussia luciferase reporter was performed as described in 4.2.3. After 
incubation, the cells were harvested by resuspension and centrifugation at 1,900rpm for 5min. The 
pellet was washed with 1ml DPBS, transferred to a 1.5ml tube and centrifuged at 1,900rpm for 5min 
at 4°C. The pellet was resuspended in an adequate volume of lysis buffer (3.6.2), corresponding to 
the volume of the pellet and incubated at 37°C on a rotating wheel for 24h. The next day, the cell 
suspension was incubated on ice for 5min before adding 0.17 volumes 5M NaCl and another, 5min 
incubation on ice. Cell debris were removed by centrifugation at 10.000rpm for 5min at 4°C and the 
supernatant was transferred to a new 1.5ml tube. The pellet was resuspended in 300µl DPBS/0.8M 
NaCl and centrifuged for a second time at 10.000rpm for 10min at 4°C. The supernatant was 
combined with the supernatant from the previous centrifugation step, 1µl benzonase (100 units) was 
added and incubated at 37°C for 1h. The crude extract was harvested by centrifugation 
(10.000rpm/10min/4⁰C) and collected in a new 1.5ml reaction tube. A small aliquot of the crude 
extract was taken and analyzed in eight serial dilutions, starting at 1:1000 in a PsV-based infection 
assay (4.5.3). The remaining crude extract was used for PsV purification (4.5.2).   
3.7.2. Purification of pseudovirions 
PsV were purified on an iodixanol (OptiPrepTM) density gradient. Therefore, a 27%, 33% and 39% 
Iodixanol solution in DPBS/0.8M NaCl was prepared from the 60% (w/v) iodixanol stock solution. 
Additionally, 100µl phenol red (0.005%) were added to 10ml of the 39% iodixanol solution and a 
SW41Ti centrifuge tube was prepared to produce the density gradient. The iodixanol solutions were 
then carefully stacked on top of each other, starting with 3.3ml 39% iodixanol solution, followed by 
3.3ml 33% and 3.3ml 27% solutions. To allow softening of the interphases, the gradient was 
incubated at 4°C o/n. For purification of PsV from the crude extract, the collected extract (4.5.1) was 
carefully loaded onto the 27% iodixanol solution of the density gradient and centrifuged at 
37,000rpm for 5h at 16°C. After centrifugation, eight fraction of 500µl were collected, starting from 
1cm below the 39%-33% interface of the gradient. A needle was inserted into the wall of the 
centrifuge tube at the desired position and used as a drip to collect eight 500µl fractions drop-wise in 
1.5ml LowBind reaction tubes. The collected fractions were put on ice immediately and the infectivity 
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was analyzed by an infection assay using a constant dilution of 1:1000 of each fraction (4.5.3). The 
fractions were stored at -80°C. 
3.7.3. Pseudovirus-based Infection Assay 
To test the crude extract (4.5.2) and the purified PsV fractions (4.5.3) for PsV infection activity, the 
crude extract was tested in a serial dilution of eight 1:2 dilution steps starting at 1:1,000. Whereas, 
purified fractions were tested in constant 1:1,000 dilutions. In each assay a neutralizing antibody 
control, using K18L2 in a final dilution of 1:1,000 and a neutralization control, using a final 
concentration of 1µg/ml carrageenan was used. The dilution of the crude extract, used for the 
neutralization control was 1:1,000 and the purified fractions used in the control were fraction 2 and 
fraction 3 of the gradient with a final dilution of 1:1,000. The neutralization controls served for 
distinguishing the luciferase activity of free Gaussia luciferase expressed during the PsV production 
process and the activity due to PsV infection during the PsV-based infection assay. First of all, the 
corresponding dilutions of either the crude extract or the fractions were prepared in supplemented 
medium and 50µl were added to each well of a 96-well cell culture plate. For the neutralization 
controls 50µl of a 1:500 dilution of K18L2 and 1:625 of a 1.25mg/ml stock solution carrageenan in 
supplemented medium were added to the corresponding PsV containing wells, respectively. The 
controls were incubated at RT for 20min. 50µl supplemented medium were added to the wells 
containing the crude extract or the purified fractions. Finally, 50µl of a 2,5x105 per ml HeLaT cell 
suspension were added to each well. The plate was wrapped in polythene foil and incubated in a 
melamine chamber containing moist paper towels for 48h at 37⁰C and 5% CO2. For read out of the 
luciferase activity, the corresponding cell culture plates were incubated at RT for 10min and 10µl 
supernatant were transferred to a white 96-well LIA plate. The Gaussia luciferase substrate was 
prepared by adding 100µl Coelenterazine (50X) to 10ml Glow Juice (3.9). 100µl substrate were added 
to 10µl supernatant and the activity was measured in a microplate luminometer after 5 and 15min.  
To determine the specific dilution of a PsV preparation for use in further experiments, active 
fractions were pooled and tested in serial dilutions as described for the crude extract. In further 
experiments the corresponding PsV preparation was used with the dilution giving a RLU of 1,000,000 
after 15min of substrate incubation. For storage 50µl aliquots of the pooled PsV preparation were 
prepared and stored at –80⁰C.      
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3.8. Lentiviruses 
3.8.1. Production using Four Plasmid Transfection System 
For the production of lentiviruses, using the four plasmid transfection system 3x106 HEK 293TT cells 
were seeded in 10cm dishes and incubated at 37⁰C and 5% CO2 o/n. HEK 293TT cells are well 
transfectable and usually show high transfection efficiency. However, unlike the Phoenix cells, this 
cell line does not express any lentiviral packaging proteins. Therefore the cells need to be transfected 
(4.2.4) with the packaging plasmids, encoding gag/pol, rev and VSV G, as well as the corresponding 
plasmid DNA to be packaged. After addition of the transfection mix, the cells were incubated at 37⁰C 
and 5% CO2 for 24h. The medium was changed and the cells were incubated at 37⁰C and 5% CO2 for 
another 24h. Forty-eight h after transfection, the supernatant was collected in a 15ml Falcon tube 
and the cells were discarded. To concentrate the produced lentiviruses, the collected supernatant 
were centrifuged at 13,500rpm for 5h at 4⁰C and the viral pellet was resuspended in 100µl 1xPBS. 
Aliquots of 20µl of each sample were prepared and stored at -80⁰C until further use.  
3.8.2. shRNA Knockdown 
The shRNA nucleotides were obtained from MWG Eurofins in Ebersberg, Germany and cloned into 
the pLKO.1 TRC control vector for production of lentiviruses (4.6.2). For transduction of the cells with 
the corresponding lentiviruses, 0,25x4 HeLa cells were seeded in a 96-well plate with a final volume 
of 200µl and incubated at 37⁰C, 5% CO2 o/n. When the cells were around 30-50% confluent, the 
medium was removed and 100µl fresh medium containing polybrene with a final concentration of 
4µg/ml were added. After gently swirling the plate, 0.8µl of the lentiviruses in 100ml fresh medium 
were added. The plate was incubated at 37⁰C, 5% CO2 o/n before the medium was changed. After 
incubation for another 48h at 37⁰C, 5% CO2 fresh medium was added to the cells containing 1µg/ml 
Puromycin for selection of transduced cells. Afterwards the cells were passaged as described in 4.2.1 
and continuously expanded to bigger cell culture plates. After expansion to the 150cm2 flask, the 
lentivirus transduced knockdown cells were used for the PsV-based infection assay (4.5.3).      
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3.9. Computer-Based Analysis of Protein Sequences (in silico) 
3.9.1. Eukaryotic Linear Motif Resource (ELM) 
The ELM is an online tool for the prediction of potential functional sites in protein sequences. The 
program can only analyze functional sites which are described as linear motifs, which are then 
predicted based on regular expression patterns. Additionally, the results are filtered by cell 
compartment, phylogeny, globular domain clash and structure to provide core functionality. Though 
the ELM contains a large collection of potential functional sites, the analysis by ELM covers not the 
complete set of potential functional sites.    
In addition to the HPV16 L2 full length sequence, also the identified short MEME motifs (4.7.1) were 
analyzed by ELM to identify potential functional sites in the sequence patterns recurring in different 
HPV types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
54 
 
4. Results 
4.1. Purification and Identification of Host Cell Proteins Interacting with HPV16 L2 
The HPV L2 protein plays an important role in the early and late of a viral infection, though it is 
dispensable for the L1 capsid formation. It is known that L2 has several structural and non-structural 
functions during viral infection for example during viral entry. However, many functions of L2 during 
the different stages of the viral life cycle are still not known. Although some functional domains, 
mainly in the N-terminal part of the L2 sequence, have been described, potential functions in the 
remaining protein are still unrevealed. Therefore, three experimental approaches were conducted to 
identify novel HPV L2 interaction partners and to determine their function during viral infection. 
 First, the tandem affinity purification (TAP, 5.1.1) was applied in which HPV16 L2, fused to the TAP 
tag, was overexpressed in mammalian cells and purified by a two-step procedure. Second, cells were 
infected with HPV16 pseudovirions (PsV) and the L2 was precipitated using specific monoclonal 
antibodies directed against L2. The infection with PsV mimics the pathway of a natural infection and 
therefore allowed the co-purification of candidates interacting during viral entry. Third, a pull down 
was performed using three epitopes of HPV16 L2 (aa 20-38, aa 28-42 and aa 64-81). These epitopes 
have been demonstrated to be targets for (cross-) neutralizing antibodies, preventing HPV infection 
in vitro and in vivo. Based on this observation, the three epitopes analyzed in this experiment are 
supposed to have a specific function during viral infection, which might be disrupted by the antibody 
binding. All experiments were conducted under non-denaturing conditions, allowing the co-
purification of L2 bound proteins for further analysis.      
4.1.1. Tandem affinity purification of HPV16 L2 and potential interaction candidates  
For a first identification of potential HPV16 L2 interaction partners, the tandem affinity purification 
(TAP) method was used. This two-step purification method is based on the expression of a HPV16 L2 
TAP-tag fusion protein, which contains a calmodulin binding protein (CBP), a Tobacco Etch Virus 
Protease cleavage site (TEV) and Protein A (ProtA) fused to the target protein HPV16 L2. Four 
different versions of the TAP-tagged protein were produced for purification. First of all, a HPV16 L2 
full length protein, containing the whole amino acid sequence of the uncleaved HPV16 L2. Besides, 
three overlapping HPV16 L2 fragments were fused to the TAP-tag: HPV16 L2_Fr.1 comprised amino 
acids 1-193, HPV16 L2_Fr.2 amino acids 130-334 and HPV16 L2_Fr.3 amino acids 262-473 (Figure 8A). 
HEK 293TT cells were transfected with the corresponding construct and the lysates were used for 
purification 72h post transfection.  
Results 
 
55 
 
In the first purification step of the TAP, the corresponding HPV16 L2 TAP tag fusion protein was 
purified by IgG Sepharose, allowing the binding of the ProtA part of the TAP tag to the beads (Figure 
9B). Cellular proteins interacting with HPV16 L2 were co-purified because of the non-denaturing 
conditions of the cell lysis and the TAP procedure. After binding of the fusion protein to the beads, 
unspecifically bound contaminants were removed by several washing steps. To prepare the protein 
for the second round of purification it was eluted from the IgG beads by cleavage with the TEV 
protease, cutting off the ProtA part of the TAP-tag. The eluted protein was then used for the second 
purification step, where it was coupled to calmodulin beads assured by the CBP still fused to the 
HPV16 L2 construct. After binding to the calmodulin beads and the following washing steps, the 
beads were boiled in 1x SDS sample buffer to elute the protein and the co-purified potential 
interaction candidates. At each step of the purification procedure, an aliquot of the supernatant (snt) 
and the beads was taken and analyzed by western blot analysis (Figure 9A HPV16 L2 full length, B 
HPV16 L2_Fr.1, C HPV16 L2_Fr.2 and D HPV16 L2_Fr.3). TEV cleavage to remove the bound HPV16 L2 
TAP-tag construct from the IgG beads, was performed twice (HPV16 L2_Fr.1, HPV16 L2_Fr.2 and 
HPV16 L2_Fr.3) or in case of the HPV16 L2 full length construct, three times. The obtained 
supernatants were used separately for binding to the calmodulin beads and the following purification 
steps. The western blots were stained with a HPV16 L2-specific antibody (K18L2 aa20-38, serum #7 
and α-C-terminal-L2 8c-1) and therefore representing the efficiency of the purification process of the 
different HPV16 L2 TAP-tag constructs. Figure 9A presents the purification of the HPV16 L2 full length 
TAP-tag protein. The first two lanes show samples of the aliquots from the snt and the beads, taken 
after binding of the target protein to the IgG beads. The detected signal showed comparable amount 
of L2 protein in both samples, indicated by the red arrow: HPV6 L2 CBP-ProtA. This indicated that 
only 50% HPV16 L2 TAP-tag was bound and 50% of the protein stayed in the snt even after binding to 
the IgG beads.  In the samples taken during the TEV cleavage, a similar result can be observed 
comparing the snt #1 sample with the sample from the beads, also indicating that about 50% of the 
target protein cannot be eluted properly from the IgG beads. Furthermore, the second and third 
round of protease cleavage could not elute additional target protein from the beads, since HPV16 L2 
is hardly detectable in snt #2 and snt #3. The shift in the molecular weight of the target protein is 
based on the cleavage of the ProtA part (~15kDa) from the TAP-tag. The second purification step is 
represented by the lanes marked with “Purification by Calmodulin beads” also containing aliquots of 
the supernatants (snt #1, snt #2 and snt #3) and the beads (beads #1, beads #2 and beads #3), boiled 
in sample buffer after binding.  
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Figure 8 HPV16 L2 TAP-tag purification and constructs. A Overview of the HPV16 L2 constructs used for TAP. HPV16 L2 full 
length contains the amino acids 1-473, therefore the complete HPV16 L2 sequence. As controls for the MS analysis in the 
later steps, three overlapping HPV16 L2 fragments were generated. HPV16 L2_Fr.1, containing aa 1-193, HPV16 L2_Fr.2, 
containing aa 130-334 and HPV16 L2_Fr.3, containing aa 262-473. All HPV16 L2 constructs are fused to the TAP-tag 
consisting of a calmodulin binding protein (CBP), a TEV (Tobacco Etch virus) protease cleavage site (TEV) and a Protein A 
(ProtA). B Overview of the Purification Process. The target protein putatively interacts with cellular proteins (green, red and 
grey) upon expression in the cell. After lysis of the cells, the complex is purified in a first purification step by binding to IgG 
beads via the ProtA part of the TAP-tag and contaminants (beige) are removed by washing. The complex is eluted by TEV 
protease cleavage and purified by a second purification step mediated by binding of the CBP to Calmodulin beads and 
further washing steps. The beads are then boiled in 1x SDS buffer and the supernatant is analyzed by western blot analysis 
and mass spectrometry. 
The detection of HPV16 L2 in these fractions demonstrated, that almost all of the target protein 
could bind to the beads, since there was no detectable signal in the snt samples. However, 
comparable amounts of HPV16 L2 protein can be detected in the TEV protease cleavage snt #1, 
representing the input of protein into the calmodulin purification and the bead fraction #1 of the 
purification by calmodulin, representing the bound target protein. In addition, the aliquots of bead 
sample #2 and bead sample #3 after calmodulin binding also show less HPV16 L2 compared to the 
bead sample #1, corresponding to the reduced HPV16 L2 input from snt #2 and snt #3 after the 
second and third TEV protease cleavage. 
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The western blots representing the TAP of HPV16 L2_Fr.1 (Figure 9B) and HPV16 L2_Fr.3 (Figure 9D) 
show similar results as the TAP of HPV16 L2 full length in A. Even though the ratios of purified protein 
were slightly different in some of the purification steps compared to the full length TAP, the amount 
of bound protein after the binding to the calmodulin beads was sufficient for MS analysis. A different 
observation could be made for the TAP process of HPV16 L2_Fr.2, shown in figure 9C.  
 
Figure 9 Tandem Affinity Purification. A western blot analysis of the purification using HPV16 L2 full length TAP-tag 
construct. During the purification process, aliquots of the supernatant (snt) and bead fractions were taken at each 
purification step. Volumes loaded to the gel for analysis were adjusted to the corresponding volumes used during the 
purification process. Red arrows indicate the HPV16 L2 full length protein containing the TAP-tag before and after TEV 
cleavage. B Purification using HPV16 L2_Fr.1 TAP-tag construct, containing HPV16 L2 aa 1-193. No antiserum was available, 
detecting this part of L2. C Purification using HPV16 L2_Fr.2 TAP-tag construct, containing HPV16 L2 aa 130-334. D 
Purification using HPV16 L2_Fr.3 TAP-tag construct, containing HPV16 L2 aa 262-473. 
At the beginning of the purification, there was still some protein detectable in the input as well as in 
the beads after the IgG binding. However, after binding to the IgG beads, there is no protein 
detectable in any of the following samples. Since the protein can be detected neither in the snt 
fraction nor in the beads after TEV cleavage, the absence of a signal rather indicates that the 
polyclonal HPV16 L2 antibody (serum #7) was not suitable to detect HPV16 L2_Fr.2. Because of a lack 
of suitable antibodies detecting the amino acid region 130-334, the elution of HPV16 L2_Fr.2 was 
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analyzed by MS even without having a confirmation by western blot analysis. The corresponding snt 
from the calmodulin beads, boiled in 1x SDS sample buffer, were pooled and assigned to the 
Genomics and Proteomics Core Facility (GPCF) at the DKFZ for MS analysis.  
4.1.2. Mass Spectrometric Analysis and Selection of Candidates from TAP  
The samples derived from the tandem affinity purification were analyzed by MS at the GPCF at the 
DKFZ. Two peptide databases were screened to identify potentially interacting candidates. The first 
database used for the identification comprised peptides and the corresponding proteins derived 
from different species. Therefore it was used to confirm the presence of the HPV16 L2 protein and 
thus served as an additional control for a successful purification. The second database was restricted 
to peptides and the corresponding proteins derived from mammalian species and served as basis for 
the actual selection of potential candidates. However, for each of the purifications, the number of 
identified proteins in the different samples required the application of additional selection criteria to 
reduce the number of potential candidates. Therefore, several selection steps were executed to filter 
for the most promising potential HPV16 L2 interaction candidates (Figure 3).  
First of all, the commonly contaminations, appearing regularly in MS analyses were discarded from 
the provided lists of identified proteins. Amongst others, these proteins were for example keratins 
and IgG proteins, which were introduced to the samples because of the handling or the material used 
during the purification process. Furthermore, identified proteins which were indicated to be derived 
from non-human species were analyzed for the existence of human equivalents. Therefore, the 
peptide sequences identified by the MS, representing the corresponding protein were compared to 
the set of peptides expected for a corresponding human protein. Only proteins that had the same 
peptide set for the human equivalent were selected for further analysis, whereas proteins without 
human equivalent were discarded. The remaining proteins were then compared between the 
different samples analyzed. For this, each protein hit was checked for its appearance in each protein 
list derived from the other TAP purifications. Proteins showing up either in a single screen or in more 
than one but in screens using overlapping target proteins were considered as potential partners of 
HPV16 L2. Proteins appearing in the protein lists of non-overlapping target proteins, not sharing any 
amino acid sequences (HPV16 L2_Fr.1 and HPV16 L2_Fr.3), were eliminated from the lists of 
potential interaction candidates. In order to further reduce the number of potential candidates and 
increase the chance of selecting the most promising candidates, also protein hits from a single screen 
were finally discarded, even though this might lead to elimination of true interaction partners. After 
the selection steps, a final set of 29 potentially specific interaction candidates remained and were 
checked in detail by literature research. For further experiments, the focus was set on proteins that 
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had already been published to have a potential function in context of viral infection of any virus, 
except HPV. This selection procedure reduced the number of potential HPV16 L2 interaction 
candidates to a set of 12 potential candidates (Table 5). 
  
 
Figure 10 Overview of candidate 
selection. The TAP was performed 
twice, using the HPV16 L2 full length 
TAP construct and once with each of 
the L2 fragments (HPV16 L2_Fr.1, 
HPV16 L2_Fr.2 and HPV16 L2_Fr.3). 
Each MS analysis revealed a different 
number of protein hits from which 
the generally known contaminants, 
like keratins were exclude in the first 
step of the selection procedure (step 
I.). Since peptides identified in the MS 
analysis were compared with a 
database of mammalian proteins, not 
all of the listed proteins were of 
human origin. Therefore the non-
human proteins listed had to be 
analyzed in detail if the detected 
peptide set is equivalent to 
corresponding human proteins (step 
II.). Proteins missing a human 
equivalent were discarded from the 
candidate list. In the third step the 
five protein hit lists were compared 
among each other, to identify 
proteins from non-overlapping 
fragments, e.g. HPV16 L2_Fr.1 and 
HPV16 L2_Fr.3 (step III.). To further 
reduce the number of potential 
candidates, proteins that have not 
been validated by a second screen 
were also discarded from the list of 
potential candidates (step IV.). From 
the remaining 29 candidates, 12 were selected based on literature research and their potential function in context of viral infection (step V.). 
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Table 5: Potential HPV16 L2 interaction candidates identified by tandem affinity purification  
Protein/Description HPV16 L2 fl. HPV16 L2_Fr.1 HPV16 L2_Fr.2 HPV16 L2_Fr.3 
HPV16 L2* 6 peptides 2 peptides 3 peptides - 
Sorting nexin 17 (SNX17) 
(aa 160-164, aa 254-258)** 
- 6 peptides 2 peptides - 
eEF1A1                     
(elongation factor 1 alpha) 
11 peptides - 2 peptides - 
CAPN2                             
(Calpain large subunit 2) 
4 peptides 3 peptides - - 
PSMD12                                
(26S proteasome non-ATPase 
regulatory subunit isoform 12) 
2 peptides 2 peptides - - 
YWHAZ 
(14-3-3 protein/cytosolic 
phospholipase A2) 
1 peptide 2 peptides - - 
PSMD11                                
(26S proteasome subunit 11) 
1 peptides 2 peptides - - 
FLG-2 
(Filaggrin 2) 
1 peptide - - 1 peptide 
CSE1L  
(Exportin-2) 
2 peptides 2 peptides - - 
Skp1 
(S-phase kinase-associated 
protein 1) 
1 peptide - - 1 peptides 
TGM3 
(Transglutaminase E3) 
- - 1 peptide 1 peptides 
hnRNPK 
(transformation upregulated 
nuclear protein) 
3 peptides - 1 peptides 1 peptides 
IRS4 
(insulin receptor substrate 4) 
2 peptides 
4 peptides 
- - 4 peptides 
CAND1 
(cullin-associated NEDD8-
dissociated protein 1) 
3 peptides 2 peptides - - 
* representing the target protein 
** previously published HPV16 L2 interaction partner 
The number of peptides indicated, describes the number of independent peptides identified for the corresponding protein. 
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4.1.3. Immunoprecipitation of L1 and L2 from PSV infected cells (PsV-IP) 
Another approach to identify potential HPV16 L2 interaction candidates was the identification of 
proteins co-purified by IP from cells infected with HPV16 PsV. In contrast to the tandem affinity 
purification, where the HPV16 L2 constructs were overexpressed in the cells, the infection with PsV 
was performed with a non-tagged version of the L2 protein in context of the HPV16 capsid. This was 
supposed to mimic the natural infection pathway in vitro. The infection with HPV16 PsV allowed the 
L2 protein to meet potential interaction partners on its way into the cells in respect of its packaging 
state within the capsid. However, a disadvantage of the IP from infected cells was based on L1/L2 
stoichiometry of the HPV capsid, containing 72 pentamers of the L1 protein but only estimated 12 
molecules of the HPV16 L2 protein.  
4.1.3.1. Selection of antibodies suitable for PsV-IP from infected cells   
To select suitable antibodies for the IP of HPV16 L2 from cell extracts, HEK 293TT cells were infected 
with HPV16 PsV for 5h, 6h, 7h, 8h and 9h after synchronization of the PsV binding to the cell surface. 
After the indicated time of infection, cells were lysed and the cell extract was used for purification of 
HPV16 proteins, using different L1- and L2-specific antibodies, respectively, coupled to Protein G 
Sepharose. Moreover, purified HPV16 PsV, in a non-cellular context, were tested in the IP, to verify 
the general precipitation capability of the specific antibodies. For this initial test, two HPV16 L1-
specific antibodies were used, the 1.3.5.15_L1 which is a mouse derived L1-specific monoclonal 
antibody and the 4543 rabbit L1-specific polyclonal antiserum. These antibodies served as a positive 
control, since both of them are able to precipitate the highly abundant L1 from the infected cells. 
Furthermore, three HPV16 L2-specific monoclonal mouse antibodies were tested for their ability to 
precipitate HPV16 L2 from infected cells. K1L2 aa64-81, targeting the amino acid region aa 64-82 
whereas the antibodies K4L2 aa20-38 and K18L2 aa20-38 are raised against the L2 region aa 20-38. In 
addition to the L1- and L2-specific antibodies, a HPV16 E7-specific antibody was used as a negative 
control. After precipitation, the beads were boiled in 1x SDS sample buffer to elute the precipitated 
proteins for the western blot analysis (Figure 11).  
Analysis of HPV16 L1-specific antibodies for PsV-IP from infected cells 
Figure 11A shows the results of the HPV16 L1 precipitation using the 1.3.5.15_L1 and the 4543 
antiserum. The detection was performed with a mouse-monoclonal HPV16 L1-specific antibody 
(MD2H11_L1). Detection of the HPV16 L2 protein was neglected, due to the low abundance of HPV16 
L2 and hypothesis that even after 9h the L1 and the L2 protein are still assembled in the capsid and 
not yet dissociated. Consistingly, L1 co-precipitated with L2, using L2-specific antibodies. In both IPs 
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(Figure 11A), the HPV16 L1 is clearly detectable at about 55kDa (red arrow HPV16 L1) with a 
detection peak at 8h post infection. Additional, the positive control (PsV only) confirms the 
precipitation ability of the used antibodies, whereas the negative control from w/o PsV does not 
show any detectable HPV16 L1. Since the 1.3.5.15_L1 as well as the antibody used for the detection 
in the western blot derived from the same species (mouse), the heavy chain of the 1.3.5.15_L1 
(~50kDa) appears as an additional signal in all of the samples derived from the IP with 1.3.5.15_L1 
(red arrow Ab heavy chain). The 1.3.5.15_L1 seemed to be more efficient, demonstrated by stronger 
HPV16 L1 signals detected in the samples of the 1.3.5.15_L1 IP.      
 
Figure 11 Western blot analysis of IP from PsV infected cell extracts. A IP was performed using the HPV16 L1-specific 
antibodies 1.3.5.15_L1 (mouse monoclonal) and 4543 (rabbit polyclonal). The analyzed samples were collected 5h, 6h, 7h, 
8h and 9h after PsV infection. In addition cell extract from non-infected cells as well as PsV only were analyzed after IP with 
the indicated antibodies. Red arrows indicate bands corresponding to either HPV16 L1 or IgG heavy chain. B The IP was 
performed with HPV16 L2-specific antibodies to select for a suitable antibody for the PsV-IP experiment. In addition the 
4749 (HPV16 E6-specific) antibody was used as negative control. Samples were collected as describe in A. The IP using the 
K1L2 aa64-81 antibody showed a faint signal in the control w/o PsV which was probably because of a spillover while loading 
of the gel. Besides, HPV16 L1 was detected in the PsV only sample of the 4749 IP probably due to unspecific precipitation.    
Analysis of HPV16 L2-specific antibodies for PsV-IP from infected cells 
In the experiment shown in figure 4B the IPs were performed with the HPV16 L2-specific antibodies 
K1L2 aa64-81, K4L2 aa20-38 and K18L2 aa20-38 and the precipitation negative E7 antibody 4749. The 
detection of the western blot was performed with the HPV16 L1-specific antibody MD2H11_L1. 
Successful precipitation of the PsV could be demonstrated with K1L2 aa64-81 and K4L2 aa20-38. The 
HPV16 L1 protein was detected in all of the samples infected with HPV16 PsV (5h, 6h, 7h, 8h and 9h) 
as well as in the positive control (PsV only). As described previously, a detection peak could be 
Results 
 
64 
 
observed after 8h, using the K1L2 aa64-81 for precipitation. Additional bands detected in these 
samples derive from the heavy chain of the antibody, since the precipitation as well as the detection 
was performed with mouse derived antibodies. For the K4L2 aa20-38 IP samples, the observation of 
a detection peak was not clear, since the L1 and the heavy chain formed a strong double band in the 
infected samples and the positive control (PsV only). Because of the signal intensity and the 
proximity of the two signals, it is not clearly visible if there are differences in the IP efficiency at the 
different time points after infection. The lower panel in Figure 4B shows the results of the IPs using 
K18L2 aa20-38 (L2-specific) and 4749 (E7-specific). Even after infection, none of the two antibodies 
showed precipitation of PsV, demonstrated by the absence of a detectable L1 signal. However, the 
western blot shows a signal after IP of PsV only with the E7-specific 4749 antibody at the expected 
molecular weight of HPV16 L1, indicating that there might be some unspecific binding of L1 to the 
beads coupled with 4749. Based on the results in Figure 4, the antibodies 1.3.5.15_L1, K1L2 aa64-81 
and K4L2 aa20-38 were selected for further experiments to identify potential HPV16 L2 interaction 
candidates.    
4.1.3.2. Covalent binding of suitable antibodies to CNBr-beads 
Since the previous experiment demonstrated a high abundance of IgG in the samples after IP when 
using Protein G coupled antibodies, an optimization of the IP protocol was necessary to reduce IgG 
contamination for MS analysis. For this, the Protein G Sepharose was replaced by CNBr beads which 
allow a covalent coupling of antibody and where supposed to reduce the amount of IgG in the 
samples. First of all the coupling efficiency of the selected antibodies (5.1.3.1) to the CNBr beads was 
determined by testing different aliquots, taken during the coupling procedure by SDS-PAGE. Aliquots 
to be tested were taken before coupling to the CNBr beads (Figure 12, input), from the supernatant 
(snt) after coupling and the beads (beads). In addition to the selected antibodies from 5.1.3.1, the 
A20_AAV2 antibody was used in the experiment. The A20_AAV2 antibody served as negative control 
in the following IP experiment.  
Coupling efficiency of different antibodies to CNBr beads 
Figure 12 demonstrates that the coupling was successful for all of the antibodies used in the 
experiment. In each sample, the input showed a high amount of heavy and light chain. The signal 
disappeared after the coupling step (snt), indicating that the IgGs are almost completely bound to 
the beads. Even after denaturation, there was only a faint signal detectable (beads), representing the 
corresponding heavy and light chain. The SDS-PAGE showed clear differences in the amount of 
antibody used in the different input samples. Nevertheless, the results showed that the coupling to 
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the CNBr beads is highly efficient and might be advantageous compared to the use of Protein G 
Sepharose because of reduced abundance of IgG contaminations in the samples. 
 
Figure 12 Coomassie staining of antibody coupling to CNBr beads. The coupling efficiency of different antibodies (K1L2 
aa64-81, K4L2 aa20-38, 1.3.5.15_L1 and A20_AAV2) to CNBr beads was tested using the standard protocol provided by the 
manufacturer. On the Coomassie-blue stained SDS gel, aliquots of the input (amount of antibody used for the coupling 
procedure), the supernatant (snt) after coupling and the beads were analyzed. The arrows indicate the heavy and light 
chain of the antibodies. 
Immunoprecipitation of PsV from infected cells using CNBr-coupled K1L2 aa64-81 
An initial IP experiment to test CNBr-coupled antibody for PsV precipitation was performed using the 
K1L2 aa64-81 in two different concentrations (1µg/µl and 2µg/µl) (Figure 13). For this, CNBr-coupled 
K1L2 aa64-81 was used in the experimental setup describe in 5.1.3.1. The western blot in Figure 13 
shows the detection of HPV16 L2 by K4L2 aa20-38 (upper panel) as well as the detection of HPV16 L1 
by MD2H11_L1 (lower panel). As described previously, the IP was performed 5h, 6h, 7h, 8h and 9h 
after infection with HPV16 PsV as well as from cell extract of non-infected cells (w/o PsV).  
 
Figure 13 Western blot analysis of IP using CNBr coupled K1L2 aa64-81 antibody. 1µg/µl K1L2 aa64-81 and 2µg/µl K1L2 
aa64-81 were coupled to CNBr beads. The following IPs were performed at different time points after PsV infection (5h, 6h, 
7h, 8h and 9h) and as a negative control cell extract of non-infected cells was used for IP (w/o PsV). The upper panel shows 
a western blot using HPV16 L2-specific antibody (K4L2 aa20-38) whereas the lower western blot shows the detection with a 
HPV16 L1-specific antibody (MD2H11_L1), suitable for the detection of denatured protein. The arrows indicate either 
HPV16 L2 or HPV16 L1 in the corresponding blots. 
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All time points post infection showed a clear HPV16 L1 signal, for the IP with either 1µg/µl K1L2 aa64-
81 or the 2µg/µl K1L2 aa64-81. In addition, the absence of an L1 signal in the non-infected control 
samples could be observed. However, for the lower concentration of K1L2 aa64-81, the previously 
described peak of HPV16 L1 detection at 8h could be observed, though, the differences in the signal 
intensity comparing the different time points are not as pronounced as in Figure 4. However, the IPs 
with the higher amount of K1L2 aa64-81 showed the strongest L1 signal at 5h post infection and a 
constant increase from 6h to 9h post infection. The detection of HPV16 L2 revealed only faint bands, 
due to the small abundance of HPV16 L2 within the HPV capsid. Nevertheless, the L2 protein could 
be detected in each sample except the w/o PsV control. The results of the precipitation experiment 
demonstrated that the IP using antibodies coupled to CNBr beads lead to efficient precipitation of 
the HPV16 capsids from infected cells and further reduced the amount of IgG contaminations within. 
4.1.3.3. PsV-IP from infected cells using CNBr-coupled antibodies 
The IP of PsV to be analyzed by MS was performed by infecting either HEK 293TT or HaCaT cells with 
HPV16 PsV, containing the L1 and the L2 protein (HPV16 L1/L2) or HPV16 PsV, containing only the L1 
protein (HPV16 L1 only) for 8h. The L1 only PsV infection served as a control to distinguish potential 
HPV16 L1- from HPV16 L2-interaction candidates, since candidates of both proteins were co-purified 
by precipitation of the assembled HPV16 capsids. As an additional control for the MS analysis, 
another batch of cells was either infected with AAV2 for 6h or mock infected (w/o virus). The IP was 
performed from each infection, using four different antibodies, two HPV16 L2-specific antibodies, 
targeting different regions of the protein (K1L2 aa 64-81 and K4L2 aa 20-38), one HPV16 L1-specific 
antibody (1.3.5.15_L1) and the A20_AAV2 antibody. The antibodies were previously coupled to CNBr 
beads in a ratio of 1µg antibody to 1µl beads. Aliquots of the input from the infection, the 
supernatants (snt) and the beads were taken during the precipitation procedure and analyzed by 
western blot before samples were analyzed by MS. 
Figure 14 shows the result of the IP of HPV16 L1/L2 and HPV16 L1 only PsV, whereas the upper panel 
was detected with an L2-specific antibody (K4L2 aa20-38) and the lower panel with the MD2H11_L1. 
The detection of HPV16 L2 did not lead to any dependable result, since the method was not sensitive 
enough to detect the small amount of HPV16 L2 in the IP samples. However, detection with the 
HPV16 L1-specific antibody demonstrated that the L1 protein could be found in the aliquots of the IP, 
the α-L1 antibody 1.3.5.15_L1 but also the L2-specific antibodies K1L2 aa64-81 and K4L2 aa20-38 
(Figure 14A). HPV16 L1, present in the aliquots of the snt indicated the unbound L1 proportion. This 
might be due to saturation of the binding capacity of the beads coupled antibody sites. The detection 
of HPV16 L1 in the aliquots taken from the bead fractions after purification demonstrated the 
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precipitated L1 by K1L2 aa64-81, K4L2 aa20-38 and 1.3.5.15_L1. Compared to K1L2 aa64-81 and 
1.3.5.15_L1, the IP using K4L2 aa20-38 showed a reduced level of precipitated L1, indicating lower 
precipitation efficiency. The IP of HPV16 L1/L2 PsV with the A20_AAV2 antibody therefore showed 
only a HPV16 L1 signal in the input and snt samples. There is no detectable L1 signal in the bead 
fraction of the IP.  
 
Figure 14 IP of HPV16 PsV from infected cell extracts. A PsV-IP from cell extracts infected with HPV16 L1/L2 PsV using 
different antibodies (K1L2 aa64-81, K4L2 aa20-38, 1.3.5.15_L1 and A20_AAV2) coupled to CNBr beads. The samples 
analyzed were taken before IP (input), and after IP (snt, beads). B PsV-IP from cell extracts infected with HPV16 L1 only PsV. 
Antibodies used for the IP and fractions analyzed were the same as described in A. The upper western blot was detected 
with a HPV16 L2 antibody (K4L2 aa20-38) whereas the lower western blot was detected with a HPV16 L1-specific antibody 
(MD2H11_L1) in A and B. 
The result of the IP of HPV16 L1 only PsV is shown in Figure 7B. Using K1L2 aa64-81, K4L2 aa20-38 
and the A20_AAV2 for precipitation lead to the detection of L1 in the input and the snt exclusively. 
Thus, confirming that the HPV16 L1-only PsV cannot be precipitated by any of the three antibodies. 
In contrast to the antibodies targeting HPV16 L2 and AAV2, the 1.3.5.15_L1 was able to precipitate 
the HPV16 L1 only PsV, represented by detection of HPV16 L1 in the input and in the bead sample. 
There was no detectable signal for HPV16 L1 in the snt fraction after binding to the beads, indicating 
that all PsV could be precipitated from the cell extract. IP samples from 293TT cells infected with 
HPV16 L1/L2, HPV16 L1 only and AAV2 (data not shown) as well as from non-infected cells (data not 
shown), using the four different antibodies were analyzed by MS by the GPCF at the DKFZ.     
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4.1.4. Mass spectrometric analysis and selection of candidates from PsV-IP 
As described previously in paragraph 5.1.2, two protein databases were screened for protein 
identification. One comprised species from different classes, also including viral proteins, thus this 
database served to identify purified HPV16 L1 and HPV16 L2. However, only the IP of HPV16 L1/L2 
and HPV16 L1-only using the 1.3.5.15_L1 antibody could identify HPV16 L1, none of the screens 
identified HPV16 L2. The database comprising species of the mammalian class was used for the 
identification of co-purified interaction candidates. The number of identified proteins was very high 
and required additional selection criteria to reduce the number of candidates (Figure 15). Like in 
5.1.2, generally known contaminants were eliminated in the first selection round (step I.). The 
second selection criterion was based on the comparison of MS results of the different antibodies 
within the same PsV-infected extracts. Co-purified proteins of the A20_AAV2 negative control IP 
were discarded as potential candidates (step II.). Since A20_AAV2 is not able to precipitate either 
HPV16 L1 or HPV16 L2, as confirmed by the MS data, co-purified proteins were suggested to be 
unspecific. For the set of IPs from HPV16 L1 only PsV infected cells, also proteins co-purified with 
K1L2 aa64-81 and K4L2 aa20-38 were used as negative control. Remaining proteins from the HPV16 
L1-only IP were assigned as potential L1 interaction candidates and served as control to distinguish 
between potential L1 and L2 candidates in a later selection step (V.). Additionally, unspecifically co-
purified proteins, identified in the screens from AAV2 (step III.) and non-infected (step IV.) cells were 
discarded from the candidate list. From the remaining 73 candidates of the HPV16 L1/L2 infections, 
15 candidates overlapped with the HPV16 L1-only candidate list. Therefore these 15 proteins were 
suggested to be potential L1 interaction candidates (step V.). Finally, proteins with no human 
equivalent (step VI.) as well as proteins with less than two independently identified peptides (step 
VII.) were eliminated. 
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Figure 15 Overview of the interaction candidate 
selection. The PsV-IP was performed using cells 
infected either with HPV16 L1/L2, HPV16 L1 
only, and AAV2 or w/o virus. For each infection 
four antibodies were used for IP (K1L2 aa64-81, 
K4L2 aa20-38, 1.3.5.15_L1 and A20_AAV2). Each 
MS analysis revealed a different number of 
protein hits from which the generally known 
contaminants, like e.g. keratins were excluded in 
the first selection step (step I.). In step II, the 
K1L2 aa64-81, K4L2 aa20-38 and 1.3.5.15_L1 
protein hit were compared to the corresponding 
A20_AAV2 protein hits of the same virus 
infection to exclude HPV16 unspecific protein 
hits. The remaining proteins were then 
compared to the four AAV2 infected and w/o 
virus IPs and overlapping hits were discarded 
(step III & step IV). Furthermore, protein hits 
appearing in the K1L2 aa64-81 and K4L2 aa20-38 
IP from cells infected with HPV16 L1 only PsV 
were excluded from the corresponding 
1.3.5.15_L1 IP to identify potential HPV16 L1 
interaction candidates. These protein hits were 
compared to the K1L2 aa64-81, K4L2 aa20-38 
and 1.3.5.15_L1 proteins hits and previously 
identified L1 interaction candidates were 
removed (step V). The last selection step (step 
VI) was based on the identification of protein 
hits with human equivalents as potential HPV16 
L2 interaction candidates. Finally, protein hits 
with less than two independent peptides 
identified by MS were discarded from the list of 
potential interaction candidates (step VII). 
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Table 6: Potential HPV16 L2 interaction candidates identified by PsV-IP 
Protein/ Description PsV-IP 
RPS2 
40S ribosomal protein S2 
3 independent peptides 
HIST1H2BB 
Histone H2B type 1-B 
5 independent peptides 
HIST1H1C 
Histone H1.2 
4 independent peptides 
HIST1H2BC 
Histone H2B type 1-C/E/F/G/I 
5 independent peptides 
H3F3A 
Histone H3.3 
4 independent peptides 
CCT5 
T-complex protein 1 subunit epsilon 
4 independent peptides 
CCT3 
T-complex protein 1 subunit gamma 
2 independent peptides 
CCT4 
T-complex protein 1 subunit delta 
2 independent peptides 
PKM 
Pyruvate kinase PKM 
5 independent peptides 
SDHA 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
2 independent peptides 
TPM2 
Tropomyosin beta chain 
4 independent peptides 
VIM 
Vimentin 
3 independent peptides 
MYH9 
Myosin-9 
3 independent peptides 
SNRPG 
Small nuclear ribonucleoprotein 
2 independent peptides 
SRI 
Sorcin 
4 independent peptides 
CAD 
CAD protein 
3 independent peptides 
CSE1L * 
Exportin-2 
1 independent peptides 
* was considered as potential candidate because of the identification as potential candidate in paragraph 5.1.2. Though, 
this protein would have been sorted out in the selection process in figure 8 step VII. 
The number of peptides indicated, describes the number of independent peptides identified for the corresponding protein. 
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4.1.5. Peptide pull down (PPD) of potential, epitope interacting candidates from cell 
extracts 
The peptide pull down (PPD) experiment was performed using three different, biotinylated HPV16 L2 
epitopes (aa 20-38, aa 28-42 and aa 64-81) which had previously been demonstrated to be targets 
for neutralizing antibodies. Binding of these regions by antibodies during viral infection has been 
demonstrated to prevent an efficient viral infection in vitro. This observation leads to the hypothesis, 
that the binding of the antibody might inhibit essential steps of the viral infection pathway possibly 
preventing the interaction with a specific cellular protein. To analyze these L2 regions in more detail, 
the corresponding biotinylated peptide was immobilized on avidin beads. The pull down was 
performed using cell extracts from HEK 293TT and HaCaT cells and co-purified proteins were 
analyzed by MS analysis.      
4.1.5.1. Coupling efficiency of biotinylated peptides to avidin beads 
The coupling efficiency of the biotinylated peptides to the avidin beads was confirmed by ELISA. For 
this, the ELISA plate was coated with streptavidin and the input of biotinylated peptide used for 
binding to the avidin beads was analyzed. In addition, the supernatant after binding (snt) and the 
supernatant after low pH glycine treatment (elution) were titrated on the plate (Figure 16). The low 
pH treatment was performed to test the peptide-bead-affinity under elution conditions. A high 
amount of eluted peptide from the beads could probably tamper with the following MS analysis. 
Thus, it was important to optimize the elution conditions to keep the coupled peptides bound to the 
beads while eluting potentially co-purified proteins.  
In Figure 16A,B and C, the titrations of the input, snt and elution sample derived from the three 
coupling processes are presented. The initial amount of peptide, used for the coupling (input), clearly 
demonstrated the presence of the corresponding peptide in the input samples. Comparing the input 
with the snt, representing unbound peptide, the snt showed reduced amount of peptide, indicating 
the successful coupling of the peptide to the avidin beads. This is represented by a lower absorbance 
and a faster decline of the titration curve. The low pH treated (elution) samples of the three HPV16 
L2 peptides show a similar detection level as the corresponding snt samples. Therefore, the result 
indicates, that low pH treatment did not lead to a notable release of the HPV16 L2 peptides from the 
avidin beads. Compared to the L2 peptides aa 20-38 and aa 28-42, the peptide aa 64-81 showed a 
slightly reduced binding efficiency to the avidin beads. In contrast to the other peptides, the snt with 
the unbound peptide of aa 64-81 showed a higher absorbance relative to the input. Nevertheless, 
most of the peptide was bound to the avidin beads, represented by the instant decline of the 
titration curve (Figure 16C).  
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Figure 16 Coupling efficiency of biotinylated peptide to avidin beads and influence of low pH treatment on peptide 
recognition in ELISA. The peptides used for the immobilization on the avidin beads were corresponding to the N-terminal 
epitopes targeted by neutralizing antibodies (HPV16 L2 aa 20-38, HPV16 L2 aa 28-42 and HPV16 L2 aa 64-81). The coupling 
of the biotinylated peptides was performed as described in 4.4.5. Aliquots of the input, used for coupling to the beads as 
well as the supernatant (snt) after binding and the supernatant after low pH elution (elution) were analyzed by ELISA. A 
Coupling efficiency of HPV16 L2 aa 20-38 to avidin beads. The detection was performed using the mouse monoclonal K18L2 
aa20-38 antibody and the corresponding secondary antibody. B  Coupling efficiency of HPV16 L2 aa 28-42 to avidin beads. 
The detection was performed using the mouse monoclonal K8L2 aa28-42 antibody and the corresponding secondary 
antibody. C Coupling efficiency of HPV16 L2 aa 64-81 to avidin beads. The detection was performed using the mouse 
monoclonal K1L2 aa64-81 antibody and the corresponding secondary antibody. D Test of the influence of the low pH 
glycine treatment on the ability of the specific antibody to recognize the corresponding peptides in ELISA. A sample of the 
input was treated with the elution buffer for 10min before neutralizing the pH with Tris pH 8 (Input+Glycine treatment, 
black). The second input sample was added to peptide coupled beads before treatment with the low pH buffer 
(Input+Beads+Elution, dark grey). The third sample represents the input finally added after Tris pH 8 neutralization 
(Input+Elution, light grey). Exemplarily D shows the result of the treatments, using HPV16 L2 aa 20-38. The detection was 
performed with the monoclonal mouse antibody K18L2 aa20-38 and the corresponding secondary antibody (HPV16 L2 aa 
28-42 and HPV16 L2 aa64-81, data not shown).  
In order to rule out any effect of the low pH treatment on the detection efficiency of the peptides in 
the ELISA, the input samples were tested in different setups for the detection ability. In the first 
approach, the low pH glycine buffer was added directly to the aa 20-38 input (Figure 9C, Input + 
Glycine treatment, black). Additionally, the input was either added to bead-coupled aa 20-38 peptide 
before the low pH treatment (Input + Beads + Elution, dark grey) or to the elution aliquot after low 
pH treatment of bead-coupled peptide (Input + Elution, light grey). The data shown in Figure 9D 
demonstrates the representative result of the experiment using the HPV16 L2 aa 20-38 (aa 28-42 and 
aa 64-81, data not shown). The detection levels of the three different samples show a similar 
titration profile development according to the titration of the samples. Thus, low pH treatment does 
not influence the detection of the corresponding peptide in the ELISA assay performed.   
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4.1.5.2. PPD of epitope-specific interaction candidates from cell extracts 
After establishing the immobilization of the peptides representing the L2 neutralizing epitopes, the 
pull down was performed as described in 4.4.5 to identify putative L2 cellular interaction partners. As 
input, either 2mg total protein derived from crude cell extract of either HEK 293TT or HaCaT were 
loaded onto the peptide coupled beads. As controls for the functionality of the assay, two additional 
samples of each peptide were prepared, containing either 25µg of the corresponding, epitope-
specific antibody or a control antibody for the respective peptide. Aliquots of each sample were 
tested by ELISA (Figure 17). In contrast to the previously described ELISA, the plate was coated with 
the biotinylated peptides and the eluted samples were tested for the presence of the co-purified 
positive control antibody.  
For the peptide aa 20-38, the K18L2 aa20-38 antibody (Figure 17B) was used as a positive control for 
the co-purification potential of the pull down protocol. K8L2 aa28-42 antibody served as positive 
control for the aa 28-42 peptide (Figure 17E) and K1L2 aa64-81 (Figure 17H) as positive control for 
the pull down with the aa 64-81 peptide. For each peptide, the input of antibody (input, black), the 
unbound antibody after pull down (snt, dark grey) and the antibody eluted from the beads (elution, 
light grey) was analyzed. The input sample demonstrates the presence of the corresponding antibody 
in the sample by a high absorbance in the ELISA. Furthermore, the results showed a successful 
binding of the antibody to the specific epitopes, since the absorbance in the snt samples is clearly 
reduced. After elution with the low pH glycine buffer, the antibody could be found in the 
corresponding fraction. The increased amount of antibody in the elution compared to the snt, 
indicates that treatment with a low pH buffer interferes with the binding of the antibody and the 
specific epitope and allows elution from the bead-coupled peptide. Comparing the three peptides, aa 
20-38, aa 28-42 and aa 64-81 slight differences could be observed. Whereas, elution of the K8L2 
aa28-42 and K1L2 aa64-81 showed almost the same absorbance as the corresponding input, the 
elution of the K18L2 aa20-38 showed a clear reduction in the amount of antibody compared to the 
input. However, around half of the antibody bound to the HPV16 L2 aa 20-38 peptide could be eluted 
from the beads by the low pH treatment. Thus, the previously described pull down protocol allows 
the binding and co-purification of proteins interacting with the corresponding epitope and the 
elution of the proteins for MS analysis.  
Moreover, the specificity of the pull down protocol was determined by testing negative control 
antibody in the previously described experimental set up. For this, the HPV16 L2 aa 20-38 (Figure 
17C) and HPV16 L2 aa 28-42 (Figure 17F) peptides were tested for pull down of the K1L2 aa64-81 and 
the HPV16 L2 aa64-81 peptide for the pull down of K18L2 aa20-38 (Figure 17I). The results 
demonstrated that the negative control antibody did not cross-react with any of the peptides since 
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there was no antibody detectable. Beside the controls, using either a specific or an unspecific 
antibody, a pull down with cell extract w/o antibody was performed for each peptide (Figure 17A, D 
and G). Since no antibody was added to the corresponding cell extract, the results of the ELISA are 
negative for all of the samples. The elutions derived from the pull down of Figure A, D and G, 
analyzed by MS. In addition to the samples of the PPD from the HEK 293TT extract, the 
corresponding PPDs, using HaCaT cell extract were performed and sent to the GPCF for MS analysis.        
 
Figure 17 Validation of the PPD protocol and the suitability to pull-down and elute potentially interacting candidates. 
Samples of the indicated fractions before (input) and after (snt) the pull down as well as after the low pH treatment 
(elution), were tested for the presence of epitope-specific antibodies by ELISA.  A, D and G Samples sent for MS analysis, no 
antibody added. B, E and H Positive controls, antibody specific for the corresponding peptides was added to the pull down. 
C, F and I Negative control, peptide unspecific antibody was added to the pull down. 
 
 
 
 
 
 
Results 
 
75 
 
4.1.6. Mass spectrometric analysis and selection of candidates from PPD 
The selection of candidates from the PPD, provided by the GPCF, was similar to the selection steps I.-
III., described in 5.1.2, starting with the elimination of generally known contaminants (Figure 18, step 
I.). Since the database screened for potential interaction candidates of the PPD comprised only 
human proteins, there were no non-human proteins to remove from the list of potential candidates. 
In step II., protein hits of the aa 20-38 and aa 28-42, respectively, were compared to the PPD of aa 
64-81 to eliminate hits appearing in non-overlapping peptides. Finally, proteins with less than two 
independent peptides identified were discarded (step III.). The selection process narrowed down the 
number of potential candidates to 124 identified for HEK 293TT and 11 in HaCaT cells. Out of these, 
four candidates were overlapping between the HEK 293TT MS screens and the MS HaCaT screens.  
The control database comprising different classes confirmed the results from the experiment in 
5.1.5.1, demonstrating that the bead-coupled peptide remains bound to the beads after elution of 
co-purified proteins. HPV16 L2 was identified only in the sample derived from the HPV16 L2 aa 20-38 
PPD prepared with the HEK 293TT cell extract but not in any of the other samples.   
 
Results 
 
 
 
Figure 18 Overview of the interaction candidate selection. The PPD was performed with three different biotinylated HPV16 L2 peptides ( aa 20-38, aa 28-42 and aa 64-81), using crude extract of 
either HEK 293TT or HaCaT cells. Each MS analysis revealed a different number of protein hits from which the generally known contaminants, like keratins were exclude in the first step of the 
selection procedure (step I.). In a second step the five protein hit lists derived from the same cell extract were compared to each other, to identify proteins from non-overlapping peptides, e.g. 
HPV16 L2 aa 20-38 and HPV16 L2 aa 64-81 and proteins appearing in the lists of non-overlapping peptides were suggested to be unspecific (step II.). In step III., proteins with less than 2 
independent peptides, identified for the corresponding protein, were also eliminated as potential interaction candidates. 
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Potential, epitope-specific HPV16 L2 interaction candidates identified by PPD 
Table 7: aa 20-38 from 293TT cell extract  
Protein Description 
TUBA1A Tubulin alpha-1A chain  
HNRNPK 
Heterogeneous nuclear 
ribonucleoprotein K  
CCT4 T-complex protein 1 subunit δ  
YBX3 Y-box-binding protein 3  
ANXA5 Annexin A5  
ILF3 
Interleukin enhancer-binding 
factor 3 
EIF5A 
Eukaryotic translation initiation 
factor 5A-1 
PUR6 Multifunctional protein ADE2  
PARK7 Protein DJ-1  
HNRH1 
Heterogeneous nuclear 
ribonucleoprotein H  
ADT2 ADP/ATP translocase 2 
HNRPD 
Heterogeneous nuclear 
ribonucleoprotein D0 
PABP1 Polyadenylate-binding protein 1 
SYIC Isoleucine--tRNA ligase, cytopl.  
CCT3 T-complex protein 1 subunit γ  
RS16 40S ribosomal protein S16  
NACAM 
Nascent polypeptide-associated 
complex subunit alpha, muscle-
specific form  
DYHC1 
Cytoplasmic dynein 1 heavy chain 
1 
ADT3 ADP/ATP translocase 3  
YWHAB 14-3-3 protein beta/alpha  
CAD CAD protein  
EF1D Elongation factor 1-delta 
IF2B1 
Insulin-like growth factor 2 mRNA-
binding protein 1 
EFTU Elongation factor Tu,mitochondrial  
RL13A 60S ribosomal protein L13a 
PCBP2 Poly(rC)-binding protein 2 
ODP2 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
RL10A 60S ribosomal protein L10a  
CN166 UPF0568 protein C14orf166  
SAHH Adenosylhomocysteinase  
CCT5 T-complex protein 1 subunit ε 
XRCC5 
X-ray repair cross-complementing 
protein 5 
HNRPC 
Heterogeneous nuclear 
ribonucleoproteins C1/C2  
PSA7 Proteasome subunit alpha type-7 
F10A1 Hsc70-interacting protein 
RL5 60S ribosomal protein L5  
RL35 60S ribosomal protein L35 
RM12 
39S ribosomal protein L12, 
mitochondrial  
LRC59 
Leucine-rich repeat-containing 
protein 59 
Table 8: aa 28-42 from 293TT cell extract 
Protein Description 
TBB4B Tubulin beta-4B chain  
PERM Myeloperoxidase  
SPB4 Serpin B4  
LEG7 Galectin-7  
STIP1 Stress-induced-phosphoprotein1  
HBA Hemoglobin subunit alpha 
H2B1B Histone H2B type 1-B  
CATD Cathepsin D  
Table 9: aa 20-38 and aa 28-42 from 293TT 
cell extract 
Protein Description 
CH60 60 kDa heat shock protein, 
mitochondrial 
PYC Pyruvate carboxylase, 
mitochondrial 
ENOA Alpha-enolase 
KPYM Pyruvate kinase PKM  
VIME Vimentin  
TPIS Triosephosphate isomerase  
RLA0 60S acidic ribosomal protein P0  
RSSA 40S ribosomal protein SA 
ATPA ATP synthase subunit alpha, 
mitochondrial  
TCPQ T-complex protein 1 subunit theta  
ATPB ATP synthase subunit beta, 
mitochondrial  
RL12 60S ribosomal protein L12  
YWHAZ 14-3-3 protein zeta/delta  
SYDC Aspartate--tRNA ligase, cytopl. 
KCRB Creatine kinase B-type 
XRCC6 X-ray repair cross-complementing 
protein 6 
YWHAE 14-3-3 protein epsilon 
LDHB L-lactate dehydrogenase B chain  
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ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial  
YWHAQ 14-3-3 protein theta  
TCPA T-complex protein 1 subunit alpha  
COF1 Cofilin-1  
PPIA Peptidyl-prolyl cis-trans isomerase 
A  
PDIA4 Protein disulfide-isomerase A4 
LDHA L-lactate dehydrogenase A chain  
C1QBP Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial  
PRDX6 Peroxiredoxin-6  
ENPL Endoplasmin  
TCPZ T-complex protein 1 subunit zeta  
MDHM Malate dehydrogenase, 
mitochondrial  
SERA D-3-phosphoglycerate 
dehydrogenase  
CH10 10 kDa heat shock protein, 
mitochondrial  
ALDOA Fructose-bisphosphate aldolase A  
EF1G Elongation factor 1-gamma  
SYRC Arginine--tRNA ligase, cytoplasmic 
RS19 40S ribosomal protein S19 
EF1B Elongation factor 1-beta  
IF4A1 Eukaryotic initiation factor 4A-I  
PCNA Proliferating cell nuclear antigen  
NDKA Nucleoside diphosphate kinaseA 
TPM3 Tropomyosin alpha-3 chain  
MCA3 Eukaryotic translation elongation 
factor 1 epsilon-1  
ROA2 Heterogeneous nuclear 
ribonucleoproteins A2/B1  
RS26 40S ribosomal protein S26  
BLMH Bleomycin hydrolase  
PCBP1 Poly(rC)-binding protein 1  
PROF1* Profilin-1  
PRDX3 Thioredoxin-dependent peroxide 
reductase, mitochondrial 
GLU2B Glucosidase 2 subunit beta  
Table 10: aa 64-81 from 293TT cell extract 
Protein Description 
LCN1 Lipocalin-1  
GSDMA Gasdermin-A  
*
Protein was identified in PPD aa 20-38 and aa 28-42 
from 293TT cell extract as well as in PPD aa 28-42 from 
HaCaT cell extract 
 
 
 
Table 11: Potential candidates, aa 20-38 from 
HaCaT cell extract 
Protein Description 
TRFL Lactotransferrin  
ZG16B Zymogen granule protein 16 
homolog B  
HS71L Heat shock 70 kDa protein 
1-like  
APOD Apolipoprotein D 
CLUS Clusterin  
BPIB1 BPI fold-containing family B 
member 1  
Table 12: Potential candidates, aa 28-42 from 
HaCaT cell extract 
Protein Description 
PROF1* Profilin-1 
*
Protein was identified in PPD aa 20-38 and aa 28-42 
from 293TT cell extract as well as in PPD aa 28-42 from 
HaCaT cell extract 
Table 13: Potential candidates, overlapping 
aa 20-38 and aa 28-42 from HaCaT cell 
extract 
Protein Description 
SPB12 Serpin B12  
SPB3 Serpin B3  
S10A7 Protein S100-A7 
No proteins, matching the exclusion criteria in Figure 18 
were identified for the peptide aa 64-81 from HaCaT cell 
extract. 
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4.1.7. Shortlisting  of candidates from the different MS analyses for further analysis 
In order to select for the most promising HPV16 L2 interaction candidates, the results of the MS 
analyses from paragraphs 5.1.2, 5.1.4 and 5.1.6 were compared. Comparing the selected candidates, 
two proteins were observed to appear in the MS results of two independent experiments. The CSE1L 
was detected in the MS analysis of the TAP (full length HPV16 L2 and HPV16 L2_Fr.1, Table 5) as well 
as in the MS analysis of the PsV-IP (HPV16 L1/L2 K1L2 aa64-81 and MD2H11_L1) (Table 6). Whereas, 
CSE1L was identified in the TAP analysis with at least 2 independent peptides, the result from the 
PsV-IP revealed only one independent peptide in the corresponding screens. Additionally, YWHAZ 
was identified in two MS analyses of basically different experiments (TAP and PPD). The TAP analysis 
showed YWHAZ to be co-purified with the full length HPV16 L2 protein as well as the HPV16 L2_Fr.1 
(aa 1-193). Furthermore, YWHAZ was identified in the PPD from HEK 293TT extracts, using the 
overlapping epitopes aa 20-38 (2 peptides) and aa 28-42 (5 peptides). The PPD from HaCaT cell 
extract identified YWHAZ only in the screen using the epitope aa 28-42 (1 peptide). No further 
overlaps could be observed between the MS analyses from the different experimental set ups. 
Nevertheless, IRS4, CAPN2 and CAND1 were selected as promising interaction candidates of HPV16 
L2. Each of these proteins was detected in the TAP MS in more than one screen of different HPV16 L2 
constructs. Moreover, the number of identified, independent peptides, corresponding to the specific 
protein, was observed to be between 2 and 5. Each protein had at least one peptide set of 3-5 
peptides. From the potential interaction candidates shown in Table 1, three proteins were discarded 
subsequently since they were identified only with a single peptide (FLG2, Skp1, and TGM3). 
Furthermore, the elongation factor 1 alpha was also rejected as potential candidate, since this 
protein appeared unspecifically in each screen of the PsV-IP as well as the PPD samples.  
The PsV-IP MS analysis revealed another set of 16 potential candidates. However, some of these 
candidates were excluded subsequently, since they might have been co-purified because of HPV16 
L2 independent interactions. Amongst others, these proteins were histone proteins, HIST1H1C, 
HIST1H2BC and H3F3A, which might rather be connected to the reporter DNA, still encapsidated by 
L1 and L2. The identification of histones could be considered as positive control for successful IP of 
the PsV from the cells extracts. Several proteins were identified, interacting with actin, a common 
contaminant of MS analyses and therefore might be co-purified with actin instead of HPV16 L2 
specifically (TPM2, VIM, MYH9). Another group of co-purified proteins belong to the T complex 
proteins (CCT5, CCT3 and CCT4), a family of chaperons, involved in protein folding and ciliogenesis. 
Moreover, the ribosomal protein (RPS2), two enzymatic proteins (PKM and CAD), a protein involved 
in mitochondrial electron transport (SDHA) as well as SNRPG (RNA binding component of the 
spliceosome) an SRI (activator of the RYR2 calcium channel) were rejected as potential candidates 
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because of the lack of sufficient evidence for a potential function as HPV16 L2 interaction candidate. 
Furthermore, there were no additional candidates selected from the MS of the PPD, since the 
number of candidates was still too large, even after the selection process (Figure 18) to select for any 
promising candidate from the list of protein hits. 
Table 14: Summary of L2 interaction candidates shortlisted for further analysis 
Protein 5.1.2 TAP 5.1.4 PsV-IP 5.1.6 PPD 
IRS4 
full length L2_1: 2 peptides 
full length L2_2: 4 peptides 
HPV16 L2_Fr.3: 4 peptides 
not identified  not identified 
YWHAZ 
full length L2_2: 1 peptide 
HPV16 L2_Fr.1: 2 peptides 
not identified 
aa 20-38: 5 peptides (293TT) 
aa 28-42: 2 peptides (293TT) 
aa 28-42: 1 peptide (HaCaT) 
CSE1L 
full length L2_2: 2 peptides 
HPV16 L2_Fr.1: 2 peptides 
K1L2 aa64-81: 1 peptide 
MD2H11_L1: 1 peptide 
not identified 
CAPN2 
full length L2_1: 4 peptides 
HPV16 L2_Fr.1: 3 peptides 
not identified not identified 
CAND1 
full length L2_2: 3 peptides 
HPV16 L2_Fr.1: 2 peptides 
not identified not identified 
The number of peptides indicated, describes the number of independent peptides identified for the corresponding protein. 
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4.2. Validation of the Selected Potential Interaction Candidates 
The previously selected interaction candidates (5.17) were further analyzed to verify their potential 
to physically interact with HPV16 L2. Therefore, specific candidates were selected and expressed as a 
fusion protein containing a myc- and flag-tag, respectively. The following experiments were 
performed using the tagged versions of the interaction candidates, as well as an untagged version of 
HPV16 L2 to validate the predicted interaction capacity of the proteins. 
4.2.1. Co-immunoprecipitation (Co-IP) of candidates and L2  after overexpression 
The Co-IP to validate the selected candidates was either performed using an α-myc monoclonal 
antibody for precipitation of the candidate or a polyclonal HPV16 L2-specific rabbit serum (serum #7) 
for precipitation of HPV16 L2. The cell extracts, containing the overexpressed proteins, for both IPs 
derived from the same transfection of cells. The amount of protein used for the IP was analyzed by 
western blot, using either the α-myc or the K4L2 aa20-38 antibody (Figure 19A, B). The candidates 
tested in the presented experiment were IRS4, CAND1, CAPN2, CSE1L, YWHAZ as well as eEF1A1 and 
hnRNPK (both serve as control for unspecific co-purification) which were overexpressed in HEK 293TT 
cells either in absence or presence of HPV16 L2. The red stars in figure 19 highlight unspecifically co-
purified candidates, whereas green stars highlight specifically co-purified candidates. Though 
detection with the α-myc antibody demonstrated that each candidate was expressed, there are 
differences in the expression levels comparing the candidates among each other (Figure 19A). Also 
expression levels of the same candidate varied slightly in absence (w/o) and presence (w/) of HPV16 
L2. It seemed that co-transfection of L2 led to a decreased expression level of the corresponding 
candidates, except for eEF1A1 which showed an increased expression level when co-expressed with 
HPV16 L2. Beside the specific bands, highlighted with stars, unspecific protein bands were detected 
in some samples (e.g. eEF1A1 and IRS4). Figure 19B shows the expression of HPV16 L2 in the 
corresponding cell lysates. The result demonstrated that HPV16 L2 was expressed at similar levels in 
each sample, except for the sample co-transfected with CAPN2.  
Co-IP of HPV16 L2 by precipitation of myc-tagged candidates using an α-myc antibody 
The result of the precipitation with the α-myc antibody is presented in figure 19C and D. The co-
precipitation of HPV16 L2 in the corresponding samples is presented in figure 19D. IP of all myc-
tagged candidates led to co-purification of HPV16 L2, while no L2 was detected when lysates without 
myc-tagged protein were used.  The signal intensity of HPV16 L2 was highly different among the 
different precipitations. YWHAZ showed only a very faint band for co-purified HPV16 L2, whereas the 
samples showed higher amounts of L2. As positive control for precipitation, the samples were tested 
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by western blot after IP for the presence of the myc-tagged candidates (C). The result showed that 
the precipitation of the target proteins was successful as each myc-tagged candidate could be 
detected. Precipitation efficiency varies for the different candidates, but also comparing the same 
candidate in the IP w/o and w/ HPV16L2. Since the IP and the detection of the western blot were 
performed both, using the α-mouse secondary antibody, the heavy (~50kDa) and the light chain 
(~25kDa) were detected additionally.  
 
Figure 19 Co-IP of interaction candidates after overexpression with and without HPV16 L2. The Co-IP was performed using 
either a polyclonal HPV16 L2 rabbit serum (serum #7, diluted 1:100) or a monoclonal α-myc antibody (undiluted). The Input 
of the myc-tagged candidate as well as the HPV16 L2 protein was analyzed by western blot detected either with an α-myc 
(A) or an  α-HPV16 L2 antibody (B). The corresponding extract was splitted into two parts, whereas one part was used for 
an IP of the myc-tagged candidates (C and D) and the other part for an IP against HPV16 L2 (E and F). Red stars highlight 
unspecifically co-purified interaction candidates, green stars highlight the verified candidates and red arrows highlight 
HPV16 L2. Heavy and light chain, derived from the antibodies used for IP, are highlighted with blue arrows.  
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Co-IP of myc-tagged candidates by precipitation of HPV16 L2  
IP of HPV16 L2 was performed using a polyclonal rabbit serum (serum #7). Figure 19F confirms the 
successful precipitation of L2 from the lysates transfected with HPV16 L2 (w/ HPV16 L2). According to 
the lower expression level of L2 when co-expressed with CAPN2 (Figure 19B) the corresponding IP 
revealed less HPV16 L2. Co-precipitation of the myc-tagged candidates was analyzed, using the α-
myc antibody for western blot detection (Figure 19E). All of the candidates were co-purified with 
HPV16 L2 (w/ HPV16 L2), however, showing different precipitation efficiency. IRS4, CAND1, CAPN2, 
CSE1L and YWHAZ were demonstrated to be specifically co-precipitated, since the corresponding 
signals were only detected in the IP w/ HPV16 L2. In contrast, eEF1A1 and hNRNPK could also be 
detected in the samples w/o HPV16 L2. These two proteins seemed to be unspecifically co-purified 
during the IP. The result confirms the ability of a physical interaction of HPV16 L2 with IRS4, CAND1, 
CAPN2, CSE1L and YWHAZ.  
4.2.2. PPD of potential candidates after overexpression 
To further validate the candidates and maybe verify potential interaction sites, the myc-tagged 
candidates were analyzed by PPD after overexpression. For this, 293TT cells were transfected with 
the specific candidate (SNX17, IRS4, YWHAZ, CSE1L, CAPN2 and SPOP) and cell extracts were used for 
pull-down with the three different, biotinylated HPV16 L2 peptides (aa 20-38, aa 28-42 and aa 64-
81). SPOP as a cellular factor for transduction was not identified in any of the previous experiments 
but derived from an independent study (Burkart et al. unpublished) screening for potential AAV VP1 
interaction candidates. Therefore it was included as negative control for further experiments. As 
controls for the specific interaction with the epitopes, blocking of the corresponding binding sites 
were included using either an epitope-specific (K18L2 aa20-38, K8L2 aa28-42 or K1L2 aa64-81) or 
unspecific antibody (mouse serum from a non-immunized mouse or K18L2 aa20-38). The results of 
the experiment are presented in figure 20. The first epitope to be tested was a biotinylated HPV16 L2 
aa 20-38 peptide, which was previously immobilized on avidin beads (Figure 20A and B). The western 
blot analysis in figure 20A shows the PPD using the immobilized peptide without blocking of the 
corresponding peptide as well as blocked with the epitope-specific antibody K18L2 aa20-38. When 
the epitope was available for protein binding (w/o antibody) the purification of YWHAZ and CAPN2 
could be observed. Furthermore, faint bands for IRS4 (~160kDa) and CSE1L (~80kDa), were detected 
in the corresponding PPDs. After blocking of the epitope with K18L2 aa20-38, none of the candidates 
was pulled down by PPD. The control western blot in figure 20B shows the samples of a second PPD 
w/o antibody and the negative mouse serum.  
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Figure 20 Binding of selected candidates to the HPV16 L2 epitopes aa 20-38, aa 28-42 and aa 64-81. The PPD was 
performed using cell extracts from transfected 293TT cells, overexpressing the indicated candidate either as myc-tagged 
protein (SNX17, IRS4, YWHAZ, CSE1L, CAPN2 and SPOP). For detection the indicated primary antibodies (α-myc antibody or 
14-3-3ζ) were used. The immobilized peptides were either not treated at all (w/o antibody), with an epitope unspecific 
antibody (neg. mouse serum or K18L2 aa20-38) or with an epitope-specific antibody (K18L2 aa20-38, K8L2 aa28-42 or K1L2 
aa64-81) to block potential interaction with the candidates. Heavy and light chains derived from the antibody, used to block 
potential binding sites, are highlighted with red arrows whereas the myc-tagged YWHAZ as well as the endogenous YWHAZ 
are highlighted with green arrows. A and B PPD using the immobilized HPV16 L2 aa 20-38 epitope. C, D and E PPD using the 
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immobilized HPV16 L2 aa 28-42 epitope. F and G PPD using the immobilized HPV16 L2 aa 64-81 epitope. Note: SPOP was 
identified as AAV interaction candidate (Burkart et al. unpublished). 
The detection via the α-myc antibody after PPD correlates with the result from A at least in case of 
the YWHAZ. Comparing the two PPD w/o antibody in A and B, the signal representing CAPN2 and 
CSE1L could not be reproduced. A similar result can be observed for the IRS4, since in this sample, 
only the not specifically detected lower band could be detected after PPD w/o antibody. However, 
after treatment of the beads with the neg. mouse serum and the following PPD, YWHAZ could still be 
co-purified with the aa 20-38 biotinylated peptide. Additionally, a faint signal for CAPN2 in the neg. 
mouse serum treated sample was detectable.   
The same experimental set up was performed using the HPV16 L2 aa 28-42 peptide. The samples 
were analyzed by western blot using either the α-myc antibody (C and E) or a α-YWHAZ antibody (D, 
14-3-3ζ). In Figure 20C, the PPD was performed w/o antibody as well as with K8L2 aa28-42, supposed 
to specifically block binding of proteins to the aa 28-42 epitope. When the epitope was available for 
protein binding, YWHAZ could be purified, whereas none of the other samples showed a detectable 
amount of myc-tagged protein. After addition of the epitope specific K8L2 aa28-42, each of the 
antibody treated samples showed a strong detection of unspecific bands, derived from the antibody 
(heavy and light chain, highlighted with red arrows) since K8L2 aa28-42 and the α-myc antibody 
derived from the same host species. Binding of YWHAZ seemed to be inhibited by the epitope-
specific antibody, though the intensity of unspecific signals was too high to conclude certainly. 
Therefore, the corresponding samples were tested, using an YWHAZ-specific antibody derived from 
rabbit for better detection of the protein (D). The result confirmed purification of YWHAZ when the 
epitope was available for binding. The upper band corresponds to the molecular weight of the myc-
tagged YWHAZ, whereas the lower signal corresponds to the endogenous YWHAZ (green arrows). 
After blocking of the epitope with the K8L2 aa28-42, neither the myc-tagged YWHAZ nor the 
endogenous YWHAZ could be detected anymore. Figure 20E presents the result of the second 
experiment, performed without antibody or with the neg. mouse serum as a control. Repetition of 
the PPD w/o antibody showed a similar result as the previous experiment, detecting only YWHAZ-
myc after PPD. Though, YWHAZ could not be purified after incubation of the coupled peptide with 
the neg. mouse serum. In addition, the detection shows pull down of CAPN2 and the unspecific band 
in the IRS4 sample, mentioned previously in Figure 20B. The PPD performed with the peptide aa 64-
81 did not show any purified protein, independent of the availability of the epitope for binding 
(Figure 20F and G). As indicated by the red arrows, the only detectable signal found in F derived from 
the heavy and light chain of the K1L2 aa 64-81, used to block the aa 64-81 for protein interaction.  
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4.2.3. Analysis of co-localization of the candidates and L2 after overexpression 
The IF was performed as previously described using myc- or flag-tagged candidates together with an 
untagged version of HPV16 L2. Both proteins were co-expressed in HeLa cells and stained afterwards 
with a rabbit derived myc-/flag-specific antibody and the K4L2 aa20-38 targeting HPV16 L2. The 
staining was analyzed using the Zeiss Cell Observer and the Zeiss Zen Black Software. As a positive 
control for interaction, a SNX17-GFP construct was used which was kindly provided by the group of 
Dr. Laurence Banks. The staining of the cells was conducted as described in 4.4.4. For quantification 
of subcellular localization of the candidates and HPV16 L2, 50 cells expressing the corresponding set 
of transfected proteins were counted on two independent slides and the localization of each protein 
was analyzed (Figure 21A and B).  
Subcellular localization of potential candidates in absence and presence of HPV16 L2  
Figure 21A presents the quantification of the potential candidates as well as the positive control 
SNX17-GFP in absence (w/o) and presence of HPV16 L2 (w/). SNX17-GFP, previously published to 
interact with L2 [109, 110] was localizes exclusively in the cytoplasm (black) when expressed w/o 
HPV16 L2. Figure 22A, demonstrates the cytoplasmic localization and shows the accumulation of 
SNX17-GFP in speckles throughout the cytoplasm (upper panel). However, co-expression with L2 
shifted SNX17 localization to 70% cytoplasmic, 20% nuclear (dark grey) and 10% cytoplasmic/nuclear. 
Independent of the localization of SNX17-GFP, the protein was found in speckle-like structures. The 
merge of SNX-GFP and the L2 staining demonstrated the co-localization in the speckles, either in the 
cytoplasm or the nucleus (Figure 22A, lower panel). Beside the positive control, YWHAZ and CSE1L 
showed a change in subcellular localization when co-expressed with L2. In absence of L2, 50% of cells 
showed a cytoplasmic localization of YWHAZ, demonstrated in figure 22C (upper panel). In the 
remaining cells, YWHAZ was found in the nucleus (20%) or distributed in nucleus and cytoplasm 
(30%). When co-expressed with HPV16 L2 (YWHAZ w/) the proportion of cells with cytoplasmic 
localization of YWHAZ increased to 75%. Figure 22C (lower panel) shows an example of the YWHAZ 
localization in presence of L2. YWHAZ was mainly found in the cytoplasm and less in the nucleus. Co-
localization could be observed when either L2 was found cytoplasmic together with YWHAZ or in 
some cells when YWHAZ was localized in the nucleus. CSE1L in absence of HPV16 L2 was observed to 
be localized in the nucleus in 98% of the cells. Co-expression of HPV16 L2 (CSE1L w/), however, led to 
an increased distribution of CSE1L in the nucleus and the cytoplasm (light grey). The change of the 
CSE1L localization pattern is demonstrated additionally in Figure 23A, comparing the upper panel 
(w/o L2) and the lower panel (w/ L2). Furthermore, figure 23A shows co-localization of CSE1L and 
HPV16 L2 at the perinuclear region (merge, lower panel). The influence of HPV16 L2 on the 
subcellular localization was observed to be less pronounced for CAPN2 and CAND1. For CAPN2 a 
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slight increase in the cytoplasmic localization (black) could be observed in presence of L2, whereas a 
decrease of cytoplasmic localization (black) was observed when CAND1 was co-expressed with L2. 
 
Figure 21 Subcellular localization of potential candidates in presence or absence of HPV16 L2. The quantification of the IF 
samples was performed by staining two slides with cells overexpressing either the indicated candidate in absence (w/o) or 
presence (w/) of HPV16 L2 or HPV16 L2 only in HeLa cells. The antibodies used for staining of the cells were rabbit derived 
α-myc and α-flag, respectively and the HPV16 L2-specific, mouse monoclonal K4L2 aa20-38. The secondary antibodies were 
coupled to Alexa595 (α-rabbit) and Alexa488 (α-mouse). On each slide, 50 cells expressing the transfected protein set were 
analyzed for the localization of the potential candidate and the localization of HPV16 L2. The quantification data was then 
summarized in the presented bar graphs. Cytoplasmic localization is shown in black, nuclear localization in dark grey and 
the light grey part does represent a localization distributed in the cytoplasm as well as in the nucleus. A Quantification of 
the candidate localization in absence (w/o) or presence (w/) of HPV16 L2. B Quantification of the distribution pattern of 
HPV16 L2 either expressed alone or in presence of the indicated candidate.  
A co-localization of HPV16 L2 and CAPN2 could be observed at the perinuclear region or in some 
cases, when L2 was localized in the cytoplasm of the cell (Figure 23B, lower panel). A similar result 
was observed for the co-localization of CAND1 and HPV16 L2 (Figure 23C). The analysis of IRS4 did 
not show any changes in the localization pattern in presence of HPV16 L2. However, a small number 
of cells showed nuclear localization of IRS4 in a speckle-like pattern (Figure 22B). Co-localization of 
IRS4 and L2 was observed in the described nuclear speckles as well as in rare cases where L2 was 
found to be localized in the cytoplasm.       
Subcellular localization of HPV16 L2 in absence or presence of the potential candidates  
In addition to the localization of potential interaction candidates, the cellular distribution of HPV16 
L2 was analyzed when expressed alone or together with the corresponding candidates (Figure 21B). 
When L2 was expressed in absence of potential interaction candidates, the protein was found to be 
localized mainly in the nucleus (dark grey, 95%). Co-expression with the known interaction candidate 
SNX17-GFP showed a strong effect on L2 localization. L2 was found to be distributed in the nucleus 
and the cytoplasm (light grey) in 50% of the cells, whereas the nuclear (black) proportion of L2 
decreased to 30%. This result was confirmed by the co-localization experiment shown in figure 22A 
(lower panel). The remaining 20% of the cells showed an exclusively cytoplasmic localization of L2 
when co-expressed with SNX17-GFP. The co-expression of L2 with CSE1L showed a shift towards a 
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more nuclear/cytoplasmic (Figure 21B,light grey and Figure 23A, lower panel) localization of L2, 
though to lower extend than the positive control. An effect on L2 localization could not be observed 
for any of the other candidates. 
  
 
 
Figure 22 Subcellular localization of potential interaction candidates in absence and presence of HPV16 L2. The staining of the samples was performed using either a rabbit derived α-myc or a 
rabbit derived α-flag antibody in combination with the corresponding α-rabbit-A488 secondary antibody (green). HPV16 L2 was stained with K4L2 aa20-38 and a α-mouse-A594 antibody (red) as 
well as DAPI (blue) to stain the DNA in the nucleus. A SNX17-GFP expressed without (upper panel) or together with HPV16 L2 (lower panel). B, C Staining of the indicated myc-tagged candidates 
expressed without (upper panel) and with (lower panel) HPV16 L2. D Localization of HPV16 L2 localization when expressed in absence of overexpressed candidate interaction partner. 
  
 
 
Figure 23 Subcellular localization of potential interaction candidates in absence and presence of HPV16 L2. The staining of the samples was performed using either a rabbit derived α-myc or a 
rabbit derived α-flag antibody in combination with the corresponding α-rabbit-A488 secondary antibody (green). HPV16 L2 was stained with K4L2 aa20-38 and a α-mouse-A594 antibody (red) as 
well as DAPI (blue) to stain the DNA in the nucleus. A Staining of flag-tagged CSE1L2 expressed without (upper panel) or together with HPV16 L2 (lower panel). B, C Staining of the indicated myc-
tagged candidates expressed without (upper panel) and with (lower panel) HPV16 L2. D Localization of HPV16 L2 localization when expressed in absence of overexpressed candidate interaction 
partner. 
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Co-localization analysis of IRS4, YWHAZ and CSE1L with HPV16 L2  
The co-localization of three selected candidates (IRS4, YWHAZ and CSE1L) as well as the positive 
control (SNX17) with HPV16 L2 was further analyzed by confocal microscopy (Figure 24). Since 
confocal microscopy is specifically designed to detect signals exclusively in the focal plane, this 
method is suitable to further analyze co-localization of the candidates with HPV16L2.  
As described previously, SNX17-GFP was localized mainly in the cytoplasm with an overall staining 
pattern when expressed in absence of HPV16 L2 (Figure 24A, upper panel). After co-expression of 
SNX17-GFP (green) with HPV16 L2 (red) (Figure 24A, lower panels), both proteins were detected in 
dot-like structures mainly in the nucleus but also in the cytoplasm. For both localization patterns 
observed, co-localization in the described speckles could be observed, independent of nuclear or 
cytoplasmic localization. Overexpression of IRS4 alone showed an exclusive localization in the 
cytoplasm of transfected cells (Figure 24B, upper panel). However co-expression of IRS4 together 
with HPV16 L2 led to a more homogenous staining of the cells including staining in the cytoplasm as 
well as in the nucleus. HPV16 L2 seems to recruit some IRS4 to the nucleus, even though only in a 
few cells a partial co-localization at the periphery of the nucleus could be observed (Figure 24B, 
lower panels). In most of the cells co-expressing IRS4 and HPV16 L2 did not show co-localization of 
IRS4 and HPV16 L2 in the nuclear proportion of the proteins. A similar result was obtained analyzing 
YWHAZ. While YWHAZ is mainly localized in the cytoplasm when expressed in absence of HPV16 L2 
(Figure 24C, upper panel), an increased proportion of the protein is located in the nucleus after co-
expression of L2 (Figure 24C, lower panels). Co-localization of YWHAZ and HPV16 L2 in the nucleus 
could be observed in some of the transfected cells. However, transition of YWHAZ to the nucleus did 
not obligatory lead to co-localization of the two proteins. Staining of CSE1L, a member of the 
exportin family, showed a nuclear localization of the protein when expressed alone in the cells 
(Figure 24D, upper panel). In rare cases, an additional staining could be observed in the cytoplasm of 
CSE1L expressing cells in absence of L2 (not shown). When CSE1L was overexpressed together with 
HPV16 L2, the L2 staining was detected exclusively in the nucleus of the transfected cells. Also the 
CSE1L was located predominantly in the nucleus however the transfected cells additionally showed 
increased cytoplasmic CSE1L staining (Figure 24D, lower panels). Even though the intensity of the 
cytoplasmic staining varied, it was observed in most of the cells co-expressing CSE1L and HPV16 L2. 
Furthermore, co-localization of CSE1L and HPV16 L2 could be detected for the proteins localized in 
the nucleus with an accumulation of both proteins towards the periphery of the nucleus.  
The results of the confocal microscopy analysis demonstrated a partial co-localization of IRS4 and 
YWHAZ, respectively, with HPV16 L2 after overexpression of the proteins. Even though the co-
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localization was not observed continuously in all of the cells, an increased nuclear localization of IRS4 
and YWHAZ was found in cells co-expressing HPV16L2. For both proteins, HPV16 L2 seemed to have 
an influence on the subcellular localization, though the interaction might by transient. Additionally 
co-localization of CSE1L with HPV16 L2 could be demonstrated towards the periphery of the nucleus 
and was observed in the majority of transfected cells.  
 
  
 
 
Figure 24 Subcellular localization of potential 
interaction candidates in absence and presence 
of HPV16 L2. Potential interaction candidates 
were expressed either in absence or presence of 
HPV16 L2. For visualization purposes, the 
candidates were used as a myc-tagged version, 
except SNX17, which was used as a fusion 
protein with GFP. The staining of the potential 
interaction candidates was performed using a 
rabbit derived α-myc antibody in combination 
with the corresponding α-rabbit-A488 secondary 
antibody (green). HPV16 L2 was stained with 
K4L2 aa20-38 and a α-mouse-A594 antibody 
(red). DAPI (blue) was used to stain the DNA in 
the nuclei. The analysis was performed by 
confocal microscopy. A Staining of SNX17-GFP 
expressed without (upper panel) or together 
with HPV16 L2 (lower panels). B, C and D 
Staining of the indicated myc-tagged candidates 
expressed without (upper panel) and with (lower 
panels) HPV16 L2.  
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4.2.4. Influence of siRNA Knockdown of potential Candidates on HPV16 PsV 
transduction 
To gain further insight in the interaction of the selected candidates with HPV16 L2, siRNA knockdown 
of the corresponding candidates followed by HPV16 PsV transduction was performed. Therefore the 
expression of a specific candidate was down-regulated by treatment with siRNAs, targeting the 
mRNA of interest for degradation. 48h after siRNA treatment, the cells were infected with HPV16 PsV 
and the transduction efficiency was measured by Gaussia luciferase activity 48h post-infection. The 
experiment was performed to analyze the effect of the knockdown of distinct candidates on the 
infectivity of HPV16 PsV. For each candidate, a set of four different siRNAs was tested, targeting 
different regions of the corresponding mRNA. SNX17 was used as a positive control, since knockdown 
of SNX17 has previously been published to reduce HPV16 as well as HPV18 PsV transduction 
efficiency [109, 110]. For each assay performed in this study, the samples were tested in duplicates 
which were individually analyzed by western blot to determine the corresponding protein levels. 
HPV16 transduction efficiency after siRNA knockdown of potential L2 interaction candidates 
Figure 25A represents the summary of three independent siRNA knockdown experiments, using four 
different siRNAs for each candidate (IRS4, YWHAZ, CSE1L, CAPN2, CAND1 and SPOP) as well as the 
positive control SNX17. SPOP was included into the study, since it was previously identified as a AAV 
VP1 interaction candidate in a colleagues study (Burkart et al. unpublished). As negative control, cells 
were treated with a scrambled siRNA control which served as reference for PsV infectivity and 
represents 100% transduction (siRNA ctrl.). Additionally, one sample was not treated with any kind of 
siRNA (w/o siRNA). As published previously, knockdown of SNX17 expression led to reduced HPV16 
PsV transduction at least in three out of the four tested siRNAs. The western blot analysis of the 
protein levels in the corresponding samples could validate successful knockdown for all of the siRNAs 
tested (Figure 25B). Also for the samples treated with the IRS4 siRNA, an inhibited transduction 
efficiency of HPV16 PsV could be observed in three of the tested samples. Even though the effect 
was slightly less pronounced compared to the positive control, the transduction was reduced to 
~60% compared to the reference, treated with the siRNA ctrl.. However, the cells treated with the 
siRNA IRS4_3 showed an increased transduction with PsV of about 20% (Figure 25A). Knockdown of 
IRS4 could not be validated by western blot, due to a lack of a proper primary antibody targeting 
endogenous IRS4.  
Additionally, HPV16 PsV transduction was observed to be decreased in three of the tested YWHAZ 
knockdown samples. Compared to the positive control, the inhibition of PsV infectivity was less 
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efficient with a transduction of about 80% remaining activity compared to the siRNA ctrl. reference. 
Cells treated with the siRNA YWHAZ_7 even showed a slightly increased infection level which was 
similar to the w/o RNA ctrl. (Figure 25A). This might indicate an insufficient knockdown, resulting in a 
higher amount of surviving cells after siRNA treatment.  
 
Figure 25 Influence of siRNA Knockdown of potential Candidates on HPV16 PsV transduction. A Cells were treated either 
with siRNAs targeting the potential interaction candidates (IRS4, YWHAZ, CSE1L, CAPN2, CAND1 and SPOP) or a scrambled 
siRNA control. For each candidate a set of four different siRNA, targeting different regions of the target mRNA, were used. 
As a positive control for reduced transduction with HPV16, siRNAs against SNX17 were included in the assay. The cells were 
infected with HPV16 PsV containing a Gaussia luciferase reporter plasmid and transduction was analyzed 48h after 
infection. B, C, D and E western blot analysis of proteins levels after knockdown of the indicated siRNAs and infection with 
HPV16 PsV. D reduced protein levels of CSE1L_3 might be due to incomplete transfer of proteins to the nitrocellulose 
membrane during western blot analysis. F Transduction of AAV2 was tested after knockdown with four different siRNAs 
targeting either CSE1L or SPOP compared to the cells treated with the scrambled siRNA control. The cells were infected 
with MOI 1000 of AAV2, containing a Gaussia reporter plasmid for 48h. Note: SPOP was previously identified as AAV 
interaction candidate (Burkart et al. unpublished). 
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The analysis of protein levels in the corresponding samples by western blot confirms an insufficient 
knockdown in the samples treated with siRNA YWHAZ_7. In the samples with reduced transduction 
of HPV16 PsV correlating knockdown efficiency on YWHAZ protein levels were observed (Figure 25C).  
The treatment of cells with siRNAs targeting CSE1L led to inhibition of PsV infectivity in all the 
samples except the siRNA CSE1L_3 treated cells. The decrease of HPV16 PsV transduction efficiency 
was observed to be between 50% (CSE1L_2) and 20% (CSE1L_4 and CSE1L_7). However, the cells 
treated with CSE1L_3 showed an opposite effect on transduction with an increase of around 40% 
compared to the siRNA ctrl. (Figure 25A). According to the western blot analyzing of the protein 
levels of CSE1L, the knockdown was most efficient for the sample CSE1L_4 and CSE1L_7 (Figure 25D), 
both showing medium reduction levels in the transduction assay (Figure 25A). The strongest effect in 
the transduction assay was measured in the sample CSE1L_2, though the protein levels in the 
duplicates were only slightly reduced. Intermediate knockdown efficiency was detected for CSE1L_3 
treated cells (Figure 25D) which showed increased transduction with HPV16 PsV (Figure 25A). 
However, the observed reduction in CSE1L protein level in this sample might also be due to 
incomplete transfer of the corresponding proteins during western blot analysis. 
For the analysis of CAPN2 knockdown on the transduction with HPV16, no effect on infectivity could 
be observed (Figure 25A) even though knockdown efficiency was validated for all samples by western 
blot (Figure 25E). A similar result was obtained for CAND1, only a single siRNA (CAND1_4) showed a 
slight inhibiting effect on PsV infection. Since no suitable antibody against CAND1 was available, 
knockdown efficiency was not analyzed for the samples treated with siRNA against CAND1. 
Knockdown of SPOP led to decreased infection levels for all of the tested samples of about 50%-20% 
compared to the siRNA ctrl.. However, protein levels of the samples could not be analyzed since the 
endogenous SPOP protein level in untreated cells was below the detection limit in the western blot 
analysis. The results of the knockdown experiment indicated an inhibiting impact of IRS4, YWHAZ, 
CSE1L and SPOP knockdown on HPV16 PsV transduction. Whereas, knockdown of CAPN2 and CAND1 
did not seem to have any influence on PsV infection.  
Influence of siRNA knockdown of potential HPV16 L2 interaction candidates on AAV2 transduction 
efficiency 
In addition to HPV16 infectivity, the transduction of AAV2 after knockdown of CSE1L and SPOP was 
analyzed. The two candidates were selected, since knockdown of CSE1L repeatedly showed a strong 
influence on AAV2 transduction while using AAV2 as a control for cell toxicity of the siRNA treatment. 
SPOP as a cellular factor for transduction originally derived colleague study (Burkart et al. 
unpublished) in which SPOP was found to be a potential AAV VP1 interaction candidate.  
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Knockdown of CSE1L followed by infection with AAV2 led to a strong increase of transduction 
efficiency for all of the siRNAs used (Figure 25F). According to the knockdown efficiency expected 
from the previously described experiment, the sample treated with CSE1L_7 had the strongest effect 
on AAV2 transduction. The infectivity with AAV2 was increased around 8 fold compared to the 
corresponding siRNA ctrl.. Additionally, SPOP knockdown was analyzed and showed no effect on 
AAV2 transduction for samples treated with SPOP_1 and SPOP_4, but a slight increase of 
transduction efficiency after knockdown with siRNA SPOP_2 and SPOP_3. However, the transduction 
with AAV2 in both cases was observed to be similar to the transduction of cells not treated with 
siRNA (w/o siRNA). These data indicate that the observed negative effects of knockdown of CSE and 
SPOP on HPV16 PSV transduction are not due to unspecific cellular toxicity. The same conclusion 
could be made for IRS4 and YWHAZ, both showing similar transduction rates as the siRNA ctrl. 
reference (data not shown). 
4.2.5. Lentivirus-mediated  shRNA knockdown of potential candidates 
To further confirm the influence of the knockdown of candidates on HPV16 PsV transduction 
lentivirus mediated shRNA knockdown experiments were performed additionally. For this four out of 
the six candidates were selected, including IRS4, YWHAZ, CSE1L and SPOP for further analysis. In 
addition, lentiviruses containing either a shRNA against a non-mammalian target (shRNA ctrl.) or a 
GFP expression plasmid were used as controls for different steps of the experiment.  
HPV16 transduction in selected Lentivirus shRNA knockdown cells 
HeLa cells were infected with shRNA encoding lentiviruses and further selected for puromycin 
resistance. In this approach, only cells transduced with the lentivirus and expressing the 
corresponding plasmid with the puromycin resistance gene were used for further analysis. For each 
lentiviral construct two independent cell cultures were prepared and further tested individually. 
After several passages under puromycin treatment, the selected cells were used for a transduction 
assay with HPV16 PsV and AAV2.  
Figure 26A and 26B represent summaries of two independent experiments. Luciferase activity in IRS4 
and CSE1L knockdown cells, respectively, showed a reduction of infectivity by 50% (IRS4) and 20% 
(CSE1L) compared to the shRNA ctrl.. This observation was in concordance with the results from the 
siRNA knockdown in paragraph 5.2 as well as the results of an experiment with transiently lentivirus 
transduced HeLa cells (data not shown). However, the CSE1L knockdown showed an opposite effect 
in the transient lentivirus transduction experiment, described previously. For knockdown cells using 
shRNA targeting YWHAZ, one out of the two lentiviral transduced cell cultures did not show any 
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effect on HPV16 transduction, whereas the other culture had a 20% reduced transduction rate 
compared to the reference (shRNA ctrl.). This might be due to insufficient knockdown of YWHAZ in 
the cells showing no effect on HPV16 transduction. Compared to the control, the SPOP shRNA 
treated cells showed a slightly increased transduction rate with HPV16 PsV (~10%). As also the 
leintivirus-GFP transduced cells showed slightly elevated HPV16 transduction rates, the effect 
observed in the shRNA SPOP treated cells might be unspecific for the SPOP knockdown.  
 
Figure 26 Transduction with HPV16 and AAV2 after lentivirus infection and selection for lentiviral transduced cells by 
puromycin. HeLa cells were transduced with lentiviruses encoding shRNAs for knockdown of selected candidates (IRS4, 
YWHAZ, CSE1L and SPOP) as well as a non-mammalian control (shRNA ctrl.) and a GFP control. 48h postinfection the cells 
were further cultured in a selection medium containing puromycin to select for lentiviral transduced cells. After several 
passages under puromycin selection, the cells were infected either with HPV16 PsV (A) or AAV2 (B) containing a Gaussia 
luciferase reporter plasmid. 48h post infection transduction was analyzed for luciferase activity.  
The infection of untreated HeLa cells with PsV showed a reduced infection efficiency compared to 
PsV transduction of HeLa cells treated with the shRNA ctrl., indicating a slight effect of either 
lentivirus infection or puromycin selection on HPV16 PsV infection.  
The same experiment was performed using AAV2 for transduction of the selected HeLa cells. After 
several passages of the cells under puromycin treatment strongly increased transduction could be 
observed for YWHAZ knockdown cells. Transduction efficiency of AAV2 was observed to be 3-fold 
over the shRNA ctrl. cultures in both of the YWHAZ knockdown cultures. Additionally, knockdown of 
CSE1L and SPOP showed increased AAV2 infectivity. However, the increase in AAV2 transduction was 
lower than the increase observed for the GFP expressing selected cells, maybe indicating an 
unspecific effect of lentiviral infection with CSE1L and SPOP encoding shRNA or puromycin selection.  
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4.3. In silico analysis of different HPV L2 protein  
In parallel to the identification of interaction candidates, an in vitro analysis of L2 protein sequences 
from different HPV types was performed. For this, a set of 20 L2 sequences, comprising two low risk 
HPV sequences (HPV 6 and 11), 13 high risk HPV sequences (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 66) and five sequences from potential high risk HPV types (HPV 25, 53, 68, 73 and 82) 
were analyzed. These sequences were screened by an online program (ELM) which predicts potential 
functional sites in protein sequences. A restriction of the program is the ability to analyze only 
functional sites which are described as linear motifs, thus missing conformational dependent sites. 
The overall analysis of the L2 sequences (between 450 and 473 aa), revealed around 150-200 
potential functional sites. The results included protease cleavage sites, ligand binding sites and sites 
for protein modifications. Since HPV L2 is highly conserved, especially at the N-terminal part of the 
protein, a high number of overlapping hits could be observed in the analysis. 
Because further evidence for the probability of specific functional sites was missing further analysis 
focused on the motifs with low probability values (0.00004-0.0005). A low probability value in the 
ELM analysis describes a high stringency of the corresponding motif sequence to be complied. The 
cut-off at a probability value of 0.0005 was selected since a known functional site, the furin cleavage 
site, which was detected for all of the HPV types shows a probability value of 0.0005. Therefore this 
value was suggested to be stringent enough for a reliable prediction based on the ELM data. Though, 
a lower probability value is not directly linked to an undependable prediction but rather describes 
functional sites with less stringent rules to be complied.  
By analyzing the ELM results based on the stringency of the motifs, some motifs did stand out of the 
high number of potential functional sites. The ELM revealed a phosphotyrosin binding (PTB) domain 
(probability value 0.0001) which is known to act as an adapter or scaffold in several physiological 
process. These domains are known to be ligand binding sites for ligand activated growth factors, 
amongst other proteins and have been strongly associated with endocytic signaling pathways. 
Between two and four corresponding motifs were described in the L2 sequence of each HPV type 
with similar position within L2. In all of the 20 types analyzed the PTB domain was found around 
position aa 154-161 and aa 248-255. Additional PTB domains were found in differing localizations of 
the L2 protein sequence. Another motif which might be involved in several signal pathways and a 
probability value of 0.0002 was the Src homology (SH2) domain. For example adaptor proteins, 
involved in signal transduction of the receptor tyrosine kinase pathway are known to contain SH2 
domains. The SH2 domain was found at position aa 71-74 in the L2 sequence of each type analyzed by 
ELM.  
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Table 15: Examples of potential functional sites of L2 derived from ELM analysis 
Motif Description Pattern 
Probabilit
y Value 
HPV types 
Furin 
cleavage site1 
Recognition site for furin 
protein convertase 
R.[RK]R.* 0.0005 all 
NLS1 
Classical nuclear 
localization signal. 
[^DE]((K[RK])|(RK)) 
[KRP][KR][^DE] * 
0.0002 
HPV 6, 16, 18, 
25, 31, 35, 39, 
45, 51, 53, 59, 
66, 68, 73, 82 
Proprotein 
convertase 7 
cleavage site 
Recognition site for 
proprotein convertase 7 
[R]...[KR]R. * 0.0005 
HPV 6, 11, 16, 
25, 33, 35, 51, 
52, 53, 56, 58, 
66 and 82 
TRFH binding 
motif 
Found in proteins recruited 
to the shelterin complex 
which recognizes telomere 
regions at the 
chromosomes 
[FY].L.P* 0.0002 all 
EVH1 domain 
Protein-protein interaction 
module. EVH1 containing 
proteins are known to be 
associated with the actin 
cytoskeleton reorganization 
[FILVY].{0,1}P.[PAILSK]P* 0.0001 
HPV 6, 11, 16, 
18, 31, 33, 51, 
52, 53, 56, 58, 
59, 66, 73 and 
82 
PDZ domain 
Found in regulatory 
proteins, spending part of 
their time in membrane 
associated complexes. In 
combination with other 
signaling/regulatory 
domains involved in 
processes like transport and 
signal transduction  
...[VLIFY].[ACVILF]$ * 0.0001 
HPV 6, 11, 16, 
18, 31, 33, 35, 
39, 45, 52, 53, 
56, 58, 66 
Fucosylation 
site 
Attachment site for fucose 
residue to a serine. 
C.{3,5}([ST])C  0.00004 all  
  1 
previously published functional sites within the HPV L2 protein sequence 
*Nomenclature see table 116 
However, the high number of potentially functional sites predicted by ELM and the lack of additional 
selection criteria prevented a significant selection of the most promising potential domains. 
Therefore, the ELM results were checked in context of previously identified interaction candidates 
from paragraph 5.1 to predict potential binding sites of the distinct proteins. For description of amino 
acid sequences ELM uses the nomenclature for peptide motifs described in the publication of 
Aasland and colleagues from 2002 [122]. 
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Table 16: Nomenclature of ELM peptide motif description 
Symbol Description 
[capital letters]  Distinct amino acids allowed 
. Unknown, other or any amino acid 
[^..] Listed amino acids are not allowed  
[… ] Amino acid at this position can be any of the indicated amino acids 
{ min, max } Minimum required, maximum allowed amino acids 
$ Matches the carboxy terminal 
(...) 
1. mark positions of, e.g. the amino acid covalently modified 
2. Used to group parts of the expression 
|  Matches either expression, separates two patterns 
Identification of potential ligand binding site of IRS4 
Literature research revealed an IRS-type PTB domain described in the sequence of the IRS4. IRS-type 
PTB domains are known to play a role in the interaction of IRS proteins and the IRS-receptor. The 
ELM describes a potential ligand binding site for proteins containing a Shc-like or an IRS-like PTB 
domain. According to the description, this domain complies one of two possible sequence patterns 
which are either (.[^P].NP.(Y)) or (.[ILVMFY].N..(Y)). The ELM analysis of L2 revealed corresponding 
sites within L2 sequences of different HPV types (Table 17). In the sequence of HPV16 L2, the 
described ligand binding site for IRS4 was identified at three different positions (aa 251-257, aa 261-
267 and aa 360-366). Since IRS4 was previously identified in the TAP for the HPV16 full length and 
the HPV16 L2_Fr.3 (aa 262-473), the result of the ELM is in concordance with the TAP result. The 
ligand binding sites at position aa 261-267 and aa 360-366 are both included in the sequence of 
HPV16 L2_Fr3. However, the third potential domain (aa 251-257) was part of HPV16 L2_Fr.2 which 
did not reveal IRS4 as a potential interaction candidate, maybe due to unfavorable conformation or 
modification of HPV16 L2_Fr.2 in the TAP. Comparing the different HPV L2 sequences for the 
identification of the predicted IRS4 binding site, 12 out of 20 sequences showed one of the ELM 
described patterns.  
Nine out of the 13 high risk HPV types (HPV16, 31, 33, 35, 39, 45, 51, 59 and 66) were observed to 
harbor at least one potential IRS4 binding domain. Furthermore, potential binding sites were 
identified in the low risk HPV types (HPV 6 and 11) and in one of the potential high risk types 
(HPV82). Seven of these HPV types showed a potential IRS4 binding site around position 246-252 and 
251-257 (HPV6, 11, 16, 31, 35, 45 and 59), matching the same ELM pattern ((.[^P].NP.(Y))). The 
corresponding L2 domains were observed to be highly conserved, differing in a single amino acid 
located either at position two or six of the identified pattern. Additionally, for HPV 16 (aa 261-267), 
HPV 33 and HPV 39 an IRS4 binding site was predicted at a more C-terminal position around amino 
acid 350. In all three cases, the protein sequence complied with the ELM pattern (.[ILVMFY].N..(Y)). 
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The sequence of HPV16 (aa 360-366) and HPV39 (aa 355-361) were found to be highly similar 
whereas the HPV33 sequence (aa 337-343) showed strong differences.  
Table 17: Overview of predicted IRS4 ligand sites in the different HPV L2 protein sequences 
HPV type Sequence Position Pattern Probability 
HPV 6 TYDNPVY aa 248-254  (.[^P].NP.(Y))* 0.0001 
HPV11 TYDNPVY aa 247-253 (.[^P].NP.(Y))* 0.0001 
HPV16 
TYDNPAY 
DVDNTLY 
SINNGLY 
aa 251-257 
aa 261-267 
aa 360-366 
(.[^P].NP.(Y))* 
(.[ILVMFY].N..(Y))* 
(.[ILVMFY].N..(Y))* 
0.0001 
0.0001 
0.0001 
HPV18 - not identified  - - 
HPV25 - not identified - - 
HPV31 TYENPAY aa 246-252 (.[^P].NP.(Y))* 0.0001 
HPV33 TVPNEQY aa 337-343  (.[ILVMFY].N..(Y))* 0.0001 
HPV35 TYDNPAY aa 250-256 (.[^P].NP.(Y))* 0.0001 
HPV39 DVDNNTY aa 355-361  (.[ILVMFY].N..(Y))* 0.0001 
HPV45 TFDNPAY aa 250-256 (.[^P].NP.(Y))* 0.0001 
HPV51 NIENPLY aa 157-163  (.[^P].NP.(Y))* 0.0001 
HPV52 - not identified - - 
HPV53 - not identified - - 
HPV56 - not identified - - 
HPV58 - not identified - - 
HPV59 TYDNPAY aa 249-255  (.[^P].NP.(Y))* 0.0001 
HPV66 TITNPLY aa 156-162 (.[^P].NP.(Y))* 0.0001 
HPV68 - not identified - - 
HPV73 - not identified - - 
HPV82 NIENPLY aa 157-163 (.[^P].NP.(Y))* 0.0001 
*Nomenclature see table 16 
Identification of potential ligand binding site of YWHAZ 
YWHAZ belongs to the family of 14-3-3 proteins, interacting with one of three patterns described by 
ELM (mode I binding motif, mode II binding motif or mode III binding motif). The three motifs are 
rather similar and differ only slightly with decreasing stringency from mode I (probability value: 
0.008) to mode III (probability value: 0.0039) (Table 18). Thus, a mode I motif is more stringent than 
mode II or mode III. The ELM analysis of HPV16 L2 identified three potential 14-3-3 ligand sites, 
which were either mode II or mode III. One of the domains was found at the N-terminus of HPV16 L2 
(aa 90-96). This domain confirmed the identification of YWHAZ in the TAP (5.1.1) with HPV16 L2 full 
length and HPV16 L2_Fr.1 (aa 1-193). The other ligand binding sites were located at aa 248-253 
(mode III) and aa 315-321 (mode II). The corresponding positions match HPV16 L2_Fr.2 (aa 130-334) 
and HPV16 L2_Fr.3 (aa 262-473) of the TAP experiment, not revealing YWHAZ as a potential 
interaction candidate. Beside HPV16 L2, the L2 sequences of HPV 31, 33, 35, 52 and 58 were found to 
have a mode II ligand binding site at aa 89-95 (HPV 33, 35 and 52) or aa 90-96 (HPV 31).  
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Table 18: Overview of predicted YWHAZ ligand sites in the different HPV L2 protein sequences 
HPV type Sequence Position Pattern Probability 
HPV 6 
HTTTSI 3 
RLITYD 3 
aa 149-154 
aa 245-250 
[RHK][STALV].([ST]).[PESRDIF]* 0.0039 
HPV11 
RLVTYD 3 
HSVTQS 3 
aa 244-249  
aa 361-366 
[RHK][STALV].([ST]).[PESRDIF] * 0.0039 
HPV16 
RPPLTVD 2 
RSGKSIG 2 
 
KLITYD 3 
aa 90-96  
aa 315-321 
 
aa 248-253 
 
R..[^P]([ST])[IVLM]. * 
 
[RHK][STALV].([ST]).[PESRDIF] * 
 
0.0016 
 
0.0039 
HPV18 
RKRASVT 2 
 
RSGTQI 3 
RSTTSF 3 
aa 9-15 
 
aa 308-313  
aa 364-369 
R..[^P]([ST])[IVLM]. * 
 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0016 
 
0.0039 
HPV25 
RQSSTP 1 
 
RDLSSIN 2 
 
RVETTR 3 
aa 244-249 
 
aa 365-371 
 
aa 451-456 
R.[^P]([ST])[^P]P* 
 
R..[^P]([ST])[IVLM]. * 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0008 
 
0.0016 
 
0.0039 
HPV31 
RPPVSID 2 
RSGATIG 2 
aa 90-96 
aa 308-314 
R..[^P]([ST])[IVLM]. * 0.0016 
HPV33 
RPPVTVD 2 
 
KLITYD 3 
HSYSTF 3 
aa 89-95 
 
aa 248-253 
aa 379-384 
R..[^P]([ST])[IVLM]. * 
 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0016 
 
 
0.0039 
HPV35 
RPPVTVE 2 
 
KLITYD 3 
aa 89-95 
 
aa 247-252    
R..[^P]([ST])[IVLM]. * 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0016 
 
0.0039 
HPV39 not identified - - - 
HPV45 KSFTYP 3 aa 366-371   [RHK][STALV].([ST]).[PESRDIF] * 0.0039 
HPV51 
RKRASVT 2 
 
RLYSKS 3 
aa 9-15 
 
aa 226-231 
R..[^P]([ST])[IVLM]. * 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0016 
 
0.0039 
HPV52 RPPVTVE 2 aa 89-95 R..[^P]([ST])[IVLM]. * 0.0016 
HPV53 not identified  - - - 
HPV56 not identified  - - - 
HPV58 
RPPVTVD 2 
 
RLVTYD 3 
HSHTSF 3 
aa 89-95 
 
aa 248-253  
aa 381-386 
R..[^P]([ST])[IVLM]. * 
 
 
[RHK][STALV].([ST]).[PESRDIF] * 
0.0016 
 
 
0.0039 
HPV59 not identified  - - - 
HPV66 not identified  - - - 
HPV68 RSHISVP 2 aa 375-381 R..[^P]([ST])[IVLM]. * 0.0016 
HPV73 RLVTYD 3 aa 253-258 [RHK][STALV].([ST]).[PESRDIF] * 0.0039 
HPV82 RKRASVT 2 aa 9-15 R..[^P]([ST])[IVLM]. * 0.0016 
*Nomenclature see table 16 
1 
mode I binding motif 
2 
mode II binding motif 
3 
mode III binding motif 
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All of the predicted YWHAZ ligand binding sites were highly similar, differing only in one of the 
variable amino acid positions. Furthermore, YWHAZ was identified in the PPD using the HPV16 L2 
peptides aa 20-38 and aa 28-42 (5.1.6, Table 3). Though, the ELM did not determine a potential 14-3-
3 interaction site at corresponding positions in the L2 sequence. However, each of the peptides 
contains a pattern similar to the ELM described 14-3-3 ligand binding site. In case of the aa 20-38 
peptide, the pattern at aa 4-10 (KQAGTCP) is comparable to a mode III 14-3-3 motif 
([RHK][STALV].([ST]).[PESRDIF]), except the additional glutamine at position 5. The peptide aa 28-42, 
harbors a pattern at position aa 9-15 (VEGKTIA) similar to a mode II pattern (R..[^P]([ST])[IVLM].). In 
this pattern, the arginine at position 9 was replaced by a valine. However, ELM did not provide any 
information if addition of an amino acid at position 2 of the pattern or a replacement by a 
hydrophobic amino acid is able to inhibit binding of 14-3-3 completely.  
Comparing all of the tested L2 sequences, 15 out of 20 L2 sequences showed at least one of the 
described patterns. Four of the high risk HPV types (HPV 39, 56, 59 and 66) and one potentially high 
risk type (HPV 53) did not harbor a domain matching the 14-3-3 ligand binding site.  
Identification of potential ligand binding site of CSE1L, CAPN2 and CAND1 
An additional potential interaction candidate of HPV16 L2, identified in paragraph 5.1 was found to 
be the CSE1L. However, no binding motif has been described for CSE1L, yet. In contrast, literature 
research about the CAPN2 showed the presence of an EF-hand domain within the CAPN2 protein 
sequence contributing to protein-protein interactions. Additionally, HEAT repeats, representing 
important domains for protein interaction in the CAND1 protein are described in the literature. 
However the ELM analysis did not reveal any sites, potentially interacting with either of the 
described motif in CAPN2 or CAND1 within the L2 protein sequences tested. This might be due to the 
limitations of the ELM program, therefore not revealing any evidence about potential interactions of 
these proteins with L2.   
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5. Discussion 
5.1. Identification and selection of  HPV16 L2 interaction candidates 
Tandem Affinity Purification 
The tandem affinity purification is a two-step purification method which is supposed to result in 
specific co-purification of interacting candidates by reducing the number of contaminants. However, 
for identification of HPV16 L2 interaction candidates this method bears also some disadvantages. 
Since this method is based on the overexpression of the target protein in the cells, the protein is 
mainly limited to the nucleus and the cytosol of expressing cells. In this regard, L2 is only able to 
interact with a selection and not all of the proteins involved in viral infection. Compared to the 
capsid-incorporated L2, exposing only a limited number of epitopes [29-32], most interaction sites of 
the TAP fusion protein are supposed to be available for potential protein interaction. The availability 
of a high number of L2 epitopes makes the TAP method a promising system for the identification of 
potential interaction candidates involved in different steps of the viral infection pathway and life 
cycle.  
Additional experiments were conducted with the aim to incorporate the Tap-tagged version of L2 
into PsV bypassing the disadvantages of the TAP method. PsV produced with the TAP-tagged L2 were 
observed to be less efficient in transduction of infected cells, however showed a similar infectivity as 
L1-only PsV (data not shown). Incorporation of the L2-TAP, though, was confirmed to be successful, 
showing a comparable amount of L2-TAP and non-tagged L2 in the different PsV productions (data 
not shown). Further investigations on the L2-TAP PsV confirmed the PsV to be able to bind to the 
target cells but fail to be internalized (data not shown). Internalization was almost completely 
abolished and demonstrated to be much less efficient than L1 only PsV internalization. Infectious 
particles could only be generated by the production of chimeric PsV containing non-tagged and TAP-
tagged L2 molecules whereas increasing amounts of non-tagged L2 correlated with increased 
transduction efficiency (data not shown). Fusion of L2 to the TAP tag might interfere with proper 
conformation of L2-TAP within the capsid. Little is known about the structure of L2 in general [43] 
and in context of viral capsids.  
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Immunoprecipitation of L2 from PsV infected cells 
As described in the previous paragraph, infectious L2-TAP containing PsV could not be produced. In 
respect to overcome the disadvantages of the TAP method, IP of L2 was therefore performed from 
PsV infected cells using L2-specific antibodies. In contrast to the TAP method, based on the 
overexpression of the bait protein, PsV infection mimics the natural infection pathway, allowing co-
purification of proteins directly involved in the infection process. Even though this method 
overcomes the limitations of L2 localization as described for the TAP method also the IP from 
infected cells bears some limitations. The viral capsid is predominately based on the assembly of L1 
capsomers, representing the main structure [4]. L2, on the contrary, is finally incorporated and with 
around 12-36 molecules represents only a minor proportion of the capsid [27]. Only a limited 
number of L2 proteins enter the target cells via the PsV strongly reducing the availability of protein 
for precipitation. Furthermore, by incorporation of L2 into the viral capsid not all potentially 
functional sites of L2 are exposed for protein interaction, since L2 is mainly hidden within the L1 
composed capsid. Several L2 epitopes, however, have been reported to be exposed even in the 
assembled HPV capsid [29-32]. The infection with PsV mimics the natural infection pathway of HPV, 
therefore allowing identification of interaction partners involved in different steps at different time 
points of HPV infection. Selection of a specific time point for IP represents another limiting factor for 
the identification of partners. Since at a specific time point only a distinct set of proteins can be 
identified and proteins interacting at earlier or later time points postinfection will be omitted due to 
the experimental set up.  
Selection of suitable antibodies for IP of L2 from PsV infected cells 
The limited availability of L2 epitopes made it indispensable to select for antibodies suitable for IP of 
PsV from infected cell extracts. Three L2-specific antibodies as well as two L1-directed antibodies 
were analyzed for their ability to precipitate L1/L2 from PsV infected cells. The two L1 antibodies 
confirmed precipitation of internalized PSV at all time points tested. PsV are entering the cell over a 
long period of time, indicated by constant increase of precipitated L1 signal intensity from 5-8h 
postinfection (Figure 4). Therefore, PsV-IP confirmed previous publications of papillomavirus entry 
kinetics, describing the half time of particle entry to be between 4-12h [94, 123, 124]. However, 
further analysis of the entry kinetics by Schelhaas and colleagues reported a dependence of entry 
kinetics on MOI used for infection [93]. While the half time of particles entering the cells using a low 
MOI was observed to be around 11h, the entry process gets faster with increasing the MOI (~4h). The 
data presented by Schelhaas et al. showed a constant increase of internalized PsV (MOI 10) until 8-9h 
postinfection before the detection by flow cytometry showed 100% internalization. This data 
correlates with the analyses of the performed PsV-IP. The specificity of the selected antibodies for 
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PsV-IP was confirmed by the negative controls. Progressing internalization to other compartments 
might lead to inaccessibility of PsV for precipitation by the applied IP protocol. The drop of L1 
detection after 9h was probably caused by inefficient lysis of PsV containing compartments with the 
standard IP protocol.  
The target regions of the L2 specific antibodies (K1L2 aa 64-81, K4L2 aa 20-38 and K18L2 aa 20-38) 
have previously been reported to be exposed at the surface of HPV capsid [29-31] therefore 
suggested to be available for IP of assembled HPV16 PsV. The results of the IP confirmed the 
availability of the corresponding L2 epitopes (aa 20-38 and aa 64-81) in the assembled PsV capsid by 
precipitation with K1L2 aa 64-81 and K4L2 aa 20-38. The epitopes are exposed even before the initial 
binding to HSPGs and the associated conformational changes confirmed by the precipitation of PsV 
only. However, precipitation targeting the epitope aa 20-38 was demonstrated to be restricted 
depending on the antibody used for the IP. While K4L2 aa 20-38 successfully precipitated L2, K18L2 
aa 20-38 failed to purify PsV from the infected cells as well as from the PsV only. This indicates that 
inefficient L2 precipitation was rather due to modifications of the epitope than the exposure of the 
corresponding epitope. For K18L2 aa 20-38 binding, two cysteines within the corresponding epitope 
are essential for antibody binding [30]. Maybe these essential cysteines are modified somehow 
therefore preventing interaction with K18L2 aa 20-38. Although modification might be a possible 
explanation, also the structure of the PsV might be a limiting factor. In improperly assembled capsids, 
the L2 protein might be incorporated in an unnatural conformation, preventing interaction of K18L2 
aa 20-38. However to make a final conclusion, the status of the corresponding cysteines and PsV 
assembly maybe inhibiting the IP of PsV by K18L2 aa 20-38 still need to be examined further.  
Peptide pull down (PPD) of potential epitope interacting candidates from cell extracts 
Rubio and colleagues identified several L2 epitopes targeted by neutralizing and cross-neutralizing 
antibodies (aa 20-38, aa 28-42 and aa 64-81) [30]. Since binding of these antibodies to the epitopes 
prevents infection in a PV-type specific or even type-independent manner, the epitopes are 
suggested to play an essential role during viral infection which is blocked by antibody binding. 
Potentially the epitopes are interaction sites for cellular proteins involved in internalization or 
trafficking of the virus necessary for the establishment of viral infection. As well as the other 
methods conducted for the identification of interaction partners, the PPD harbors several 
restrictions. Since only small epitopes are used for the identification of binding proteins, the co-
purification is limited to a small set of cellular proteins potentially purified by this method. The 
limitation might probably be an advantage as well by identification of proteins at a restricted 
epitope, thus leading to a simultaneous identification of the corresponding interaction domain. 
However, it has not been shown that these epitopes are the actual target site of a protein interaction 
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inhibited by the neutralizing antibodies. It could also be possible that binding of the neutralizing 
antibody blocks interaction of a cellular protein close to the antibody site by covering only part of the 
interaction domain or by conformational terms. Therefore, proteins binding only part of the epitopes 
or even only close to these epitopes might not be identified due to the reduced number of available 
amino acids.  
Shortlisting of potential interaction candidates of HPV16 L2 for further analysis 
Since exclusion of generally known contaminants, like keratins and IgG, did not lead to a sufficient 
reduction of protein hits, additional criteria were necessary to select for the most promising 
interaction candidates. As an example, proteins were excluded based on the identification in non-
overlapping fragments/peptides (TAP or PPD) or with HPV unrelated antibodies (PsV-IP). Not all of 
these criteria necessarily imply the excluded proteins to be unspecific protein hits, however were 
conducted for more stringent shortlisting of candidates. The exclusion of proteins from non-
overlapping HPV16 L2 fragments, as an example, did not provide direct evidence to the contrary 
about the general existence of a specific protein interaction. Even though the existence of more than 
one protein interaction site might be rather unlikely, it cannot be excluded per se. This is also true, 
considering other criteria, like the elimination of protein hits appearing in a single screen within the 
same experimental set up. Even after selection based on the described criteria, a high number of 
potential candidates remained, thus proteins identified in more than one independent experiment 
were favored.  
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5.2. HPV16 L2 interaction with CSE1L/CAS protein  
Identification of CSE1L (2 peptides) with two overlapping fragments in the TAP was confirmed by 
PsV-IP (1 peptide). Even though, identification of a single peptide (PsV-IP) is not a valid evidence for 
identification of proteins by MS, since a general agreement requires at least two independent 
peptides to be identified, repeated identification in three independent screens supported as true 
interaction candidate.  
CSE1L is also known as exportin-2 or chromosome segregation-1 (yeast homolog) like protein. It was 
first reported as essential factor for importin α re-export to the cytoplasm after cargo release [125].  
However, further investigation revealed additional functions in gene regulation by interaction with 
e.g. p53 [126] and CSE1L is supposed to play a role in apoptosis and proliferation [127, 128]. 
Additionally, CSE1L plays a role in viral infection e.g. in context of HIV [129]. Takeda et al. claimed 
CSE1L to have an essential role in nuclear import of the HIV Vpr protein. Even though there was no 
direct interaction of Vpr and CSE1L, CSE1L has been demonstrated to be important for the NPI-1 
(importin α isotype) mediated nuclear transport of the protein [129]. It is known that HPV L2 protein 
contain two NLS sequences which might be involved in nuclear transport of the protein via importin 
α theoretically bridging HPV L2 with the CSE1L. The obtained data (Co-IP) on the interaction of CSE1L 
with HPV16 L2 validated interaction of the two proteins either directly or in a complex with importin 
α. Furthermore, the interaction with CSE1L in a importin α/importin β complex seems rather likely 
since for HPV11 and BPV1 L2 interaction with the importin complex has been reported already [58, 
130]. There are several hypothesis on the mechanism of nuclear import, with some publications 
claiming nuclear envelope breakdown to be crucial for nuclear transport of the L2/viral DNA complex 
[119]. However, there are still many open questions on the nuclear transition of the L2/viral genome 
complex. Even though the described L2 NLS might not have a specific function during viral infection, 
the sequences might still be essential for establishment of a persistent infection or generation of new 
virions. A function of CSE1L in context of the importin complex might further be confirmed by the 
identification of importin 5 (note: also referred to as importin subunit β-3, member of the importin β 
family) in the TAP MS (HPV16 L2 full length). Importin was excluded for further analysis, however, 
based on the limited number of identified peptides. Members of the importin β family can either act 
to transport cargo proteins alone or in a heterodimeric complex with importin α subunits [131-133]. 
Maybe HPV16 L2 interaction with the heterodimeric importin complex leads to temporary 
interaction of CSE1L which be sufficient for co-purification of CSE1L with L2. This would indicate 
either direct interaction of L2 and CSE1L inducing release of the L2 from the importin complex or an 
indirect interaction of CSE1L with L2 via the interaction with importin α. After overexpression of 
CSE1L together with HPV16 L2, CSE1L shifted from an exclusive nuclear localization to an increased 
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cytoplasmic localization. This might indicate an increased transport through the nuclear envelope, 
thus an increase of importin α re-export to the cytoplasm. Maybe this is due to the overexpression of 
L2 and the involved high abundance of L2 to be transported. Also the co-localization of CSE1L with L2 
mainly at the nuclear periphery and the lack of co-localization in the cytoplasm might support the 
hypothesis that CSE1L is involved in the transport of L2 to the nucleus. Transient interaction of the 
two proteins might for example induce the cargo release after passing the nuclear membrane. The 
role of CSE1L in HPV16 infection was additionally confirmed by a decreased transduction level of 
HPV16 PsV after downregulation of CSE1L. The impaired transduction might in this case not rely on 
reduced internalization or trafficking through endosome or TGN of the PsV but maybe due to 
improper release of the L2/DNA complex from the importin complex with the nucleus.  
5.3. HPV16 L2 interaction with 14-3-3 zeta (YWHAZ) 
YWHAZ was confirmed as potential interaction candidate by MS analysis of five independent 
experiments: the TAP analysis (HPV16 L2 full length → 1 peptide and HPV16 L2_Fr.1 → 2 peptides) as 
well as the PPD MS (HEK 293TT: aa 20-38 and aa 28-42 → both 2 peptides, HaCaT: aa 28-42 → 1 
peptide). Even though in two samples the number of identified peptides did not fulfill general 
criteria, the repeated identification in several independent experiments indicated, YWHAZ is a true 
interaction partner of L2. 
YWHAZ belongs to the 14-3-3 protein family representing the 14-3-3 zeta isoform (note: the 
phosphorylated from of 14-3-3 zeta is referred to as 14-3-3 delta). Proteins of this family represent 
adaptor proteins involved in a variety of signaling pathways, like apoptosis and cell cycle regulation 
[134, 135]. 14-3-3 proteins interact with a wide range of cellular proteins, including kinases, 
phosphatases and transmembrane receptors. Interaction of 14-3-3 proteins, with a specific protein, 
usually regulates the activity of the bound protein. The two major functions of YWHAZ have been 
described to be regulation of cell survival and cell cycle progression. In context of cell survival, 
YWHAZ has been reported to interact with a large number of apoptotic proteins [135, 136]. In 
addition, it is supposed to negatively regulate the G2-M phase checkpoint by modification of cyclin-
dependent kinase activity [137-139]. In this context, 14-3-3 proteins and especially YWHAZ interact 
with phosphorylated regulators of the cell cycle, e.g. CDC25-B and C [137]. These phosphatases 
control G2-M transition by phosphorylation cyclin dependent kinases (CDK) [140]. Interaction of 
YWHAZ, CDC25-C prevents dephosphorylation of CDKs therefore impairing the assembly of e.g. the 
CDK1-cyclinB complex [140]. Additionally, YWHAZ is found in the cytoplasm where it has the ability 
to prevent nuclear import of NLS containing proteins [141] but also in the nucleus where it is 
expected to influence gene expression by regulating distinct transcription factors (e.g. p53) [142]. 
Several interactions with viral proteins have been reported e.g. with NS2 of MVM parvovirus and 
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HPV18 E6 [143, 144]. In context of HPV18 E6 interaction, YWHAZ is supposed to maintain the steady-
state level of E6 expression [143]. In addition to an interaction of YWHAZ and L2 (IP), co-localization 
was demonstrated in the nuclei of overexpressing cells which was induced by a shift of the 
cytoplasmic YWHAZ to the nucleus. According to several publications, 14-3-3 proteins also contribute 
to the nuclear export of proteins as well as their retention in the cytoplasm [145-147]. Additionally, it 
has been demonstrated that 14-3-3 proteins regulate nuclear entry of cellular proteins [141, 148, 
149]. In this regard it has been reported that 14-3-3 proteins mediate nuclear translocation by 
promoting the interaction of NLS containing proteins with importin α [149].  The efficiency of nuclear 
translocation strongly depends on the interaction affinity of the cargo protein to importin α [150], 
making the target sequence recognition a limiting factor [151]. Modifications of several proteins as 
the SV40 LT by phosphorylation have been demonstrated to increase the interaction with importin 
α/importin β complexes [152]. The deletion of the corresponding sites led to significantly lower 
translocation efficiency due to impaired recognition of the SV40 LT NLS sequence by the importin α 
[153]. Proteomic analyses suggested importin α to interact with 14-3-3 proteins [154], even though 
14-3-3 proteins do not harbor an intrinsic NLS sequence. Further investigation demonstrated that the 
cellular proteins e.g. myopodin, binding both, 14-3-3 and importin α, mediating the interaction of the 
14-3-3/myopodin/importin α complex [149]. The authors hypothesized that binding of myopodin to 
14-3-3 might affect the conformation of myopodin, exposing the NLS and therefore making it 
available for binding to importin α [149]. Since the co-localization studies on YWHAZ and HPV16 L2 
revealed an increase in nuclear localized YWHAZ, a function of YWHAZ in L2 nuclear translocation 
might be possible. The partial co-localization of the nuclear YWHAZ and L2 might therefore indicate 
the dissociation of the complex after successful import. Furthermore, the reduced transduction 
efficiency after YWHAZ knockdown indicates a beneficial effect of YWHAZ during the infection 
process, maybe in the translocation process of the L2/DNA complex to the nucleus. However, a 
different function of the interaction of YWHAZ and L2 might also be conceivable. In this regard L2 
might impair a specific function of YWHAZ or recruit YWHAZ to modify the activity of cellular proteins 
by the interaction. Binding of 14-3-3 proteins with their interaction partners is mainly based on the 
recognition of phosphoserines and phosphothreonins [155, 156]. In HPV16 L2, three motifs, comply 
with the recognition criteria for 14-3-3 binding were identified of which the N-terminal binding motif 
(~90-96) was found to be conserved in several other types (HPV 31, 33, 35, 52 and 58). 
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5.4. HPV16 L2 interaction with insulin receptor substrate 4 (IRS4)  
The insulin receptor substrate 4 was identified only by MS in TAP-tag purification, though the protein 
showed up in three independent approaches (both screens with HPV16 L2 full length and the screen 
eith HPV16 L2_Fr.3). In two of the three samples the protein was identified by 4 independent 
peptides, indicating a high likelihood for reliable identification. The third sample also provided two 
independent peptides complying general criteria for MS based protein identification.  
IRS4 belongs to the family of insulin receptor substrates, consisting of IRS1, IRS2 and IRS4 in human 
cells. IRS3 is described to be expressed only in rodents and lacks a human equivalent. The human 
family members of IRS proteins represent a family of proteins strongly connected to signal 
transduction from activated growth factors. IRS members are phosphorylated upon receptor 
stimulation of e.g. the insulin receptor, IGF1R and FGFR [157]. After phosphorylation, IRS proteins 
bind to SH2 domain containing proteins, inducing a signal cascade, regulating cell metabolism and 
proliferation in several human cell lines [157-159]. Beside proliferation, interaction of IRS4 with 
distinct proteins, e.g. Brk was reported to have an influence on cell growth, survival and 
differentiation [160]. IRS4 also plays a role in the Akt signaling pathways through direct interaction 
with the p85 subunit of PI3K [157, 161]. According to the IRS4 activation by the IGF1 receptor, 
phosphorylated IRS4 has additionally been demonstrated to transduce the mitogenic signal derived 
from the activated IGF1R. Furthermore, for different viruses IRS4 was identified to function during 
infection. In this context, elevated IRS4 protein and mRNA level and activation of PI3K have been 
observed after infection with Adenovirus 5 (Ad5) [162, 163]. Interaction of IRS4 and Ad5E1A leads to 
constitutively activated IRS4 and association with PI3K. IRS4 might therefore enhance growth and 
proliferation of Ad5E1 expressing cells [163]. Additionally, a direct interaction of IRS4 and the AAV 
Rep protein was identified by TAP and validated, however the function of this interaction was not 
analyzed further [164].  It is generally known that PI3K/Akt/mTOR activation controls several cellular 
mechanisms, like metabolism growth and survival and proteins synthesis [165]. In viral infection Akt 
represents an essential factor for inhibition of apoptosis to extend the infection cycle. Therefore, 
several viruses acquired strategies to exploit Akt function to benefit in infection [166, 167]. Many 
DNA viruses so far have been reported to activate the PI3K pathway using different strategies. 
Members of the Polyomaviridae, as simian virus 40 (SV40) and mouse polyoma (Py) virus render PI3K 
and Akt constantly activated for transforming purposes [168-175]. One report described IRS1 to be 
required for SV40 transformation and claimed the large T (LT) antigen to IRS1 phosphorylation of Akt 
[176]. For HPV the activation of PI3K and Akt has primarily been described by functions of E6 and E7 
inhibiting apoptosis by activation of the Akt pathway [177-179]. However, recent publication could 
demonstrate an early activation of the PI3K/Akt/mTOR pathway in HPV infection. In this context it 
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has been demonstrated that HPV activates the PI3K/Akt/mTOR pathway via interaction of HPV 
bound to heparan sulfate (HS) and growth factors (GF) with GF receptors [62, 82]. Probably the 
interaction prevents autophagy, playing an essential role in antiviral host cell response [180]. Since 
an activation of PI3K/Akt pathway seems to play a crucial role during viral infection through direct 
activation upon HPV binding, the constant regulation of this pathway during the initial infection 
might also be important. Since the IF data on the co-localization suggests a transient interaction of 
IRS4 and L2, this might indicate an activation of IRS4 function by L2 rather than a binding associated 
function of L2 and IRS4 in a complex. However, the link between L2 predominantly localized in the 
nucleus after overexpression and cytoplasmic IRS4 is still unclear similar to publication about SV40 LT 
and IRS1 [176]. IF analysis revealed an increase in nuclear localized IRS4 when co-expressed with 
HPV16 L2, however the mechanism of this recruitment is not revealed. Interaction domains of IRS4 
have been identified at the C-terminal part of HPV16 L2 correlating with the identification in the TAP-
tag purification. This potential interaction domain was observed to be conserved in seven of the 
tested HPV types (HPV 6, 11, 16, 31, 35, 45 and 59). However, even though HPV18 was not described 
to have a corresponding site for potential IRS4 interaction, transduction experiments using HPV18 
PsV showed decreased transduction after IRS4 knockdown (data not shown). This might indicate the 
existence of an alternative interaction domain for IRS4 in HPV types lacking the described domain for 
HPV16.     
5.5. HPV16 L2 interaction with calpain 4 (CAPN4)  
Calpain 2 was identified in the MS analysis derived from the TAP co-purification using the HPV16 L2 
full length (4 peptides) as well as the HPV16 L2_Fr.1 protein (3 peptides).  
CAPN2 is a calcium-dependent non-lysosomal cysteine protease known to catalyze proteolysis of 
substrates in context of cytoskeletal reorganization and signal transduction. Calpains are involved in 
several processes, including signal transduction, cell proliferation, cell cycle progression, apoptosis 
and membrane fusion [181-183]. CAPN2 represents the catalytic subunit of m-calpain in which forms 
a heterodimer with the regulatory subunit CAPN4. Dissociation of the regulatory subunit from the 
catalytic subunit activates the proteolytic function of CAPN2 [184, 185]. In context of HPV, calpain 
has already been published to have distinct functions. In 2007 Darnell et al. described an interaction 
of HPV E7 with µ-calpain (CAPN1) to be essential for E7-mediated Rb degradation [186]. Calpain has 
also been demonstrated to be important for proteolytic processing of the E1^E4 protein of HPV16 
and HPV18 for the formation of amyloid-like fibers and reorganization of the keratin network [187]. 
Furthermore calpains were identified to enhance herpes simplex virus 1 (HSV-1) intracellular 
trafficking and coxsackie virus B3 (CVB3) entry, trafficking and replication upon infection [188-190]. 
Regarding the function of calpain during viral trafficking, it has been reported that calpains are 
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activated by intracellular calcium (Ca2+) release from the endoplasmatic reticulum (ER). The increase 
in intracellular Ca2+ concentration and calpain activation was demonstrated to facilitate infection 
with many viruses, like HIV, HSV, HCV and rotavirus [191-195]. For HSV-1, CAPN1 had been found to 
trigger entry and migration [189] whereas for CVB3 CAPN2 was found to be activated by Ca2+ release 
[190]. The confirmed interaction of CAPN2 with HPV16 L2 might correlation with a function during 
initial infection similar to other viruses. Instead of a calpain activation through increased intracellular 
Ca2+, HPV16 L2 might bind CAPN2 directing CAPN2 to the actual site of function where CAPN4 is 
displaced. The obtained data on HPV16 PsV transduction after siRNA mediated CAPN2 knockdown do 
not correlate with this hypothesis, since no effect on PsV infectivity was observed. On the one hand 
this might either indicate CAPN2 to have a different role than the expected beneficial effect on initial 
virus infection. On the other hand it might also be possible, that experimental system was not 
suitable to detect a potential influence of CAPN2 on PsV transduction. First of all, Bozym et al. 
reported cell type specific differences of the function of CAPN2 in CVB3 infection, claiming a function 
of CAPN2 in endothelial but not in epithelial cell line [190]. Other reports also revealed a low level of 
calpain expression levels in HeLa cells, compared to e.g. other cancer cell lines, including e.g. a head 
and neck squamous carcinoma cell line [196]. The identification of CAPN2 (TAP) as well as the 
validation of the interaction with L2 by Co-IP, was both performed in HEK293TT cells whereas the IF 
as well as the knockdown experiments was performed in HeLa cells. The selection of a suitable cell 
line to analyze CAPN2 in context with HPV infection and L2 interaction might be crucial. Potentially 
there are differences in CAPN2 expression and function even in cell lines derived from the same 
organ but with different properties (e.g. cancer and non-cancer cell line).  
5.6. HPV16 L2 interaction with cullin-associated and neddylation-
dissociated 1 (CAND1)  
Cullin-associated and neddylation-dissociated protein 1 (CAND1) was identified by MS analysis of the 
TAP co-purified proteins. In this experiment it was determined as potential interaction candidate in 
the HPV16 full length (3 peptides) and HPV16 L2_Fr.1 (2 peptides) TAP. Though there was no 
confirmation of a potential interaction by an additional experiment (e.g. PsV-IP or PPD), the number 
of peptides identified indicated a reliable detection of CAND1 as potential candidate.  
CAND1 is known to directly interact with cullin1 in context of the SCF complex. This complex 
comprises four proteins, Cul1 and the RING domain protein Rbx1, forming the cullin-RING ubiquitin 
ligase, the adapter protein Skp1 and the substrate-binding F-box protein [197]. SCF complexes in 
general allow the recognition of substrates for ubiquitination, the cullin-RING ligases (CRL) function 
as E3 ubiquitin ligases [198]. Neddylation of Cul1 induces rearrangement of the SCF complex, 
specifically in the Cul1-Rbx binding which dissociates CAND1 and allows transfer of ubiquitin from the 
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associated E2 ligase to the substrate [199, 200]. In vitro and in vivo data about CAND1 are 
controversial. While the in vitro analyses of CAND1 suggest an inhibitory function on SCF complex 
assembly and ligase activity, in vivo data in Arabidopsis indicates a positive effect of CAND1 on the 
SCF complex [197, 201-204]. In this context CAND1 is supposed to have a regulatory function in the 
recycling process of substrate receptor modules maintaining proper CRL function. Regarding a 
potential association with viral infection, many viral proteins are reported to act on CRLs, mainly to 
initiate degradation of distinct cellular proteins. Examples are the adenovirus E4orf6 and E1B-55 
[205] and the BZLF1 protein of EBV [206] inducing degradation of APOBEC3G (RNA-editing enzyme) 
and p53, respectively. Additionally, BPFL1, like other herpesvirus homologues of this protein has 
described to have NEDD8 specific deconjugase activity [207, 208]. Interaction of the catalytic site of 
BPLF1 with cullins prevents the binding of CAND1 and induces the proteasomal degradation of 
deneddylated cullins [209]. The inactivation of cullins is supposed to be beneficial for viral infection 
by inhibiting the innate immunity of the host [210-215] but also seems to be crucial for viral 
replication [208]. For HPV L2 proteins no protease activity has been described therefore a direct link 
between the EBV BPLF1 protein and L1 cannot be concluded. However, CAND1 is known to mediate 
the recycling of substrate receptor modules in context of the SCF complexes [198, 203, 204, 216, 
217]. Recent publication reported the CAND1 protein to exchange F-box proteins therefore having an 
essential influence on verity of different SCF complexes. Specifically the promoting function of 
CAND1 in the F-box-cullin 1 assembly was described. Furthermore CAND1 was suggested to even 
favor specific F-box proteins depending on the availability of substrates [218]. Since CAND1 was 
found to bind different cullins, it is suggested that CAND1 similarly affects multiple CRLs [204, 219-
222] and was suggested to function as substrate receptor exchange factor (SREF) for CRLs in general. 
Inhibition of CAND1 was observed to have a negative effect on some but not SCF complexes [204, 
220-222] which might be explained by the differences in the exchange rates of the different SCF 
complexes [218]. Since an interaction of HPV16 L2 with CAND1 was validated (Co-IP and IF), HPV16 
L2 might influence homeostasis of specific cellular proteins by deregulating CRLs through interaction 
with CAND1. The transduction rate of HP16 PsV was not affected by the downregulation of CAND1 
therefore indicating that interaction of HPV16 L2 and CAND1 is not involved in any process of the 
initial infection. However, the deregulation of CRLs might play a role in steps of the viral life cycle 
occurring after the actual viral entry, like the viral assembly.  
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5.7. Conclusion 
In the present study, several proteins have been identified as potential HPV16 L2 interaction partners 
by selection criteria from different MS analyses. The most promising candidates, IRS4, YWHAZ, 
CSE1L, CAPN2 and CAND1 were further validated for their binding capacity and the subcellular 
distribution in presence of HPV16 L2. In transduction experiments analyzing HPV16 PsV efficiency 
after downregulation of the corresponding candidates, the identified interactions were analyzed for 
their contribution in HPV infection. While downregulation of IRS4, YWHAZ and CSE1L inhibited PsV 
transduction, CAPN2 and CAND1 could not be demonstrated to play a role during the initial infection.  
Based on the obtained data, IRS4 is suggested to play a role in maintaining the activation of the 
PI3K/Akt/mTOR pathway which was reported to be activated upon GFR stimulation by virus 
interaction with the host cell surface [62, 82]. Based on the results in this thesis, HPV16 L2 is 
hypothesized to recruit IRS4 to the nucleus where IRS4 gets activated to further supports constant 
PI3K activation and Akt signaling. However, the mechanisms underlying this hypothesis are not 
revealed and require further investigation. YWHAZ was also observed to reduce HPV16 PsV 
infectivity in the knockdown experiments and therefore suggesting YWHAZ either contributing to 
nuclear translocation of the L2/DNA complex or being regulated by L2. For IRS4 and YWHAZ, 
conservation of potential binding motifs in several HPV types could be identified in an in silico 
approach. Results from knockdown experiment including the transduction of HPV18, lacking the 
predicted IRS4 interaction domain led to the suggestion that an alternative binding site might exist in 
HPV18 L2. In addition, knockdown of CSE1L protein expression had also an inhibitory effect on the 
transduction with HPV16 PsV. Since this protein is known to be involved in cargo release from 
importin α/importin β complexes and the re-export of importin α, CSE1L is suggested to be an 
important factor contributing to the translocation of L2 to the nucleus upon initial infection. 
Downregulation of CAPN2 and CAND1 did have any influence on HPV16 PsV transduction in the 
performed experiments. While the interaction with CAND1 is supposed to have a function in CRL 
regulation at a later time point of the viral life cycle CAPN2 is still suggested to play a role in the 
infection pathway. Even though there are strong indications of functional interactions of the 
described proteins with HPV16 L2 further investigation of the mechanisms are indispensable. A 
closer look should be taken to the single steps of viral infection, including entry, trafficking and 
nuclear localization of the HPV16 L2/DNA complex to be able to distinguish the function of the 
proteins at different steps. In case of CAND1 further analysis should be conducted regarding later 
processes of the viral life cycle like the assembly of new virions under knockout conditions. The 
disclosure of the distinct functions of the described L2 interaction partners would maybe reveal 
further insight into the function of the minor capsid protein L2 during the viral life cycle.     
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7. Appendix 
7.1. Supplementary data MS analysis 
Table 19: Overlapping protein hits from L2 full length TAP #1 and #2 
Protein 
complement component 1 Q subcomponent-binding protein, mitochondrial 
DnaJ protein homolog 2 
ruvB-like 1 [Homo sapiens] 
Chain A, Human Mitochondrial Single-Stranded Dna Binding Protein 
ruvB-like 2  
tubulin beta-4B chain 
elongation factor 1-alpha 1 
importin 5 (Importin subunit beta-3) 
 
7.2. Amino Acids 
Table 20: Amino acid one letter code 
A  Alanine 
C  Cysteine 
D  Aspartate 
E  Glutamate 
F  Phenylalanine 
G  Glycine 
H  Histidine 
I  Isoleucine 
K  Lysine 
L   Leucine 
M  Methionine 
N  Asparagine 
P  Proline 
Q  Glutamine 
R  Arginine 
S  Serine 
T  Threonine  
V  Valine 
W  Tryptophan 
Y  Tyrosine 
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7.4. Abbreviations 
A 
aa  amino acid 
AAV  Adeno-associated virus 
Ad  Adenovirus 
Akt  Protein kinase B 
al.  alteres 
APS  Ammonium persulfate 
 
B 
bp  base pairs 
BPV  Bovine papillomavirus 
BSA  Bovine serum albumin 
 
C 
⁰C  Degree Celsius 
CAND1  Cullin-associated and  
neddylation dissociated  
protein 1 
CAPN2  Calpain 2 
CBP  Calmodulin binding peptide 
CDK  cyclin-dependent kinase 
CIA  Chloroform isoamylalcohol 
CIN  Cervical intraepithelial  
neoplasia 
CIP  Calf intestinal alkaline  
phosphatase 
CMV  Cytomegalovirus 
Co-IP  Co-immunoprecipitation 
CRL  Cullin-RING ligase 
CSE1L  exportin-2 or chromosome 
segregation-1 (yeast homolog) 
like protein 
C-terminus Carboxyl-terminus 
CV  coxsackievirus 
 
D 
DAPI  4´,6´-diamidino-2-phenylindol 
DAXX  Death-associated protein 
DMEM  Dulbecco´s modified Eagles 
medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid  
dNTP  Deoxyribonucleotide 
triphosphate 
ds   Double stranded 
DTT  Dithiothreitol 
 
E 
E6  Human papillomavirus early 
protein 6 
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E7 Human papillomavirus early 
protein 7 
EBV  Epstein-Barr virus 
ECL  Enhanced luminescence 
ECM  Extracellular matrix 
E.coli  Escherichia coli 
EDTA  Ethylen-di-amino-tetra-
acetate 
e.g.   Example given 
EGF Epidermal growth factor 
ELISA  Enzyme-linked  
immunosorbent assay 
ER   Endoplasmatic reticulum 
EtOH  Ethanol 
 
F 
FCS  Fetal calf serum 
fwd.  Forward 
 
G 
GAMPO goat anti mouse peroxidase 
GARPO  goat anti rabbit peroxidase 
GF  Growth factor 
GFR  Growth factor receptor 
GLuc  Gaussia luciferase 
GPCF  Genomic & Proteomics Core 
Facility 
 
H 
h  Hours 
HCV  Hepatitis C virus 
HEK  Human embryonic kidney cells 
HeLa  Henrietta Lack´s cells 
HEPES  4-(2-hydroxyethylen)-1-
piperazineethanesulfonic acid 
HIV  Human immunodeficiency 
virus 
HPV  Human papillomavirus 
HRP  Horseradish peroxidase 
HSPG  Heparan sulfate proteoglycan 
HSV  Herpes simplex virus 
 
I 
Ig   Immunglobulin 
IgG  Immunglobulin G 
IGF1  Insulin-like growth factor 1 
IP  Immunoprecipitation 
IRS4  Insulin receptor substrate 4 
 
K 
kb  Kilo base pair 
kDa  Kilo Dalton 
kV  Kilo Volt 
 
L 
l  Liter 
L1 Human papillomavirus major 
capsid protein 
L2  Human papillomavirus minor 
capsid protein 
LB   Luria Broth 
 
M 
M  Molar 
mA  milli Ampère 
MeOH  Methanol 
µg  Microgram 
µl  Microliter 
µM   Micromolar 
µm  Micrometer 
min  minutes 
ml  Milliliter 
mM   Millimolar 
MOI  Multiplicity of infection 
mRNA  Messenger RNA 
MS  Mass-spectrometry 
mTOR  mammalian target of 
rapamycin complex 1 
MVM  Parvovirus minute virus of 
mice 
 
N 
NAc  Sodium acetate  
NES  Nuclear export signal 
NLS  Nuclear localization signal 
nM  Nanomolar 
NPC  Nuclear pore complex 
NS2  MVM nonstructural protein 
nt  Nucleotide 
N-termi nus Amino-terminus 
 
O 
OD  Optical density 
ORF  Open reading frame 
Ori  Origin of replication 
 
P 
PAGE  Polyacrylamid gel 
electrophoresis 
PBS  Phosphate buffered saline 
PBS-T  Phosphate buffered saline-
tween 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyd 
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PI3K  Phosphatidylinositol-4,5-
bisphosphate 3-kinase 
P/S  Penicillin/Streptavidine 
PsV  Pseudovirion 
PV   Papillomavirus  
 
R 
Rb  Retinoblastoma protein 
rev.  Reverse 
RNA  Ribonucleic acid 
rpm   Revolutions per minute 
RT  Room temperature 
 
 
 
S 
SCF  Skp, cullin, F-box containing 
complex 
SDS  Sodium dodecyl sulfate 
sec   Second 
siRNA  Short interference RNA 
shRNA  Short hairpin RNA 
snt  Supernatant 
SPOP  Speckle-type POZ protein 
SREF  Substrate receptor exchange 
factor 
ss  Single stranded 
SV40   Simian virus 40 
SV40 LT Simian virus 40 large T-antigen 
 
T 
TAE  Tris-acetate-EDTA buffer 
TAP  Tandem affinity purification 
TE  Tris-EDTA buffer 
TEMED  N,N,N´,N´-tetra-
methylethylendiamin 
TEV  Tobacco etch virus 
TGN  Trans-Golgi network 
TGS  Tris-glycin-SDS buffer 
Tris  Tris(hydroxymethyl)-
aminomethan 
 
U 
U  International units for enzyme 
activity  
UV   Ultra violet 
 
V 
Vif  HIV-1 virion infectivity factor 
Vpr  HIV viral protein R 
VLP  Virus-like particle 
v/v   Volume per volume 
 
W 
w/v  Weight per volume 
 
Y 
YWHAZ  14-3-3 zeta 
